Page last updated: 2024-12-05

triiodothyronine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L-homocysteine thiolactone : A thiolactone arising from formal condensation of the mercapto (sulfanyl) and carboxylic acid groups of L-homocysteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID134505
CHEMBL ID4078313
CHEBI ID60315
SCHEMBL ID2167191
MeSH IDM0021977
PubMed CID5920
CHEMBL ID1544
CHEBI ID18258
SCHEMBL ID8300
MeSH IDM0021977

Synonyms (205)

Synonym
2(3h)-thiophenone, 3-aminodihydro-, (s)-
PDSP1_001273
PDSP2_001257
06DCC220-D06A-4793-8958-6383A1C2218C
homocysteine thiolactone
(s)-3-aminodihydro-2(3h)-thiophenone
(3s)-3-aminodihydrothiophen-2(3h)-one
CHEBI:60315
2338-04-7
l-homocysteine thiolactone
(3s)-3-aminothiolan-2-one
AKOS006240739
nsc_134505
cas_134505
bdbm86198
SCHEMBL2167191
(s)-3-aminodihydrothiophen-2(3h)-one
KIWQWJKWBHZMDT-VKHMYHEASA-N
Q27127188
mfcd08458359
CHEMBL4078313
A924139
PD054222
triiodothyronine, l-
l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-
lyothyronine
nsc 80203
3,5,3'-tri-iodo-l-thyronine
3,3',5-triiodothyronine, l-
hsdb 3110
l-3,3',5-triiodothyronine
4-(3-iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine
liothyroninum [inn-latin]
liotironina [inn-spanish]
liothyronine [inn:ban]
brn 2710227
alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, l-
t3 (amino acid)
3,3',5-triiodothyronine
thyronine, 3,3',5-triiodo-, l-
einecs 229-999-3
t3 (van)
l-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
BRD-K89152108-001-03-3
3,5,3'-triodo-l-thyronine
gtpl2634
CHEBI:18258 ,
o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-l-tyrosine
4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-l-phenylalanine
3,5,3'triiodothyronine
l-t3
liothyroninum
liotironina
smr000058402
MLS000028458
t-3
SPECTRUM_001445
BCBCMAP01_000192
SPECTRUM5_001793
PRESTWICK_135
4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine
SMP1_000179
CMAP_000088
nsc-80203
tresitope
l-liothyronine
liothyronin
NCGC00013556
BPBIO1_000953
PRESTWICK2_000853
BSPBIO_003394
PRESTWICK3_000853
BSPBIO_000865
C02465
T3 ,
l-3,5,3'-triiodothyronine
triothyrone
LIOTHYRONINE ,
6893-02-3
3,5,3'-triiodo-l-thyronine
triiodothyronine
3,3',5-triiodo-l-thyronine
3,5,3'-triiodothyronine
3,3',5-triiodo-l-thyronine, >=95% (hplc), powder
1XZX
DB00279
NCGC00096669-02
KBIO2_005136
KBIOSS_002577
KBIOGR_000671
KBIO2_007704
KBIO2_001925
KBIO2_004493
KBIOGR_002568
KBIOSS_001925
KBIO2_007061
KBIO2_002568
KBIO3_003046
KBIO3_002897
SPECTRUM3_001887
SPECTRUM4_000326
SPECTRUM2_001984
SPBIO_002786
PRESTWICK0_000853
PRESTWICK1_000853
NCISTRUC1_000449
SPBIO_002167
NCGC00096669-01
thyrolar-5
chembl1544 ,
3,5,3'-triiodo-l-thyronine (t3)
(2s)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
triiodothyronine (t3)
[125i]t3
bdbm18860
rathyronine, (s)-
thyrolar-3
triiodothyronine (t3 or liothyronine, active) (6-11%)
euthroid-1
thyrolar-0.25
euthroid-0.5
euthroid-2
thyrolar-1
euthroid-3
3,5,3'-triiodothyronine, l-
thyrolar-2
cyronine
thyrolar-0.5
D08128
liothyronine (inn)
sr-01000003143
SR-01000003143-4
T0453
HMS1570L07
(s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid
A836290
HMS2097L07
tox21_301943
dtxsid8023216 ,
NCGC00255336-01
cas-6893-02-3
dtxcid403216
tox21_110029
NCGC00013556-01
HMS2235A22
AKOS016003266
NCGC00013556-03
NCGC00013556-02
NCGC00013556-04
06lu7c9h1v ,
unii-06lu7c9h1v
3,3',5-triiodo-d-thyronine
liothyronine [usp impurity]
liothyronine [vandf]
(2s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid
57164-27-9
liothyronine [usp-rs]
liothyronine [who-dd]
levothyroxine sodium impurity a [ep impurity]
liothyronine [hsdb]
liothyronine [mi]
liothyronine [inn]
EPITOPE ID:131324
S5726
CCG-220853
AM83597
SCHEMBL8300
CS-4141
REGID_FOR_CID_5920
HY-A0070A
AC-31935
mfcd00002593
liothyronine, united states pharmacopeia (usp) reference standard
3,3',5-triiodo-l-thyronine, 95%
3,3',5 triiodothyronine (t3), irmm(r) certified reference material
SR-05000000455-3
SR-05000000455-2
sr-05000000455
liothyronine, pharmaceutical secondary standard; certified reference material
SBI-0206718.P001
HMS3714L07
l-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-alanine
l-3,3',5-triiodo-thyronine
(s)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoicacid
NCGC00013556-05
Q327362
Z1557400301
AS-17446
o-(4-hydroxy-3-iodophenyl-3,5-diiodo-l-tyrosine
NCGC00013556-15
l-3,3',5-triiodothyronine, free acid
EN300-123970
3,3 inverted exclamation mark ,5-triiodo-l-thyronine
o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-l-tyrosine,labeled with(125i)iodine
CS-0622788
HY-A0070AG
liothyronine (gmp)
HB7470
d-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]alanine
liothyronine (usp impurity)
liotironina (inn-spanish)
liothyroninum (inn-latin)
h03aa02
liothyronine (usp-rs)
therapeutic t3

Research Excerpts

Overview

Free triiodothyronine (FT3) is an independent risk factor for nonalcoholic fatty liver disease (NAFLD) in patients with euthyroid. Triiodothyronsine (T3) mediates several physiological processes including cellular growth, development, and differentiation via binding to the nuclear thyroid hormone receptor (TR) Free triiod Timothyronine is a marker of comorbidity in end-stage renal disease.

ExcerptReferenceRelevance
"Free triiodothyronine (FT3) is an independent risk factor for nonalcoholic fatty liver disease (NAFLD) in patients with euthyroid. "( Free Triiodothyronine Is Independently Associated with Nonalcoholic Fatty Liver Disease in Hospitalized Type 2 Diabetes Mellitus Patients.
Chen, Y; Hong, Y; Li, S; Lin, C; Shi, R; Xia, X; Xiu, L, 2021
)
1.65
"Triiodothyronine (T3) is a key regulator of bone, muscle and articular cartilage. "( [Osteoarthropathies and Myopathies associated with Disorders of the Thyroid Endocrine System].
Nehls, V, 2018
)
1.92
"Triiodothyronine (T3) is a potent form of thyroid hormone mediates several physiological processes including cellular growth, development, and differentiation via binding to the nuclear thyroid hormone receptor (TR). "( Thyroid hormone receptor inhibits hepatoma cell migration through transcriptional activation of Dickkopf 4.
Chen, CY; Chen, WJ; Chi, HC; Chung, IH; Huang, YH; Liao, CH; Liao, CJ; Lin, KH; Lin, YH; Tsai, CY; Tseng, YH; Wu, SM; Wu, TI, 2013
)
1.83
"Free triiodothyronine (FT3) is a marker of comorbidity in end-stage renal disease and in many acute and chronic diseases. "( Free triiodothyronine in hemodialysis patients: link with malnutrition and inflammation.
Altinoglu, A; Altunoglu, A; Arat, Z; Canoz, MB; Elsürer, R; Ozdemir, FN; Sezer, S; Yavuz, D; Yavuz, R, 2014
)
1.43
"Triiodothyronine is an inductor of iodothyronine deiodinase expression in brown fat, liver and kidney."( [Role of thyroid system in adaptation to cold].
Chauski, E; Gorbunov, AS; Khaliulin, IG; Maslov, LN; Tsybul'nikov, SIu; Vychuzhanova, EA, 2014
)
1.12
"Triiodothyronine (T3) is an important modulator of cardiac metabolism and function, often through modulation of gene expression. "( Interrelationship between 3,5,3´-triiodothyronine and the circadian clock in the rodent heart.
Nunes, MT; Peliciari-Garcia, RA; Prévide, RM; Young, ME, 2016
)
2.16
"Free triiodothyronine (FT3) is a marker of comorbidity in end-stage renal disease and in many acute and chronic diseases. "( Pretransplantation serum FT3 concentration in kidney recipients is useful to identify higher risk of graft failure.
Haberal, M; Karakan, S; Ozdemir, FN; Sezer, S, 2011
)
0.88
"Triiodothyronine (T3) is a known hepatic mitogen."( Triiodothyronine attenuates hepatic ischemia/reperfusion injury in a partial hepatectomy model through inhibition of proinflammatory cytokines, transcription factors, and adhesion molecules.
Chen, KJ; He, Y; Taki-Eldin, A; Xie, HY; Yu, D; Zheng, SS; Zhou, L, 2012
)
2.54
"Triiodothyronine (T3) is a thyroid hormone that can have varying effects on skin. "( Triiodothyronine (T3) inhibits hyaluronate synthesis in a human dermal equivalent by downregulation of HAS2.
Papp, S; Pouyani, T; Sadaka, BH; Schaffer, L, 2013
)
3.28
"Triiodothyronine is an important regulator of cellular metabolism and may have potential use as an inotropic agent. "( The effects of cardiopulmonary bypass on thyroid function in infants weighing less than five kilograms.
Donaghey, SF; Jamieson, MP; Logan, RW; Mitchell, IM; Paton, RD; Pollock, JC, 1992
)
1.73

Effects

Triiodothyronine has been found to enhance gonadotropin- and insulin-stimulated morphologic luteinization and progesterone production by porcine granulosa cells in culture. The drug has many effects on the heart, and marked changes in cardiac function and structure occur in patients with (subclinical) thyroid disease.

ExcerptReferenceRelevance
"Low triiodothyronine (T3) syndrome has recently been evaluated as a prognostic marker of acute heart failure (AHF). "( Relation of Low Triiodothyronine Syndrome Associated With Aging and Malnutrition to Adverse Outcome in Patients With Acute Heart Failure.
Asai, K; Asano, K; Goda, H; Hata, N; Kiuchi, K; Kobayashi, N; Matsushita, M; Okajima, F; Okazaki, H; Shibata, Y; Shigihara, S; Shimizu, W; Shirakabe, A; Tani, K, 2020
)
1.46
"Triiodothyronine (T3) has been shown to exert a defensive role in many pulmonary diseases, however, rare data are available regarding the role of T3 on silica-induced injury."( Triiodothyronine ameliorates silica-induced pulmonary inflammation and fibrosis in mice.
Chen, W; Fan, L; Gan, S; Ma, J; Wang, B; Wang, D; Xie, Y; Yang, M; Yu, L, 2021
)
2.79
"triiodothyronine) have been associated with adverse cardiovascular sequelae in CKD and ESRD patients, but these metrics are confounded by malnutrition, inflammation and comorbid states, and hence may signify nonthyroidal illness (i.e."( Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients.
Brent, GA; Brunelli, SM; Budoff, MJ; Kalantar-Zadeh, K; Kovesdy, CP; Nguyen, D; Rhee, CM; Soldin, OP, 2015
)
1.14
"Triiodothyronine (T3) has no role in the treatment of primary hypothyroidism."( Management of thyroid disorders in primary care: challenges and controversies.
Todd, CH, 2009
)
1.07
"Triiodothyronine (T3) has many effects on the heart, and marked changes in cardiac function and structure occur in patients with (subclinical) thyroid disease. "( Thyroid hormone levels within reference range are associated with heart rate, cardiac structure, and function in middle-aged men and women.
De Buyzere, ML; Gillebert, TC; Kaufman, JM; Rietzschel, ER; Roef, GL; Taes, YE; Van Daele, CM, 2013
)
1.83
"Triiodothyronine has been introduced as a promising new supplement for patients undergoing open-heart surgery. "( Supplementation of thyroid hormone in children undergoing cardiac surgery.
Mainwaring, RD; Nelson, JC, 2002
)
1.76
"Triiodothyronine (T(3)) has been implicated in the control of the metabolic rate and is decreased during fasting in most bird species."( Do T3 levels in incubating eiders reflect the cost of incubation among clutch sizes?
Criscuolo, F; Gabrielsen, GW; Le Maho, Y; Raclot, T,
)
0.85
"Oral triiodothyronine (T3) has never been described in literature as a major form of perioperative therapy. "( Oral triiodothyronine in the perioperative management of central hypothyroidism.
Chacko, AG; Khan, D; Ponniah, M; Rajshekhar, V; Thomas, N; Venkatesan, T, 2007
)
1.37
"Low triiodothyronine (T3) has been associated with increased short-term mortality in intensive care unit patients and long-term mortality in patients with heart disease. "( Low triiodothyronine: a strong predictor of outcome in acute stroke patients.
Alevizaki, M; Pappa, T; Synetou, M; Vemmos, KN; Xynos, K, 2007
)
1.46
"Triiodothyronine has only a marginal effect on fatty-acid synthase expression, in the absence or presence of glucose and insulin."( Regulation of lipogenic enzyme and phosphoenolpyruvate carboxykinase gene expression in cultured white adipose tissue. Glucose and insulin effects are antagonized by cAMP.
Ferre, P; Foufelle, F; Girard, J; Gouhot, B; Perdereau, D, 1994
)
1.01
"L-triiodothyronine (T3) has previously been shown to enhance fast-phase, depolarization-induced 45Ca uptake and 3H-gamma-aminobutyric acid release by rat brain synaptosomes at low nanomolar concentrations comparable to those reported for whole brain. "( L-triiodothyronine: is this peripheral hormone a central neurotransmitter?
Mason, GA; Prange, AJ; Walker, CH, 1993
)
1.73
"Triiodothyronine has no effect on functional hepatic nitrogen clearance, but given together with growth hormone, it abolishes the effect of growth hormone on functional hepatic nitrogen clearance."( Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man.
Grøfte, T; Jørgensen, JO; Møller, N; Vilstrup, H; Wolthers, T, 1996
)
1.28
"Triiodothyronine (T3) has been shown to accelerate and potentiate the clinical response to tricyclic antidepressant (TCA) treatment in depressive disorders. "( Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
Jeanningros, R; Mazzola-Pomietto, P; Moreau, X, 2001
)
2.08
"Triiodothyronine (T3) toxicity has been well documented in adults, but only isolated cases have been reported in children. "( T3 toxicosis in children.
Fawcett, DM; Harland, PC; McArthur, RG, 1977
)
1.7
"Free triiodothyronine (T3) in serum has been measured directly in dialysates of serum, using a wick chromatographic radioimmunoassay. "( Ultrasensitive radioimmunoassay for direct determination of free triiodothyronine concentration in serum.
Orskov, H; Weeke, J, 1975
)
1.01
"Triiodothyronine (T3) has been shown to augment the therapeutic effect of tricyclic antidepressants as well as monoamine oxidase inhibitors. "( Triiodothyronine potentiation of fluoxetine in depressed patients.
Joffe, RT, 1992
)
3.17
"Free triiodothyronine (FT3) has rarely been studied in neonates, primarily because of obvious problems in obtaining serum samples from neonates for research purposes. "( Free triiodothyronine measured in dried blood spots from normal, low-birth-weight, and hypothyroid neonates.
Fernandez, Y; Laroche, D; Lemonnier, F; Travert, G; Viel, JF, 1988
)
1.3
"L-Triiodothyronine (T3) has been reported to potentiate the antidepressant effects of tricyclic antidepressants (TCAs) in patients who do not respond to these drugs, while thyroxine (T4) has been used to treat rapid-cycling bipolar disorder patients. "( Appearance of mania in drug-resistant bipolar depressed patients after treatment with L-triiodothyronine.
Burnett, GB; Evans, DL; Garbutt, JC; Haggerty, JJ; Pedersen, CA; Strawn, SK, 1986
)
1.21
"Triiodothyronine has been found to enhance gonadotropin- and insulin-stimulated morphologic luteinization and progesterone production by porcine granulosa cells in culture. "( Triiodothyronine receptors in porcine granulosa cells.
Ramani, N; Rao, CV; Wakim, NG, 1987
)
3.16
"of triiodothyronine have been used to treat patients with hypothyroidism of varied aetiology."( Combined thyroxine and triiodothyronine for thyroid replacement therapy.
Adie, R; Kapur, M; Taylor, S, 1970
)
1.07

Actions

Triiodothyronine (T3) plays an important role in the production of cystatin C.

ExcerptReferenceRelevance
"Triiodothyronine was lower in the affected fish than in controls."( CHARACTERIZATION OF A FOLLICULAR CELL CARCINOMA OF THE THYROID IN A YELLOWBAR ANGELFISH (POMACANTHUS MACULOSUS).
Nollens, HH; Schmitt, TL; Simeone, CA; St Leger, J, 2015
)
1.14
"Triiodothyronine plays an important role in the regulation of kidney cell growth, differentiation and metabolism. "( Triiodothyronine regulates cell growth and survival in renal cell cancer.
Brzezianska-Lasota, E; Czarnecka, AM; Czarnecka, KH; Lewicki, S; Matak, D; Szczylik, C; Szymanski, L; Zdanowski, R, 2016
)
3.32
"Triiodothyronine (T3) plays an important role during development of the central nervous system. "( T3 differentially regulates TRH expression in developing hypothalamic neurons in vitro.
Carreón-Rodríguez, A; Charli, JL; Pérez-Martínez, L, 2009
)
1.8
"Triiodothyronine-induced increase in the production of cystatin C may be related to an increased cell metabolism and proteolysis control demand."( Triiodothyronine stimulates cystatin C production in bone cells.
Ghirlanda-Keller, C; Schmid, C; Zoidis, E; Zwimpfer, C, 2012
)
2.54
"Triiodothyronine levels were lower in heart failure patients who had a cardiovascular event than in event-free patients (82.7+/-24.8 vs."( Long-term prognostic value of triiodothyronine concentration in elderly patients with heart failure.
Gebara, OC; Nussbacher, A; Pierri, H; Rays, J; Rosano, G; Serro-Azul, JB; Telles, RM; Wajngarten, M,
)
1.14
"Triiodothyronine levels were lower in feed-deprived chicks, and the effect was greater in late hatchers."( The effects of the spread of hatch and interaction with delayed feed access after hatch on broiler performance until seven days of age.
Bruggeman, V; Buyse, J; Careghi, C; Decuypere, E; Onagbesan, O; Tona, K, 2005
)
1.05
"Triiodothyronine failed to enhance the synthesis of angiotensin-converting enzyme in rabbit alveolar macrophages or in human monocytes in culture, suggesting that the increased serum enzyme is a consequence of an effect other than increased angiotensin-converting enzyme synthesis."( Elevated serum angiotensin-converting enzyme in hyperthyroidism.
Friedland, J; Schussler, GC; Silverstein, E, 1983
)
0.99
"Triiodothyronine (T3) can also inhibit synthesis of hyaluronate in fibroblasts (Smith, T."( Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones.
Smith, TJ, 1984
)
0.99
"Triiodothyronine was able to enhance the phagocytic capacity and chemiluminescent activity of polymorphonuclear granulocytes."( Stimulating effect of triiodothyronine on cell-mediated immunity.
Bakó, G; Balázs, C; Leövey, A; Szabó, M, 1980
)
1.3
"The triiodothyronine level was lower on the 2nd day of the disease, the thyroxine content decreased on the 10th day of the disease but became normal on the 20-25th day."( [Thyroid hormones, cholesterol, erythrocyte aggregation and fibrinogen degradation products in acute myocardial infarct].
Kellner, K; Liusov, VA; Marek, H; Rudakov, AV; Titlbach, O, 1980
)
0.74
"Triiodothyronine did not inhibit kidney, spleen, or lung protein kinase activity."( Inhibition of thyroidal cyclic AMP-dependent protein kinase by thyroid hormone.
Burke, G; Friedman, Y; Lang, M, 1978
)
0.98
"Triiodothyronine levels increase in brain in all experimental groups."( Modulation of insulin receptors and catecholamines in rat brain in hyperthyroidism and hypothyroidism.
Azam, M; Baquer, NZ, 1990
)
1
"Triiodothyronine also could increase DAP-I levels, but only between 1.5- and 2.0-fold."( Hormonal regulation of dipeptidyl-aminopeptidase I activity in cultured human fibroblasts.
Davis, MH, 1987
)
0.99

Treatment

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support) NCT04348513, date of trial registration: April 16, 2020, EudraCT Identifier: 2020-001623-13. Full protocol is attached as an additional file, accessible from the Trials website.

ExcerptReferenceRelevance
"Triiodothyronine (T3) pretreatment decreased the INaL in a concentration-dependent manner. "( Thyroid Hormone Diminishes Ca2+ Overload Induced by Hypoxia/Reoxygenation in Cardiomyocytes by Inhibiting Late Sodium Current and Reverse-Na+/Ca2+ Exchange Current.
Liao, X; Liu, L; Ruan, H; Zeng, B; Zhang, C, 2020
)
2
"Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support), ClinicalTrials.gov Identifier: NCT04348513, date of trial registration: April 16, 2020, EudraCT Identifier: 2020-001623-13, date of trial registration: April 22, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). "( Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Armaganidis, A; Kostopanagiotou, G; Mourouzis, I; Pantos, C; Trikas, A; Tseti, I, 2020
)
3.44
"Triiodothyronine treatment, from days P0-P5, increased the skeletal muscle myoglobin mRNA 1.5- to 4.5-fold; a 2.5-fold increase was observed in ventricle muscle, but only when triiodothyronine treatment was extended to day P15."( Neonatal hyper- and hypothyroidism alter the myoglobin gene expression program in adulthood.
Nunes, MT; Souza, Kde P, 2014
)
1.12
"Triiodothyronine treatment resulted in a significant increase in adaptation parameters, villus height-crypt depth, and enterocyte proliferation, whereas significant decrease was seen in apoptotic index in jejunum. "( Effects of thyroid hormone on the adaptation in short bowel syndrome.
Ekinci, O; Pasaoglu, H; Poyraz, A; Sahin, T; Salman, B; Tatlicioglu, E; Yilmaz, U; Yuksel, O, 2009
)
1.8
"Triiodothyronine pretreatment did not cause any change in cyclic AMP levels in the control (2.50 +/- 0.29) or in the stunned myocytes (2.60 +/- 0.40)."( Effects of triiodothyronine pretreatment on beta-adrenergic responses in stunned cardiac myocytes.
Gandhi, A; He, YQ; Tse, J; Weiss, HR; Yan, L, 2003
)
1.43
"Triiodothyronine pretreatment enhanced beta-adrenergic responses in both the control and the stunned myocytes."( Effects of triiodothyronine pretreatment on beta-adrenergic responses in stunned cardiac myocytes.
Gandhi, A; He, YQ; Tse, J; Weiss, HR; Yan, L, 2003
)
1.43
"Triiodothyronine (T3) treatment from birth until Postnatal Day 10 reduced Sertoli cell proliferation to minimal levels in WT and TRbetaKO mice versus that in their untreated controls, whereas T3 had a diminished effect on TRalphaKO Sertoli cell proliferation."( Regulation of neonatal Sertoli cell development by thyroid hormone receptor alpha1.
Cooke, PS; Holsberger, DR; Kiesewetter, SE, 2005
)
1.05
"Like triiodothyronine (T3), treatment with the mono-ortho-substituted PCB-118 (2,3',4,4 ,5-pentachlorobiphenyl; 0.01-1 microM) leads to a dose-dependent increase of oligodendrocyte formation."( Polychlorinated biphenyls disturb differentiation of normal human neural progenitor cells: clue for involvement of thyroid hormone receptors.
Abel, J; Cline, JE; Fritsche, E; Nguyen, NH; Scanlan, TS, 2005
)
0.78
"Triiodothyronine level after treatment correlated negatively with baseline urea level."( Influence of low protein diet on nonthyroidal illness syndrome in chronic renal failure.
Kozlowska, L; Rosolowska-Huszcz, D; Rydzewski, A, 2005
)
1.05
"In triiodothyronine-treated animals, all haemodynamic parameters were elevated during the first 72 h."( Correlation between haemodynamic and metabolic changes in three models of experimental cardiac hypertrophy.
Zimmer, HG, 1984
)
0.78
"In triiodothyronine-treated animals only the cardiac pool of 5-phosphoribosyl-1-pyrophosphate turned out to be elevated."( Significance of the hexose monophosphate shunt in experimentally induced cardiac hypertrophy.
Gerlach, E; Ibel, H; Zimmer, HG,
)
0.65
"Triiodothyronine (T3) treatment was initiated 3 days after the rats were made diabetic and was carried out for 6 weeks thereafter."( Lack of effect of thyroid hormone on diabetic rat heart function and biochemistry.
McNeill, JH; Tahiliani, AG, 1984
)
0.99
"In triiodothyronine-treated rats increased oxidation and decreased triacylglycerol formation from palmitate and oleate was observed."( The metabolism of fatty acids in hepatocytes isolated from triiodothyronine-treated rats.
Bremer, J; Stakkestad, JA, 1982
)
1.02
"If triiodothyronine treatment was restricted to the first 17 culture days, the level of choline acetyltransferase specific activity at day 33 was 84% of that in chronically treated cultures and 270% of that in cultures receiving triiodothyronine between days 17 and 33, indicating that relatively undifferentiated cells were more responsive to the hormone."( Triodothyronine enhancement of neuronal differentiation in aggregating fetal rat brain cells cultured in a chemically defined medium.
Honegger, P; Lenoir, D, 1980
)
0.78
"Triiodothyronine treatment in ob/ob mice resulted in lower values for body weight, liver weight, hepatocyte number, liver protein, epididymal fat pad weight, and white adipocyte number and size than in saline-treated ob/ob mice."( Early treatment of obese (ob/ob) mice with triiodothyronine increases oxidative metabolism in muscle but not in brown adipose tissue or liver.
Kaplan, ML; Oh, SS, 1995
)
1.28
"Triiodothyronine treatment was associated with significantly decreased coronary resistance and increased coronary flow through a range of diastolic loading conditions in the postischemic hearts."( Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia.
Berman, K; Helm, RE; Isom, OW; Klein, I; Klemperer, JD; Krieger, K; Ojamaa, K; Zelano, J, 1995
)
2.46
"Triiodothyronine (T3) treatment of pregnant rats for 6 days, 10 micrograms/100 g, resulted in a pronounced induction of enzymes related to gluconeogenesis and lipogenesis and of mitochondrial FAD-glycerophosphate dehydrogenase in the maternal liver, as previously observed in male rats. "( Modulation of fetal and placental metabolic pathways in response to maternal thyroid and glucocorticoid hormone excess.
Barash, V; Diamant, YZ; Kissilevitz, R; Shafrir, E; Zederman, R, 1994
)
1.73
"L-triiodothyronine (L-T3) treatment of the cultures increased the levels of beta 1-mRNAs by fivefold without changing either the levels of the alpha 1- and alpha 2-mRNAs or L-T3 binding capacity."( Thyroid hormone up-regulates thyroid hormone receptor beta gene expression in rat cerebral hemisphere astrocyte cultures.
Dussault, JH; L'Hérault, S; Lebel, JM; Puymirat, J, 1993
)
0.84
"Triiodothyronine treatment abolished the sepsis-induced decrease in free T3 levels (S = 68 +/- 5 ng/dL, CLP < 15 ng/dL, CLP/T3 = 91 +/- 20 ng/dL)."( Pulmonary biophysical effects of triiodothyronine augmentation during sepsis-induced hypothyroidism.
Dulchavsky, SA; Dutta, S; Hendrick, SR, 1993
)
1.29
"Triiodothyronine (T3) treatment of larvae resulted in the complete absence of skin glands with a limited number of gland nests (epidermal precursors of dermal skin glands), but stimulated epidermal growth."( Hormonal regulation of skin gland development in the toad (Bufo boreas): the role of the thyroid hormones and corticosterone.
Gill, TN; Hayes, TB, 1995
)
1.01
"Triiodothyronine treatment did not modify the duration of the action potential recorded in vitro at 25 degrees C from ventricular muscles stimulated at 1 Hz."( Effect of T3 administration on electrophysiological properties of lizard ventricular muscle fibres.
De Leo, T; de Martino Rosaroll, P; Di Meo, S; Venditti, P, 1996
)
1.02
"Triiodothyronine-treated patients had a lower incidence of atrial fibrillation (24% versus 46%; p = 0.009), and fewer required cardioversion (0 versus 6; p = 0.012) or anticoagulation (2 versus 10; p = 0.013) during hospitalization."( Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations.
Gomez, M; Helm, RE; Isom, OW; Klein, IL; Klemperer, JD; Krieger, KH; Ojamaa, K, 1996
)
2.46
"Triiodothyronine treatment (3 micrograms/100 body wt per day) given during the last week prior to sacrifice resulted in reduced testicular growth in 2-week-old animals."( Effect of triiodothyronine administration on estrogen receptor contents in peripuberal Sertoli cells.
Andò, S; Fugassa, E; Lanzino, M; Mauro, L; Morrone, EG; Palmero, S; Panno, ML; Pezzi, V; Salerno, M; Sisci, D, 1996
)
1.42
"Triiodothyronine (T3) treatment at 1, 3 and 5 days after birth significantly increased the binding capacity (density) of the thymus glucocorticoid receptor of male and female rats in adult age. "( Effect of perinatal triiodothyronine (T3) treatment on thymic glucocorticoid and estrogen receptors and uterus estrogen receptors. Receptor selectivity during hormonal imprinting.
Csaba, G; Inczefi-Gonda, A, 1996
)
2.06
"Triiodothyronine (T3) treatment of progenitor cells blocks their proliferation and induces their differentiation into oligodendrocytes."( Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone.
Baas, D; Bourbeau, D; Dussault, JH; Ittel, ME; Puymirat, J; Sarliève, LL, 1997
)
1.02
"Triiodothyronine treatment at the most effective concentration (50 nM) increased ER and ER mRNA levels twofold."( Hormonal regulation of the estrogen receptor in primary cultures of hepatocytes from female rats.
Eriksson, HA; Freyschuss, B; Stavreus-Evers, AC, 1997
)
1.02
"Triiodothyronine-treated lambs had significantly higher mean arterial pH and lower PCO2 than controls (P < .05) with a trend toward higher mean PO2. "( Antenatal triiodothyronine improves neonatal pulmonary function in preterm lambs.
Chan, L; Chander, A; Farina, C; Miller, TF; Shaffer, TH; Wolfson, MR; Yuxin, J,
)
1.98
"Triiodothyronine-treated animals already have higher cytochrome c oxidase activity before resection."( The effect of triiodothyronine on cell oxidative capacity in regenerating rat liver.
Cervinková, Z; Drahota, Z; Kalous, M; Rauchová, H; Svátková, R, 1997
)
1.38
"In triiodothyronine-treated rats, the increase in total protein was the same (70%), however, the increase in total liver DNA content and total cytochrome c oxidase acitivity was 100 and 135%, respectively during the first 3 days of regeneration."( Effect of triiodothyronine administration on the recovery of liver oxidative capacity after partial hepatectomy.
Cervinka, M; Cervinková, Z; Drahota, Z; Kalous, M; Rauchová, H; Svátková, R, 1998
)
1.22
"Triiodothyronine treated rats were hyperthyroid compared to controls, with an elevation in serum T3 levels (3.8+/-0.9 mmol/L vs 1.3+/-0.4 mmol/L, p<0.05). "( Altered thyroid status modulates portal pressure in normal rats.
BenHaim, M; Brill, S; Dotan, I; Halpern, Z; Jones, BE; Oren, R; Sikuler, E, 1999
)
1.75
"In triiodothyronine-treated piglets, UCP3 mRNA is more expressed in LT than in RH muscle."( First evidence of uncoupling protein-2 (UCP-2) and -3 (UCP-3) gene expression in piglet skeletal muscle and adipose tissue.
Damon, M; Herpin, P; Lombardi, A; Vincent, A, 2000
)
0.82
"In triiodothyronine treated rats, L-tryptophan eliminated a light stimulatory effects of thyroid hormones on the processes of formations and retention of the active avoidance reaction, increased the exploratory activity, but decreased grooming in the open-field."( [Effect of alpha-tryptophan on conditioning and behavior in rats with experimental pathology of the thyroid gland].
Fedotova, IuO; Sapronov, NS,
)
0.65
"Triiodothyronine treatment increased the [3H]ouabain binding site concentration in the liver, kidney, and skeletal muscle but failed to affect it in the brain."( Increased (Na+,K+)-ATPase concentrations in various tissues of rats caused by thyroid hormone treatment.
Akera, T; Lin, MH, 1978
)
0.98
"Triiodothyronine (T3) treatment induced marked hypertrophy of the brown adipose tissue (BAT), similar to that observed in cold-acclimated animals, although partly due to fat deposition. "( Metabolic activity of brown adipose tissue in T3-treated hamsters.
Cassuto, Y; Rabi, T, 1976
)
1.7
"L-Triiodothyronine (L-T3) treatment as well as propylthiouracil (PTU) treatment decreased the immediate insulin secretory response of the pancreas slightly."( Thyroid function and insulin secretion from the perfused pancreas in the rat.
Hasselblatt, A; Joost, HG; Lenzen, S, 1976
)
0.81
"On triiodothyronine treatment morphometric examinations revealed an increased proliferation and resorption of cartilage associated with a transitory acceleration of linear bone growth."( Effect of triiodothyronine treatment, thyroparathyroidectomy and mercaptoiminazole treatment on enchondral bone growth. Changes in the histological structure of the growth organ.
Gyarmati, J; Laczkó, J; Lévai, G; Varga, S, 1975
)
1.17
"Triiodothyronine (T3) treatment of 2-day-old euthyroid rats induced a precocious stimulation of SERCA1 mRNA levels, indicating that T3 is the determining factor in the stimulation of SERCA1 message levels and that this stimulation underlies the previously reported effect of the thyroid status on the neonatal development of SR Ca(2+)-ATPase activity."( Thyroid hormone regulates Ca(2+)-ATPase mRNA levels of sarcoplasmic reticulum during neonatal development of fast skeletal muscle.
Simonides, WS; van der Linden, GC; van Hardeveld, C, 1992
)
1
"Triiodothyronine pretreatment enhanced CP proteinuria in young and adult rats, and increased blood urea nitrogen concentration in 55-day-old rats."( Triiodothyronine (T3) increases cisplatin nephrotoxicity in young and adult rats.
Appenroth, D; Bakhteeva, V; Bräunlich, H; Gambaryan, S; Gerhardt, S; Schröter, H; Winnefeld, K, 1990
)
2.44
"The triiodothyronine treatment duplicated the effects of insulin on the hemodynamic measurements in vivo, and corrected nearly all depressed indexes of performance of diabetic SHR hearts ex vivo."( Insulin, thyroid hormone, and heart function of diabetic spontaneously hypertensive rat.
Davidoff, AJ; Rodgers, RL, 1990
)
0.76
"Triiodothyronine treatment (10 micrograms/kg, s.c., twice daily during 10 days) of 4-week athyroidic rats increased serum T3 levels, but not T4 serum levels."( Thyroidectomy and central catecholamine neurons of the male rat. Evidence for the existence of an inhibitory dopaminergic mechanism in the external layer of the median eminence and for a facilitatory noradrenergic mechanism in the paraventricular hypothal
Andersson, K; Eneroth, P, 1987
)
0.99
"As triiodothyronine (T3) treatment has been shown to normalize depression of cardiac myosin ATPase in diabetic rats, we repeated the study using a combination of T3 (30 micrograms kg-1 day-1 sc daily) and methyl palmoxirate."( Prevention of diabetes-induced myocardial dysfunction in rats by methyl palmoxirate and triiodothyronine treatment.
McNeill, JH; Tahiliani, AG, 1985
)
1.01
"Triiodothyronine (T3) treatment of T animals restored the levels to normal values."( Thyroid hormone and the mitochondrial population in the rat heart.
De Leo, T; de Martino Rosaroll, P; Di Maio, V; Di Meo, S; Valente, M, 1988
)
1
"Triiodothyronine (T3) treatment of the hypothyroid rat (25 micrograms/100 g body weight/day for four days) corrected phospholipase A2 and lysophospholipase activities to the level of the control rat, but failed to correct the increased mitochondrial GPAT activity and not only corrected but lowered GPCAT activity to the level of the hyperthyroid rat."( Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Carter, WJ; Dang, AQ; Faas, FH, 1985
)
0.99
"Triiodothyronine-treated rats showed the same decrease in ketone-body concentrations after administration of glycerol as the untreated rats."( Changes in the concentrations of hepatic metabolites on administration of dihydroxyacetone or glycerol to starved rats and their relationship to the control of ketogenesis.
Ellington, EV; Krebs, HA; Veloso, D; Williamson, DH, 1969
)
0.97
"In triiodothyronine-treated thyroidectomized rats, activation of Na(+) transport accounted for 90% or more of the increment in Q(o2) in liver and 40% or more of the increment in diaphragm."( Mechanism of thyroid calorigenesis: role of active sodium transport.
Edelman, IS; Izmail-Beigi, F, 1970
)
0.76
"Treatment with triiodothyronine significantly, diminished polyADP-ribosylation of three specific groups of polyADP-ribosylated non-histone chromatin proteins corresponding to 130 kDa, 90-80 kDa and 80-65 kDa."( Evidence for the macromolecular basis of regulation of heart hypertrophy.
Jackowski, G; Kun, E, 1984
)
0.61
"Pretreatment with triiodothyronine for 5 days strongly inhibited the response of the n.sl outflow to TRH."( Stimulation by thyrotropin-releasing hormone of vagal outflow to the thyroid gland.
Tonoue, T, 1982
)
0.59
"Treatment with triiodothyronine diminished poly(ADP)-ribosylation of certain groups of proteins more than others, implying some degree of selectivity of action of the hormone."( The effect of in vivo treatment with triiodothyronine on the in vitro synthesis of protein-poly(ADP)-ribose adducts by isolated cardiocyte nuclei and the separation of poly(ADP)-ribosylated proteins by phenol extraction and electrophoresis.
Jackowski, G; Kun, E, 1983
)
0.88
"Pretreatment with triiodothyronine or tetraiodothyronine (10 micrograms/100 g b.wt."( Thyroid hormones influencing renal electrolyte excretion in saline loaded rats of different ages.
Bräunlich, H, 1984
)
0.59
"Treatment with triiodothyronine had no effect on plasma estradiol or thyroxine levels."( Changes in plasma estradiol and effects of triiodothyronine on plasma estradiol during smoltification of coho salmon, Oncorhynchus kisutch.
Gorbman, A; Sower, SA; Sullivan, CV, 1984
)
0.87
"Treatment with triiodothyronine (T3) in a high dose (10 micrograms/day) doubled ER mRNA levels."( The hormonal regulation of the oestrogen receptor in rat liver: an interplay involving growth hormone, thyroid hormones and glucocorticoids.
Eriksson, H; Freyschuss, B; Masironi, B; Sahlin, L, 1994
)
0.63
"Treatment with triiodothyronine for 5 or 10 days decreased the sensitivity of glycogen synthesis but increased the sensitivity of lactate formation to insulin."( The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats.
Bevan, S; Challiss, RA; Dimitriadis, G; Krause, U; Leighton, B; Newsholme, EA; Parry-Billings, M; Piva, T; Tegos, K; Wegener, G, 1997
)
0.64
"A pretreatment with triiodothyronine (20 micrograms/100 g b.wt.) or dexamethasone (60 micrograms/100 g b.wt.), both given intraperitoneally once daily for 3 days, stimulated the renal amino acid transport capacity in 5/6NX rats: the increase in FEAA after amino acid load was significantly lower compared to non-pretreated animals."( Renal handling of amino acids in 5/6-nephrectomized rats: stimulation of renal amino acid reabsorption after treatment with triiodothyronine or dexamethasone under amino acid load.
Fleck, C; Gräfe, K; Kart, I, 1999
)
0.82
"4. Treatment with triiodothyronine of euthyroid rats which had been sympathectomized did not significantly alter specific [3H]-ouabain binding to heart or skeletal muscle membrane preparations."( Stimulation of specific [3H]-ouabain binding to microsomal preparations from rat heart and skeletal muscle by thyroid hormones: effects of 6-hydroxydopamine.
Banerjee, SP; Sharma, VK, 1979
)
0.58
"Treatment with triiodothyronine had no effect on the mRNAs measured."( The effects of pituitary stalk transection, hypophysectomy and thyroid hormone status on insulin-like growth factor 2-, growth hormone releasing hormone-, and somatostatin mRNA prevalence in rat brain.
Levy, A; Lightman, SL; Matovelle, MC; Young, WS, 1992
)
0.62
"Treatment with triiodothyronine (T3) but not thyroxine (T4) (at 1 ppm in the diet from hatch) consistently and significantly reduced the growth rate and decreased the plasma concentrations of GH following TRH injection in normal (DwDw males or Dw-females), hemizygous dwarf (dw-) female, and heterozygous (Dwdw) male lines of broiler chickens."( Effect of thyroid hormones on growth hormone secretion in broiler chickens.
Bowen, SJ; Denver, RJ; Scanes, CG, 1986
)
0.61
"Treatment with triiodothyronine (T3, 0.1 microgram ."( Postnatal development of pulmonary alveoli: modulation in rats by thyroid hormones.
Massaro, D; Massaro, GD; Teich, N, 1986
)
0.61
"Treatment with triiodothyronine enhanced the activity of the mitochondrial sn-glycerol-3-phosphate dehydrogenase but did not affect the cytoplasmic enzyme."( Effect of diet and triiodothyronine on the activity of sn-glycerol-3-phosphate dehydrogenase and on the metabolism of glucose and pyruvate by adipose tissue of obese patients.
Bray, GA, 1969
)
0.92

Toxicity

Triiodothyronine (T3) induces several beneficial effects on lipid metabolism. Its use is hampered by toxic side-effects, such as tachycardia, arrhythmia, heart failure, bone and muscle catabolism and mood disturbances. This study investigated the effect of T3 to mitigate toxic effects of diazinon in the endangered Persian sturgeon.

ExcerptReferenceRelevance
" Toxicity assessments in the mouse yielded a LD50 of 297 mg/kg and in the rat 389 mg/kg."( Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates.
Ali-Osman, F; Chin, L; Dwyer-Hansen, L; Grunbaum, Z; Krohn, KA; Livesey, J; Nelson, N; Rasey, JS; Spence, AM; Stein, D, 1995
)
0.29
") is equally toxic to both wild-type and adenosine-kinase-deficient BHK cells at concentrations up to 100 microM; at higher concentrations, wild-type cells are more sensitive, as are cells over-expressing adenosine kinase."( The bis(adenosin-N6-yl) alkanes, a family of potential dinucleoside polyphosphate analogue precursors. Mechanism of growth inhibition and suppression of adenosine toxicity in lymphoid cells.
Chen, H; McLennan, AG, 1993
)
0.29
" This study has shown that it is possible to modulate homocysteine toxicity by preventing its conversion to a more toxic HTL by S-nitrosation."( Modulation of homocysteine toxicity by S-nitrosothiol formation: a mechanistic approach.
Morakinyo, MK; Simoyi, RH; Strongin, RM, 2010
)
0.36
" Hcy-thiolactone has been implicated in these diseases because it has the ability to modify protein lysine residues and generate toxic N-Hcy-proteins with auto-immunogenic, pro-thrombotic, and amyloidogenic properties."( Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase.
Borowczyk, K; Jakubowski, H; Tisończyk, J, 2012
)
0.38
" Cadmium and mercury treatment at LD50 levels resulted in severe thyrotoxicosis in the rabbit."( Thyrotoxicity of the chlorides of cadmium and mercury in rabbit.
Bhattacharya, S; Ghosh, N, 1992
)
0.28
" Supplementing 35 or 350 ppm iodine to the basal diet resulted in toxic effects (P less than or equal to ."( Iodine toxicity in large white turkey breeder hens.
Christensen, VL; Ort, JF, 1991
)
0.28
"The toxic effects of cadmium on the thyroid gland of pregnant rats were studied with an electron microscope and an X-ray microanalyzer."( Cadmium toxicity in the thyroid gland of pregnant rats.
Araki, H; Doi, Y; Hamasaki, K; Hara, K; Mori, N; Sakamoto, Y; Tanaka, I; Umezu, Y; Yokoyama, M; Yoshizuka, M, 1991
)
0.28
" Oral administration of phenobarbital enhanced the toxic effect of RM on (b), (d) and (e) and did not modify the toxic effect of RM on (a), (c) and (f)."( Glucosinolates toxicity in growing rats: interactions with the hepatic detoxification system.
Nugon-Baudon, L; Rabot, S; Raibaud, P; Szylit, O, 1990
)
0.28
" The adverse reactions to Plethoryl almost always occur in the unofficial indications of the product, notably in the "treatment" of obesity."( [Probable side effects caused by plethoryl. Common acute hepatitis, anicteric hepatitis, cirrhosis due to hypervitaminosis A, inflammatory arthralgias].
Constantin, JM; Maroy, B; Moullot, P, 1989
)
0.28
" These results, interpreted in relationship to previous studies, suggest that the therapeutic efficacy of T3 in canine hemorrhagic shock may be related to antagonism of adverse effects of endogenous rT3."( Triiodothyronine (T3) antagonizes adverse effects of high circulating reverse-T3 (rT3) during hemorrhagic shock.
Dewitt, DS; Prough, DS; Shatney, CH; Smith, RA; Yuan, XQ, 1988
)
1.72
" Clinically, in both species L-T3 appeared more toxic to males than females but this was not supported histologically."( Comparison of the toxicity of orally administered L-triiodothyronine (T3) in rat and cynomolgus monkey.
Atterwill, CK; Davies, S; Jones, CA; Kennedy, S; Lee, DM; Poole, A, 1988
)
0.53
" It is suggested that alcohol may have a toxic effect on the thyroid gland independent of the degree of liver damage."( Independent effects of liver disease and chronic alcoholism on thyroid function and size: the possibility of a toxic effect of alcohol on the thyroid gland.
Aldershvile, J; Hegedüs, L; Kastrup, J; Krogsgaard, K; Rasmussen, N; Ravn, V, 1988
)
0.27
" Toxic effects were observed only at the 10 mg/kg dose in the tPCP-treated calves."( Assessment of pentachlorophenol toxicity in newborn calves: clinicopathology and tissue residues.
Forsell, JH; Hughes, BJ; Kuo, C; Shull, LR; Sleight, SD, 1985
)
0.27
" Provided the results obtained from these animal experiments can be applied to the situation in man, the inhibition of peripheral deiodination could have an adverse effect at least in the treatment of T3-thyrotoxicosis."( Inhibition of peripheral deiodination of 3, 5, 3'-triiodothyronine: an adverse effect of propylthiouracil in the treatment of T3-thyrotoxicosis.
Heinen, E; Herrmann, J; Krüskemper, HL; Moreno, F; Mosny, D; Teschke, R,
)
0.38
" There were 287 nontoxic and 62 toxic lesions."( Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules.
Hamburger, JI, 1980
)
0.26
" It is concluded that hyperthyroidism increases the susceptibility of the liver to the toxic effects of lindane, which seems to be accomplished by potentiation of the hepatic oxidative stress status."( Influence of hyperthyroidism on lindane-induced hepatotoxicity in the rat.
Fernández, V; Junqueira, VB; Simon, KA; Smok, G; Troncoso, P; Videla, LA, 1995
)
0.29
" Using drugs together may increase the risk of adverse effects, through potentiation of existing adverse effects or alterations in plasma concentrations of the drug."( Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.
Schweitzer, I; Tuckwell, V, 1998
)
0.3
" It is concluded that hyperthyroidism increases the susceptibility of the liver to the toxic effects of iron, which seems to be related to the development of a severe oxidative stress status in the tissue, thus contributing to the concomitant liver injury and impairment of Kupffer cell phagocytosis and particle-induced respiratory burst activity."( Derangement of Kupffer cell functioning and hepatotoxicity in hyperthyroid rats subjected to acute iron overload.
Basualdo, A; Boisier, X; Bosco, C; Carrión, Y; Cornejo, P; Fernández, V; Galleano, M; Puntarulo, S; Schön, M; Sepúlveda, A; Tapia, G; Videla, LA, 1999
)
0.3
"Although exposure to cyanogenic plants or cyanide during pregnancy has adverse effects, no teratological study with cyanide has been conducted in goats or any other ruminant."( Prenatal toxicity of cyanide in goats--a model for teratological studies in ruminants.
Górniak, SL; Soto-Blanco, B, 2004
)
0.32
" These results suggest that exposure to maternally toxic doses of iodine may have a potential developmental toxic effect."( Developmental toxic effects of chronic exposure to high doses of iodine in the mouse.
Guo, HL; Hao, LP; Hou, XH; Liu, LG; Sun, XF; Xu, J; Yang, XF; Yao, P, 2006
)
0.33
" These micromolar T(3) concentrations were significantly higher than the concentration range of T(3) receptor binding, indicating that other non-receptor-mediated mechanisms beyond the receptor level must be responsible for the observed toxic effects of T(3) in vitro."( Triiodothyronine (T3)-mediated toxicity and induction of apoptosis in insulin-producing INS-1 cells.
Jörns, A; Lenzen, S; Lortz, S; Ximenes, HM, 2007
)
1.78
" Phenobarbital, Aroclor 1254 and beta-naphthoflavone (indirect toxic mechanism) enhanced thyroidal radioiodide accumulation, and the administration of potassium perchlorate had no effect on thyroid: blood (125)I ratio."( Standardization of the perchlorate discharge assay for thyroid toxicity testing in rats.
Coelho-Palermo Cunha, G; van Ravenzwaay, B, 2007
)
0.34
" T3 was well tolerated in most of the studies and adverse effects do not seem to be an impediment to clinical use."( Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors.
Cooper-Kazaz, R; Lerer, B, 2008
)
0.66
" This case illustrates the potential for hypothyroid-induced renal dysfunction to lead to adverse clinical consequences in patients taking medications cleared by the kidneys."( Lithium toxicity precipitated by profound hypothyroidism.
Gohh, R; Gopalakrishnan, G; Hennessey, JV; Phillips, BD, 2008
)
0.35
" Cutaneous adverse effects of topical methimazole were determined."( Safety of topical methimazole for the treatment of melasma. Transdermal absorption, the effect on thyroid function and cutaneous adverse effects.
Eshraghian, A; Handjani, F; Kasraee, B; Nikbakhsh, M; Omrani, GR; Parhizgar, A; Safaee Ardekani, GH; Samani, M; Saurat, JH; Sorg, O; Tanideh, N, 2008
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" In conclusion, free gossypol in diet induced adverse effects on semen quality in rams, but selenium supplementation successfully counteracts most of the hazardous effects of gossypol on semen characteristics."( Alleviation of reproductive toxicity of gossypol using selenium supplementation in rams.
El-Mokadem, MY; Samak, MA; Taha, TA; Yassen, AM, 2012
)
0.38
"Recent work has demonstrated the importance of post-transcriptional gene regulation in toxic responses."( Decreased translation of Dio3 mRNA is associated with drug-induced hepatotoxicity.
Darras, VM; Dudek, KM; Gant, TW; Marczylo, EL; Suter, L, 2013
)
0.39
"Methimazole (MMI) is usually used at an initial dose of 30 mg/day for severe Graves' disease (GD) hyperthyroidism, but adverse effects are more frequent at this dose than at MMI 15 mg/day."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
" MMI 30 mg/day (M30)) in terms of therapeutic effect, adverse effects, and remission rate."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
" Adverse effects that required discontinuation of MMI were more frequent in the M30-treated than in the M15+I-treated group (14."( Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Ito, K; Kunii, Y; Matsumoto, M; Mukasa, K; Nagataki, S; Noh, JY; Sato, S; Sugino, K; Suzuki, M; Taniyama, M; Yasuda, S, 2015
)
0.42
"The toxic effects of three polybrominated diphenyl ether (PBDE) congeners (BDE-47, -99, and -209), tetrabromobisphenol A (TBBPA) and bisphenol A (BPA), were evaluated by determining their 24h and 96 h median lethal concentrations using a zebrafish liver cell line, ZFL."( Evaluation of the toxic effects of brominated compounds (BDE-47, 99, 209, TBBPA) and bisphenol A (BPA) using a zebrafish liver cell line, ZFL.
Chan, KM; Yang, J, 2015
)
0.42
" The findings demonstrate that dietary Se from HPSeKS at 5-10mg/kg is not considered a toxic level for laying hens."( Evaluation of the toxicity of selenium from hydroponically produced selenium-enriched kale sprout in laying hens.
Borisuth, L; Chantiratikul, A; Chantiratikul, P; Chinrasri, O; Chookhampaeng, S; Saenthaweesuk, N; Sriart, N; Thosaikham, W, 2016
)
0.43
" We hypothesized that low-dose oral T3 will offer safe therapeutic benefits in MI."( Safe Oral Triiodo-L-Thyronine Therapy Protects from Post-Infarct Cardiac Dysfunction and Arrhythmias without Cardiovascular Adverse Effects.
Balasubramanian, K; Chen, YF; Gerdes, AM; Ojamaa, K; Pingitore, A; Pol, CJ; Rajagopalan, V; Saunders, D; Towner, RA; Zhang, Y, 2016
)
0.43
" Compared to vehicle-treated MI, the oral T3-treated MI group at 2 mo had markedly improved anesthetized Magnetic Resonance Imaging-based LV ejection fraction and volumes without significant negative changes in heart rate, serum TH levels or heart weight, indicating safe therapy."( Safe Oral Triiodo-L-Thyronine Therapy Protects from Post-Infarct Cardiac Dysfunction and Arrhythmias without Cardiovascular Adverse Effects.
Balasubramanian, K; Chen, YF; Gerdes, AM; Ojamaa, K; Pingitore, A; Pol, CJ; Rajagopalan, V; Saunders, D; Towner, RA; Zhang, Y, 2016
)
0.43
"Low-dose oral T3 dramatically improved post-MI cardiac performance, decreased atrial arrhythmias and cardiac remodeling, and reversed many adverse changes in gene expression with no observable negative effects."( Safe Oral Triiodo-L-Thyronine Therapy Protects from Post-Infarct Cardiac Dysfunction and Arrhythmias without Cardiovascular Adverse Effects.
Balasubramanian, K; Chen, YF; Gerdes, AM; Ojamaa, K; Pingitore, A; Pol, CJ; Rajagopalan, V; Saunders, D; Towner, RA; Zhang, Y, 2016
)
0.43
"Thyroid hormone extract is used for the treatment of thyroid disorders, but limited data exist on adverse events commonly noted by the physicians associated with this use."( ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017
)
0.46
" Food and Drug Administration (FDA)'s reported adverse events for levothyroxine that would effectively assess the clinical experience of frequent prescribers of thyroid hormone."( ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017
)
0.46
"A total of 174 reports of adverse events occurring in patients on thyroid hormone extract were received."( ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017
)
0.46
"These adverse event reports should stimulate consideration by the FDA to regulate and monitor thyroid hormone extract use and consider standardizing these extracts to meet current standards of manufacture, hormone content, availability, and shelf-life, like the rigor with which preparations such as levothyroxine are monitored."( ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017
)
0.46
"AE = adverse event ATA = American Thyroid Association FDA = Food and Drug Administration LT3 = liothyronine LT4 = levothyroxine PTF = Pharmacovigilance Task Force T3 = triiodothyronine TSH = thyroid-stimulating hormone."( ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT.
Haugen, BR; Hennessey, JV; Levy, EG; Malabanan, A; Shrestha, RT, 2017
)
0.65
" This study aimed to evaluate whether thyroid hormones predicts early (30 days) and mid-term (12 months) aorta-related adverse events (ARAE) and readmissions (ARAR) in patients after TEVAR."( Association of Thyroid Function with Early/Mid-term Aorta-Related Adverse Events and Readmissions after Thoracic Endovascular Aortic Repair.
Chen, X; He, Z; Lu, N; Ma, X; Tan, X; Xu, T, 2017
)
0.46
"The optimal levothyroxine (LT4) dose to treat congenital hypothyroidism (CH) remains unclear, with debate over whether higher starting doses (>10 µg/kg) are necessary and safe for a normal intelligence quotient (IQ)."( Mean High-Dose l-Thyroxine Treatment Is Efficient and Safe to Achieve a Normal IQ in Young Adult Patients With Congenital Hypothyroidism.
Aleksander, PE; Blankenstein, O; Brückner-Spieler, M; Craig, ME; Ernert, A; Grüters, A; Krude, H; Kühnen, P; Lankes, E; Schnabel, D; Stäblein, W; Stoehr, AM, 2018
)
0.48
" Therefore, it is necessary to assess the toxic effects of those kind of industrial chemicals during liver development."( Establishment of a human embryonic stem cell-based liver differentiation model for hepatotoxicity evaluations.
Faiola, F; Liang, S; Yin, N, 2019
)
0.51
"Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)."( Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019
)
0.51
" This study investigated the effect of triiodothyronine (T3) to mitigate toxic effects of diazinon in the endangered Persian sturgeon (Acipenser persicus) eggs and embryos."( Triiodothyronine reduces toxic effects of diazinon in Persian sturgeon (Acipenser persicus) embryos.
Farahmand, H; Mojazi Amiri, B; Nazeri, S; Raine, JC, 2019
)
2.23
"Although triiodothyronine (T3) induces several beneficial effects on lipid metabolism, its use is hampered by toxic side-effects, such as tachycardia, arrhythmia, heart failure, bone and muscle catabolism and mood disturbances."( Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
Bellusci, L; Chiellini, G; Columbano, A; D'Amore, VM; Gul, S; Kowalik, MA; La Pietra, V; Marinelli, L; Novellino, E; Perra, A; Rapposelli, S; Runfola, M; Sestito, S, 2020
)
0.98
"The adverse effects of triphenyltin (TPT) on aquatic systems have attracted much attention because TPT is widely used and prevalent in aquatic environments."( Thyroid disruption and developmental toxicity caused by triphenyltin (TPT) in zebrafish embryos/larvae.
Chen, D; Li, Y; Ni, Z; Ru, H; Wu, L; Xiao, Z; Yao, F; Zhong, L, 2020
)
0.56
"73 µg T3 in 300 µl for 5 consecutive days had no clinically relevant T3-related adverse clinical, histopathologic, or clinical pathology findings."( A Preclinical Safety Study of Thyroid Hormone Instilled into the Lungs of Healthy Rats-an Investigational Therapy for ARDS.
Coicou, LG; Flory, CM; Ingbar, DH; Koniar, BL; Larson, NA; Mysz, MA; Norris, BJ; Rich, TP; Schumacher, RJ, 2021
)
0.62
" Hypothyroidism is an uncommon side effect of pomalidomide."( Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide.
Qureshi, A; Rhee, JH, 2021
)
0.62
" Regarding safety, adverse events were observed in 12/13 patients, but none discontinued treatment."( Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan.
Arima, H; Fujio, S; Matsushita, Y; Nakamura, A; Nishioka, H; Satoh, F; Shimatsu, A; Tahara, S; Takahashi, Y; Takano, K; Tateishi, S; Tominaga, A; Yamashita, M, 2021
)
0.62
"The cognitive adverse effects (AEs) of electroconvulsive therapy (ECT) limit the wider use of the treatment."( Reconsideration of the Benefits of Pharmacological Interventions for the Attenuation of the Cognitive Adverse Effects of Electroconvulsive Therapy.
Andrade, C, 2022
)
0.72
" These findings uncover WAT as a viable target mediating the therapeutic benefits of TH and provide a safe and efficient therapeutic strategy for obesity and its complications by delivering TH to adipose tissue."( Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects.
Chen, K; Cheong, LY; Feng, T; Gao, Y; Honoré, E; Hui, X; Jin, L; Lam, KSL; Wang, Q; Wang, W; Xu, A; Zhang, Y, 2022
)
1.06
" Liothyronine was tolerated well without treatment-related severe/serious adverse events or evidence of disease activation/clinical deterioration."( A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS.
Bhargava, P; Calabresi, PA; Cassard, SD; Cooper, DS; Fiol, J; Fitzgerald, KC; Mammen, JSR; Mowry, EM; Newsome, SD; Shoemaker, T; Snoops, S; Tian, F, 2023
)
0.91

Pharmacokinetics

No evidence was found for the importance of initial plasma levels of thyroxine or triiodothyronine on pharmacokinetic parameters of thiamazole.

ExcerptReferenceRelevance
" The estimated pharmacokinetic values of antipyrine (AP) in EP-infected goats were similar to those in the goats when healthy."( Effects of Ehrlichia phagocytophila infection on serum thyroid hormone concentrations and on antipyrine clearance and metabolite formation in dwarf goats.
Nijmeijer, SM; Offiah, VN; van Duin, CT; van Miert, AS; Witkamp, RF, 1992
)
0.28
"Some pharmacokinetic interactions between digoxin and amiodarone were studied in experiments on rabbits."( Effects of amiodarone on the pharmacokinetics and toxicity of digoxin in laboratory animals.
Kristeva, E; Staneva-Stoytcheva, D, 1991
)
0.28
" In six patients with hyperthyroidism and six patients with hypothyroidism, constant TRH infusions were carried out for determination of plasma clearance rate (PCR) and half-life of disappearance (t1/2) of TRH, with simultaneous determination of half-life of disappearance in serum in vitro (t1/2p)."( Pharmacokinetics of thyrotrophin-releasing hormone in patients in different thyroid states.
Iversen, E, 1991
)
0.28
" No evidence was found for the importance of initial plasma levels of thyroxine or triiodothyronine on pharmacokinetic parameters of thiamazole."( Pharmacokinetic parameters of thiamazole in hyperthyroid patients responding rapidly and slowly to the treatment.
Czekalski, S; Gawrońska-Szklarz, B; Syrenicz, A; Wójcicki, J,
)
0.36
"The performed studies covered 48 subjects, inhabiting the Western Pomerania, therein 40 patients with hyperthyroidism in the course of Graves-Basedow's disease (32 females and 8 males, aged 21-64 years) as well as 8 healthy individuals (5 females and 3 males, aged 23-36 years, with negative anamnesis towards thyroid diseases), who made up the control group at determining the pharmacokinetic parameters after a single oral dose containing 60 mg of thiamazole."( [Serum thyroxine and triiodothyronine levels after a single dose and after 2-month-long thiamazole treatment of Graves' disease with reference to drug's pharmacokinetics].
Syrenicz, A, 1990
)
0.6
" The half-life of 3,5,3'-triiodothyroacetic acid was 6 h 22 min +/- 29 min, the volume of distribution was 114 +/- 9 1/70 kg, and the plasma clearance rate was 298 +/- 141."( Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels.
Burger, AG; Juge, C; Menegay, C, 1989
)
0.28
" This study was designed to evaluate the pharmacokinetic basis of this interaction in 10 normal subjects."( Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
Fenster, PE; Hanson, CD; White, NW, 1985
)
0.27
" Experiments on thyroidectomized and T4 substituted rats have demonstrated as an additional pharmacodynamic effect of Lith."( Antihormonal effects of plant extracts. Pharmacodynamic effects of lithospermum officinale on the thyroid gland of rats; comparison with the effects of iodide.
Kemper, FH; Sourgens, H; Winterhoff, H, 1983
)
0.27
" Blood and urine samples for pharmacokinetic analysis were collected over a 24-hour period."( Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs.
Elfarra, AA; Hutson, PR; Panciera, DL; Vail, DM, 1994
)
0.29
"Twelve mature (5 sexually intact males, 4 castrated males, and 3 females) mixed-breed dogs were surgically thyroidectomized and used in a Latin-square design pharmacokinetic study of orally administered L-thyroxine."( Pharmacokinetics of L-thyroxine after its oral administration in dogs.
Hauptman, J; Nachreiner, RF; Pedersoli, WM; Ravis, WR; Refsal, KR; Rosser, EJ, 1993
)
0.29
" Following administration of exogenous triiodothyronine to saline- and cyclophosphamide-treated rats, the area under the plasma concentration time curve (AUC), apparent clearance (CLapp) and half-life of triiodothyronine were measured."( The effects of cyclophosphamide on the pharmacokinetics of triiodothyronine in the male rat.
Angley, MT; Sansom, LN; Smeaton, TC; Stupans, I, 1996
)
0.81
"To examine the pharmacokinetic profile of propranolol in cats before and during experimentally induced hyperthyroidism."( Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
Calvert, C; Ferguson, D; Jacobs, G; Sams, R; Whittem, T, 1997
)
0.3
" The calculated half-life of T(3) was 7 hours."( Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure.
Acosta, M; Capparelli, E; Mainwaring, RD; Nelson, JC; Schell, K, 2000
)
0.6
"The half-life of intravenous T(3) in children is approximately one-third of that reported for adults."( Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure.
Acosta, M; Capparelli, E; Mainwaring, RD; Nelson, JC; Schell, K, 2000
)
0.6
" We also discuss the different pharmacodynamic effects that iopanoic acid has on FT(3) and FT(4) levels."( Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis.
Falciglia, M; Matrka, L; Nikiforov, Y; Steward, D, 2008
)
0.35
" The aim of this study was to determine the pharmacokinetic parameters of LT4 in severely obese individuals and compared them with similar data in lean control subjects."( Impaired pharmacokinetics of levothyroxine in severely obese volunteers.
Faltaka, A; Gkotsina, MI; Kalfarentzos, F; Mamali, I; Markantes, GK; Markou, KB; Michalaki, MA; Vagenakis, AG, 2011
)
0.37
"Severely obese individuals may need higher LT4 suppressive or replacement doses than normal-weight individuals due, among other factors, to impaired LT4 pharmacokinetic parameters."( Impaired pharmacokinetics of levothyroxine in severely obese volunteers.
Faltaka, A; Gkotsina, MI; Kalfarentzos, F; Mamali, I; Markantes, GK; Markou, KB; Michalaki, MA; Vagenakis, AG, 2011
)
0.37
" The former can be determined through in vitro assays, and the latter is influenced by pharmacokinetic properties, along with environmental exposure levels."( Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-Throughput in vitro Data, High-Throughput Exposure Modeling, and Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.
El-Masri, H; Gilbert, M; Isaacs, K; Leonard, JA; Tan, YM, 2016
)
0.43

Compound-Compound Interactions

PTU alone and in combination with Li lowered serum T4, while a high level of T4 by its supplement was suppressed by co-administration of Li.

ExcerptReferenceRelevance
" Group A patients (n = 31) received either methimazole (40-100 mg daily) or propylthiouracil (400-900 mg daily) combined with T3 daily throughout treatment."( The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
Bromberg, N; Romaldini, JH; Sgarbi, JA; Werner, MC; Werner, RS, 1992
)
0.5
" Serum triiodothyronine (T3) and T4 by radioimmunoassay showed that PTU alone and in combination with Li lowered serum T4, while a high level of T4 by its supplement was suppressed by co-administration of Li."( Effect of lithium carbonate administration singly or in combination with some psychotropic drugs on the radioiodide uptake by mouse thyroid.
Akamatsu, S; Kamata, N; Kawada, J; Kurata, M; Kuwae, T; Minakuchi, K; Nishida, M; Takasugi, M; Teraoka, K, 1989
)
0.73
" There was no change in alpha MT6s excretion, and thus the previously reported potentiation of the efficacy of tricyclic antidepressants in combination with T3 does not appear to be mediated through an alteration in noradrenergic neurotransmission."( A study of the effects of desipramine treatment alone and in combination with L-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients.
Arendt, J; Bearn, J; Checkley, SA; Franey, C, 1989
)
0.5
" Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2- to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold)."( Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Baxter, RC; Bouillon, R; Bowers, CY; de Zegher, F; Lauwers, P; Schetz, M; Van den Berghe, G; Van der Vorst, E; Veldhuis, JD; Verwaest, C; Wouters, P, 1998
)
0.3
" This study evaluated the effect of DHEA or placebo combined with a low-fat/high-fiber diet in spontaneously obese dogs in a clinical trial."( The effect of dehydroepiandrosterone combined with a low-fat diet in spontaneously obese dogs: a clinical trial.
Kurzman, ID; MacEwen, EG; Miller, JB; Panciera, DL, 1998
)
0.3
"We studied the influence of TSH suppressive therapy combined with carbimazole (CBZ) on treatment outcome in Graves' disease."( TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates.
Baldet, L; Boegner, C; Bringer, J; Daurès, JP; Galtier-Dereure, F; Grabar, S; Jaffiol, C; Osman, A; Pujol, P; Raye, R, 1998
)
0.3
"TSH suppression combined with CBZ has little or no effect on remission and relapse rates in Graves' disease patients."( TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rates.
Baldet, L; Boegner, C; Bringer, J; Daurès, JP; Galtier-Dereure, F; Grabar, S; Jaffiol, C; Osman, A; Pujol, P; Raye, R, 1998
)
0.3
"The effects of 3,5',3'-triiodo-L-thyronine (T3; 10 or 100 ng ml(-1)), alone or combined with cortisol (500 ng ml(-1)), on the physiological properties of cultured pavement cell epithelia from freshwater rainbow trout gills were assessed."( The physiological effects of 3,5',3'-triiodo-L-thyronine alone or combined with cortisol on cultured pavement cell epithelia from freshwater rainbow trout gills.
Kelly, SP; Wood, CM, 2001
)
0.31
" Free T3 levels combined with concurrent TSH levels permit differentiation of mild hyperthyroidism from delayed pituitary recovery."( Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
Boudreau, C; Slyper, AH; Wyatt, D, 2005
)
0.56
"This study investigated the effect of non-ventilation of the incubator during the first 10 days of incubation and its combination with dexamethasone administration at day 16 or 18 of incubation on hatching parameters and embryo and post-hatch chick juvenile physiology."( Non-ventilation during early incubation in combination with dexamethasone administration during late incubation: 1. Effects on physiological hormone levels, incubation duration and hatching events.
Bruggeman, V; De Smit, L; Decuypere, E; Figueiredo, D; Onagbesan, O; Tona, K, 2007
)
0.34
" This study was designed to evaluate the effects of retinoic acid (RA)-pretreated Wharton's jelly mesenchymal stem cells (WJ-MSCs) in combination with triiodothyronine (T3) in the ischemia stroke model."( Retinoic acid-pretreated Wharton's jelly mesenchymal stem cells in combination with triiodothyronine improve expression of neurotrophic factors in the subventricular zone of the rat ischemic brain injury.
Akbari, M; Ataeinejad, N; Hassanzadeh, G; Kashani, IR; Moini, A; Mortezaee, K; Sabbaghziarani, F; Soleimani, M; Zendedel, A, 2017
)
0.88
" The first two groups were administered with distilled water and soya oil (1 ml/kg) respectively."( Taurine ameliorated thyroid function in rats co-administered with chlorpyrifos and lead.
Akande, MG; Shittu, M; Uchendu, C; Yaqub, LS, 2016
)
0.43
" The goal of this study was to evaluate the effectiveness of RIT combined with radiofrequency ablation (RFA) in patients with goitres and to determine which ablative procedure is the most suitable for a combined therapy."( Minimally invasive local ablative therapies in combination with radioiodine therapy in benign thyroid disease: preparation, feasibility and efficiency - preliminary results.
Ahmad, S; Gröner, D; Grünwald, F; Happel, C; Korkusuz, Y; Kranert, WT; Mader, A; Mader, OM, 2017
)
0.46
" We hypothesized that targeting HIF-1α alone or in combination with other metabolic regulators could promote the metabolic maturation of hiPSC-CMs."( Targeting HIF-1α in combination with PPARα activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived cardiomyocytes.
Brown, LA; Duan, M; Gentillon, C; Gibson, GC; Jha, R; Li, D; Preininger, MK; Qu, CK; Rampoldi, A; Saraf, A; Xu, C; Yu, WM, 2019
)
0.51
" The purpose of the present study was to investigate the effects on the thyroid gland of the bioindicator Podarcis siculus of OP alone and in combination with NP."( OctylPhenol (OP) Alone and in Combination with NonylPhenol (NP) Alters the Structure and the Function of Thyroid Gland of the Lizard Podarcis siculus.
De Falco, M; Di Lorenzo, M; Rosati, L; Sciarrillo, R; Valiante, S, 2021
)
0.62

Bioavailability

Triiodothyronine (T(3), formed chiefly by deiodination of T(4), is the active hormone at the nuclear receptor. Deiodination is the major pathway regulating T(3) bioavailability in mammalian tissues.

ExcerptReferenceRelevance
" This interaction may modulate their bioavailability and effectiveness."( N- and S-homocysteinylation reduce the binding of human serum albumin to catechins.
Arru, D; Carru, C; Cossu, A; Giordo, R; Mangoni, AA; Pintus, G; Posadino, AM; Scanu, B; Sotgia, S; Zinellu, A, 2017
)
0.46
" The decrease in the DR of T4 suggests a reduction in the bioavailability of L-T4 during propranolol, possibly due to a decrease in intestinal absorption."( Effect of propranolol on extrathyroidal metabolism of thyroxine and 3,3',5-triiodothyronine evaluated by noncompartmental kinetics.
Faber, J; Friis, T; Kirkegaard, C; Lumholtz, IB; Siersbaek-Nielsen, K, 1978
)
0.49
" Results from previous studies attempting to examine the comparative bioavailability of these formulations are difficult to interpret because of subject heterogeneity, single time-point blood sampling, varying degrees of hypothyroidism, and other factors."( A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine.
Berg, JA; Mayor, GH, 1992
)
0.28
" However, when the mass of gut wall in each segment is taken into account, absorption rate is highest at the duodenum and decreases distally."( Transport of the thyroid hormones across the feline gut wall.
Hays, MT; Hsu, L; Kohatsu, S, 1992
)
0.28
" By measuring the bioavailability of the earlier type of tablet in five patients, we inferred that the strength of the previous tablet had been overestimated."( Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans.
Bantle, JP; Cavanaugh, J; Fish, LH; Oppenheimer, JH; Schwartz, HL; Steffes, MW, 1987
)
0.48
" Because recent formulation changes have rendered these earlier data obsolete, we did a crossover study to determine differences in bioavailability of the two principal brands of thyroxine, Synthroid and Levothroid."( The equivalency of two L-thyroxine preparations.
Burman, KD; Hennessey, JV; Wartofsky, L, 1985
)
0.27
"The bioavailability of [125I]T4 or [3H]testosterone in serum obtained from normal subjects and from subjects with familial dysalbuminemic hyperthyroxinemia (FDH) was studied with a portal vein injection technique in ketamine-anesthetized rats."( Hepatic bioavailability of thyroxine and testosterone in familial dysalbuminemic hyperthyroxinemia.
Cefalu, WT; Pardridge, WM; Premachandra, BN, 1985
)
0.27
" At low luminal concentrations, under conditions where calcium is transported predominantly by active processes, the calcium absorption rate was reduced though not abolished in hyperthyroid patients (16 +/- 4 (SE) mumol/h ."( The defect of intestinal calcium transport in hyperthyroidism and its response to therapy.
Keck, E; Krüskemper, HL; Peerenboom, H; Strohmeyer, G, 1984
)
0.27
" To explore the bioavailability of circulating protein-bound thyroid hormones under steady state conditions in vivo, we altered serum thyroid hormone-binding proteins in rats by inducing nephrotic syndrome with puromycin aminonucleoside."( Low serum thyroxine and high serum triiodothyronine in nephrotic rats: etiology and implications for bioavailability of protein-bound hormone.
Burman, KD; Glass, AR; Pardridge, W; Rajatanavin, R; Smallridge, RC; Vigersky, RA; Wartofsky, L, 1984
)
0.54
" This approach appears to be useful in determining bioavailability of thyroid hormones from oral preparations and to assess the possibility of thyroid hormone malabsorption."( Bioavailability of thyroid hormones from oral replacement preparations.
Kaplan, MM; Larsen, PR; LeBoff, MS; Silva, JE, 1982
)
0.26
" Due to endogenic hormone production and regulation, it is impossible to determine the bioavailability of exogenic hormone using conventional trial designs since exogenic hormone cannot be distinguished from endogenic hormone in serum unless radiolabelled."( A new method for the determination of the bioavailability of thyroid hormone preparations.
Gegenheimer, L; Herzog, R; Lücker, PW; Trantow, T, 1994
)
0.29
" These results suggest ATP dependence of transport of iodothyronines into the liver in vivo and show that, in the rat liver and in humans, uptake of T4 may be regulated by intracellular energy stores; in this way the tissue uptake process may affect intracellular metabolism and bioavailability of thyroid hormone."( T4 uptake into the perfused rat liver and liver T4 uptake in humans are inhibited by fructose.
Bernard, BF; De Jong, M; Docter, R; Hennemann, G; Krenning, EP; van der Heijden, JT; van Toor, H, 1994
)
0.29
" A possible mechanism is the known effect of thyroid hormones in reducing the bioavailability of insulin-like growth factor-I."( Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man.
Grøfte, T; Jørgensen, JO; Møller, N; Vilstrup, H; Wolthers, T, 1996
)
0.55
"05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg)."( Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
Calvert, C; Ferguson, D; Jacobs, G; Sams, R; Whittem, T, 1997
)
0.3
"To compare relative bioavailability of Synthroid, Levoxine (Levoxine has been renamed Levoxyl), and 2 generic levothyroxine sodium preparations."( Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
Bubp, JL; Dong, BJ; Gambertoglio, JG; Gee, L; Greenspan, FS; Hauck, WW; White, JR, 1997
)
0.3
"The most probable cause of the inadequate TSH suppression in our patients was the reduction in bioavailability in certain batches of Levothroid, although we are unable to rule out the possibility that the results obtained after the changeover to Dexnon were due to its greater bioavailability."( Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
Almaraz, MC; Garriga, MJ; Gonzalez-Romero, S; Olveira, G; Ruiz de Adana, MS; Soriguer, F; Tinahones, F, 1997
)
0.3
" A fall in FT4 and FT3 combined with increase in TSH suggests a reduced bioavailability of T4 and T3 during tamoxifen treatment."( Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.
Aakvaag, A; Anker, GB; Lien, EA; Lønning, PE, 1998
)
0.3
"Insulin-like growth factor binding proteins (IGFBPs) modulate the actions and bioavailability of insulin-like growth factors (IGFs), however, their regulation in vivo is incompletely understood."( Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women.
Blum, WF; Brixen, K; Flyvbjerg, A; Kassem, M; Mosekilde, L, 1998
)
0.3
" The role of this uterine sulfotransferase activities in regulating the bioavailability of thyroid hormone in the developing fetus remains to be elucidated."( Iodothyronine sulfotransferase activity in rat uterus during gestation.
Fisher, DA; Florsheim, WH; Galton, VA; Huang, WS; St Germain, DL; Wu, SY, 2000
)
0.31
" Because of variable bioavailability of some levothyroxine preparations, designation of a specific high-quality brand is appropriate; TSH should be monitored to titrate the dose."( Hypothyroidism and women's health.
Redmond, GP,
)
0.13
" The enema form appeared to provide better bioavailability than the suppository form."( Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form.
Akarawut, W; Chailurkit, L; Chantasart, D; Jongjaroenprasert, W; Rajatanavin, R, 2002
)
0.31
" Therefore, high MTs may become to protective in young age to harmful during ageing leading to low zinc ion bioavailability for many body homeostatic mechanisms, including brain function."( Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform.
Cipriano, C; Gasparini, N; Giacconi, R; Mocchegiani, E; Muzzioli, M; Orlando, F, 2003
)
0.32
" Each levothyroxine preparation must comply with FDA standards for bioavailability but may vary with respect to its dissolution and absorption properties and are not interchangeable."( Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease.
Danzi, S; Klein, I, 2003
)
0.32
" D2 and D3 play important roles in the local bioavailability of T(3)."( Iodothyronine levels in the human developing brain: major regulatory roles of iodothyronine deiodinases in different areas.
Howatson, A; Hume, R; Kester, MH; Marinkovic, D; Martinez de Mena, R; Morreale de Escobar, G; Obregon, MJ; Visser, TJ, 2004
)
0.32
" Triiodothyronine (T(3)), formed chiefly by deiodination of T(4), is the active hormone at the nuclear receptor, and it is generally accepted that deiodination is the major pathway regulating T(3) bioavailability in mammalian tissues."( Alternate pathways of thyroid hormone metabolism.
Chopra, IJ; Green, WL; Hays, MT; Huang, WS; Wu, SY, 2005
)
1.24
" administration, the value of the area under the blood concentration-time curve from 0 to 24 hr and the bioavailability of CyA in the LTX group were decreased to only about one-fifth and a quarter of those in the control group, respectively."( Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.
Jin, M; Miyamoto, K; Nomura, M; Shimada, T; Shintani, M; Yokogawa, K, 2005
)
0.33
" The bioavailability of the Levothyroxine sodium tablet formulation THYROHORMONE/Ni-The Ltd (0."( A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.
Benakis, A; Koukoulis, G; Lyberi, S; Potamianos, S; Pouli, A; Savari, E; Stefanidis, I; Triposkiadis, F; Yannovits, N; Zartaloudis, E; Zintzaras, E,
)
0.13
" Deiodinase enzymes are important in determining the bioavailability of thyroid hormones: deiodinases D1 and D2 convert T4 to T3, whereas deiodinase D3 inactivates T3 and produces rT3 from T4."( Developmental control of iodothyronine deiodinases by cortisol in the ovine fetus and placenta near term.
Curtis, K; Forhead, AJ; Fowden, AL; Kaptein, E; Visser, TJ, 2006
)
0.33
" Changes in T(3) bioavailability may mediate some of the maturational effects of antenatal glucocorticoid treatment in the preterm fetus."( Differential effects of maternal dexamethasone treatment on circulating thyroid hormone concentrations and tissue deiodinase activity in the pregnant ewe and fetus.
Forhead, AJ; Fowden, AL; Gardner, DS; Giussani, DA; Jellyman, JK; Kaptein, E; Visser, TJ, 2007
)
0.34
"To evaluate the relative bioavailability of T4 sodium and liothyronine sodium (T3), administered in single doses as oral solution (drops) and tablet forms, according to two separate study protocols."( Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers.
Drago, F; Incognito, T; Leggio, GM; Marano, MR; Privitera, G, 2006
)
0.33
"The bioavailability of the two oral solutions (T4-Ibsa and T3-Ibsa oral solutions) and the corresponding tablet forms (Eutirox 100 and Ti-tre tablets) were confirmed and they can be considered bioequivalent and therapeutically interchangeable."( Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers.
Drago, F; Incognito, T; Leggio, GM; Marano, MR; Privitera, G, 2006
)
0.33
"L-Carnitine plays an important role in skeletal muscle bioenergetics, and its bioavailability and thus its import may be crucial for muscle function."( Hormonal and nutritional control of L-carnitine uptake in myoblastic C2C12 cells.
Demarquoy, J; Georges, B; Le Borgne, F; Rigault, C, 2008
)
0.35
" Because of the low oral bioavailability of PA 22c, a series of prodrugs was synthesized and screened for oral efficacy in the CFR assay."( Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
Boyer, SH; Cable, EE; Erion, MD; Fujitaki, JM; Godwin, JL; Hecker, SJ; Hou, J; Jacintho, JD; Jiang, H; Li, H; Li, W; Reddy, MV; Schulz, WG; Wu, R, 2008
)
0.35
"An investigation was conducted to study insulin-like growth factor (IGF)-I, IGF-II, insulin, glucagon, leptin, triiodothyronine (T(3)), and thyroxine (T(4)) levels in a chicken population divergently selected for P bioavailability (PBA)."( Physiological responses to divergent selection for phytate phosphorus bioavailability in a randombred chicken population.
Aggrey, SE; Edwards, HM; McMurtry, JP; Pesti, GM; Sethi, PK, 2008
)
0.56
" We postulate that altered TH bioavailability to trophoblasts may contribute to the pathogenesis of IUGR."( Differential triiodothyronine responsiveness and transport by human cytotrophoblasts from normal and growth-restricted pregnancies.
Chan, SY; Franklyn, JA; Kilby, MD; Loubière, LS; Martín-Santos, A; McCabe, CJ; Vasilopoulou, E, 2010
)
0.73
" This newly demonstrated enzymatic activity identifies a new role for thyroid hormones in regulating mammalian amino acid metabolism, and a possible reciprocal role of enzyme activity regulating bioavailability of intracellular T3."( Mammalian forebrain ketimine reductase identified as μ-crystallin; potential regulation by thyroid hormones.
Cooper, AJ; Hallen, A; Haynes, PA; Jamie, JF; Willows, RD, 2011
)
0.37
" The presence of both deiodinases in WAT suggests important roles in regulating T3 bioavailability for adipose tissue function and regulation of lipid metabolism and thermogenesis."( Presence and regulation of D1 and D2 deiodinases in rat white adipose tissue.
Calvo, RM; Obregon, MJ, 2011
)
0.37
" Considering that levothyroxine sodium is classified as Class III drug according to the Biopharmaceutics Classification System, drug bioavailability will be less sensitive to the variation in its dissolution characteristics and it can be assumed that the differences observed in vitro in some of investigated media probably do not have significant influence on the absorption process, as long as rapid and complete dissolution exists."( An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.
Dacevic, M; Homsek, I; Kocic, I; Miljkovic, B; Parojcic, J, 2011
)
0.37
" Applying the same concept as bioidentical hormone replacement therapy, compounding pharmacists can deliver an 11:1 ratio using a commercial T4 product and taking into account oral bioavailability of each entity."( Bioidentical thyroid replacement therapy in practice: Delivering a physiologic T4:T3 ratio for improved patient outcomes with the Listecki-Snyder protocol.
Listecki, RE; Snyder, S,
)
0.13
"Thyroxine (T4) administration is advocated in the management of organ donors; however, the bioavailability of oral thyroxine is unknown in this patient population."( Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study.
Haddara, W; Sharpe, MD; van Rassel, B, 2013
)
0.39
" Oral bioavailability of T4 was 93% of the intravenous group at six hours and 91% overall."( Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study.
Haddara, W; Sharpe, MD; van Rassel, B, 2013
)
0.39
"Orally administered T4 is well absorbed and achieves a bioavailability of approximately 91-93% of intravenous T4 in organ donors."( Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study.
Haddara, W; Sharpe, MD; van Rassel, B, 2013
)
0.39
" An association of thyroid dysfunctions with reduced bioavailability of NO and alterations of ADMA levels could be established."( Treatment with the nitric oxide donor SNP increases triiodothyronine levels in hyper- and hypothyroid Sprague-Dawley rats.
Ainoedhofer, H; Bernecker, C; Gruber, HJ; Kieslinger, P; Pailer, S; Ragginer, C; Truschnig-Wilders, M, 2013
)
0.64
" Their bioavailability in utero depends on development of the fetal hypothalamic-pituitary-thyroid gland axis and the abundance of thyroid hormone transporters and deiodinases that influence tissue levels of bioactive hormone."( Thyroid hormones in fetal growth and prepartum maturation.
Forhead, AJ; Fowden, AL, 2014
)
0.4
"Myocardial infarction leads to a reduction in nitric oxide (NO) bioavailability and an increase in reactive oxygen species (ROS) levels."( T3 and T4 decrease ROS levels and increase endothelial nitric oxide synthase expression in the myocardium of infarcted rats.
Belló-Klein, A; Campos, C; Conzatti, A; da Rosa Araujo, AS; de Castro, AL; Fernandes, RO; Fernandes, TR; Llesuy, S; Sartório, CL; Schenkel, PC; Siqueira, R; Tavares, AV, 2015
)
0.42
" In conclusion, TH effects seem to involve a modulation of eNOS expression and an improvement in NO bioavailability in the infarcted heart."( T3 and T4 decrease ROS levels and increase endothelial nitric oxide synthase expression in the myocardium of infarcted rats.
Belló-Klein, A; Campos, C; Conzatti, A; da Rosa Araujo, AS; de Castro, AL; Fernandes, RO; Fernandes, TR; Llesuy, S; Sartório, CL; Schenkel, PC; Siqueira, R; Tavares, AV, 2015
)
0.42
"05) feed intake and egg production; however, Se bioavailability decreased (P<0."( Evaluation of the toxicity of selenium from hydroponically produced selenium-enriched kale sprout in laying hens.
Borisuth, L; Chantiratikul, A; Chantiratikul, P; Chinrasri, O; Chookhampaeng, S; Saenthaweesuk, N; Sriart, N; Thosaikham, W, 2016
)
0.43
" In this research for the first time we have assessed the bioavailability of iodine from raw or cooked carrot biofortified with this trace element on iodine concentration in selected tissues and various biochemical parameters as well as mRNA expression of some genes involved in iodine metabolism in Wistar rats."( The Impact of Carrot Enriched in Iodine through Soil Fertilization on Iodine Concentration and Selected Biochemical Parameters in Wistar Rats.
Bieżanowska-Kopeć, R; Kapusta-Duch, J; Kopeć, A; Koronowicz, AA; Ledwożyw-Smoleń, I; Maślak, E; Piątkowska, E; Pysz, M; Rakoczy, R; Skoczylas, Ł; Smoleń, S, 2016
)
0.43
" Many proteins are involved with regulation of TH bioavailability in the brain: the TH distributor protein transthyretin (TTR), TH transmembrane transporters (e."( The affinity of transthyretin for T
Darras, VM; Delbaere, J; McAllan, BM; Richardson, SJ; Van Herck, S, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Today it still remains unclear whether the change in the bioavailability of thyroid hormones in the myocardium is a favorable physiological mechanism or a replication of an adaptation disorder."( [Use of thyroid hormones in the treatment of cardiovascular diseases: literature review].
Borisov, DV; Gubaeva, DN; Praskurnichiy, EA, 2020
)
0.56
" T3 quantifications in the exposure media indicated adsorption of the hormone on GBMs, increasing its bioavailability for organisms because GBMs are accumulated in the gut and the gills of these amphibians."( Graphene oxide and reduced graphene oxide promote the effects of exogenous T3 thyroid hormone in the amphibian Xenopus laevis.
Evariste, L; Flahaut, E; Gauthier, L; Mottier, A; Mouchet, F; Pinelli, E, 2021
)
0.62
" Microplastics (plastic particles < 5 mm) and nanoplastics (plastic particles < 100 nm) can interact with organic pollutants already present in the aquatic environment, potentially acting as carriers for pollutants entering organisms and thus influencing the bioavailability and toxicity of those pollutants."( Parental transfer of nanopolystyrene-enhanced tris(1,3-dichloro-2-propyl) phosphate induces transgenerational thyroid disruption in zebrafish.
Duan, X; Liu, Z; Ren, X; Zhao, X, 2021
)
0.62
" Their bioavailability is determined by specific transporter proteins at the cell surface."( The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice.
Bassett, JHD; Heuer, H; Hofbauer, LC; Lademann, F; Leitch, VD; Mayerl, S; Rauner, M; Tsourdi, E; Verrey, F; Williams, GR, 2022
)
0.72
" Most respondents prescribed L-T4 tablets and did not expect any major changes with alternative formulations such as soft-gel capsules or liquid formulations in situations influencing the bioavailability of L-T4."( Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society.
Attanasio, R; Hegedüs, L; Lantz, M; Nagy, EV; Papini, E; Perros, P; Planck, T, 2021
)
0.62

Dosage Studied

Triiodothyronine in the studied dosage and formulation was safe but not more effective than placebo. The Bayesian kernel machine regression (BKMR) and restricted cubic spline (RCS) models showed a U-shaped dose-response relationship between bisphenol A (BPA) and free triiodothyronsine (FT3) (p < 0.5)

ExcerptRelevanceReference
" In all the RIAs, the dose-response curves obtained on delayed addition by 24 to 48 h of labeled antigens (curves B), were shifted downwards and to the left of those obtained on simultaneous addition of the reagents (curves A), resulting in improved sensitivity of the assay."( Kinetic aspects of the antigen-antibody reaction in various radioimmunoassays: effect of delayed addition of labeled or unlabeled antigens on sensitivity of assay.
Azukizawa, M; Ichihara, K; Miyai, K; Yamamoto, T, 1979
)
0.26
" The first group received metizol (thiamazol) in a daily dosage of 60 mg, the second group lithium carbonate (1."( [Short-term use of lithium carbonate in the treatment of thyrotoxicosis].
Jonderko, G; Marcisz, C, 1979
)
0.26
" It is suggested that a depletion of pituitary TSH and Prl stores readily secretable in response to a constant dosage level of TRH may be responsible for the secretory patterns observed."( Thyrotropin and prolactin secretory patterns during 24-hours infusion of thyrotropin-releasing hormone in calves.
Anfinson, MS; Davis, SL; Klindt, J; Ohlson, DL, 1978
)
0.26
" The hypothalamus was completely unaffected by similar treatment and the uterus responded with decreased receptor level only at the highest dosage used."( Modulation by thyroid hormones of cytoplasmic estrogen receptor concentrations in reproductive tissues of the rat.
Cidlowski, JA; Muldoon, TG, 1975
)
0.25
" The dichotomy in the dose-response pattern between the two parameters indicated that the effect of high TSH concentrations on the release was induced at a step beyond cAMP accumulation."( The mechanism of damping of the serum thyroxine and triidothyronine levels caused by increasing thyrotropin dosage in mice.
Gafni, M; Gross, J; Saddok, C; Sirkis, N, 1977
)
0.26
" The dosage should be adapted to the age of the patient the duration of the course of the hypothyroidism and the state of the heart."( [Surveillance of hypothyroidism treatment].
Jenny, M, 1977
)
0.26
" The 24-h dose-response studies were used to generate R as a continuous function of q, both in hypothyroid as well as in euthyroid animals."( Nonlinear (amplified) relationship between nuclear occupancy by triiodothyronine and the appearance rate of hepatic alpha-glycerophosphate dehydrogenase and malic enzyme in the rat.
Coulombe, P; Gutfeld, NW; Oppenheimer, JH; Schwartz, HL, 1978
)
0.5
" A dose-response study indicated that high doses of T4 may stimulate Mg++ activated ATPase."( Effects of thyroxine treatment on the hepatic plasma membrane ATPase activity in rats.
Berdanier, CD; Ecklund, RE; Tobin, RB,
)
0.13
" L-T4 dosage was increased or decreased by 25 or 50 mug/day at 2-12 mo."( Age-related change in pituitary threshold for TSH release during thyroxine replacement therapy for cretinism.
Ishiguro, K; Nakajima, H; Sato, T; Suzuki, Y; Taketani, T, 1977
)
0.26
" After a dosage of 6 mg DT4 the D/L T4 plasma concentration rose about 4-fold 4 hours after application and was only moderately elevated 14 hours later."( Influence of D-thyroxine on plasma thyroid hormone levels and TSH secretion.
Gless, KH; Hüfner, M; Oster, P, 1977
)
0.26
" This difference was observed when thyrotropin was given intraperitoneally or intravenously and the slope of the dose-response curves to TRH showed a flattening of the curve of rats treated with ether and a steeper slope of response in animals anesthetized with pentobarbital."( Effects of ether and pentobarbital anesthesia on thyroid function in the rat.
Bray, GA; Ohtake, M, 1977
)
0.26
" Iobenzamic acid, tyropanoic acid, iopanoic acid, and ipodate sodium, in a dosage of 3 g for 3 days, respectively, induced a significant decrease in serum T3 and an increase in rT3 within 24 h after the initial dose, followed by an increase in TSH and a slight increase in T4."( Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-thyroid axis.
Kadena, N; Nakagawa, S; Suzuki, H; Takeuchi, K, 1979
)
0.26
" Heart rates, left ventricular isovolumic pressure (P) and dP/dt were recorded, and concentration dose-response curves to NA were constructed."( Lack of acute effect of triiodothyronine on noradrenaline responses of isolated sympathectomized cat hearts.
Brandt, U; Carlsson, E; Wahlberg, P, 1977
)
0.56
" The physiopathogenetic bases for this are examined in relation to dosage and early diagnosis."( [Radiotherapy with 131J and 125J of Basedow's disease. Indications and results relative to the incidence of post-actinic hypothyroidism].
Biagioli, R; Dradi, C; Riceputi, G; Riva, P, 1979
)
0.26
" The T4 level, because it is low whether symptoms are present or not, may inadvertently suggest the need for higher dosage of desiccated thyroid in patients who have already received adequate replacement."( Why does anyone still use desiccated thyroid USP?
Cobb, WE; Jackson, IM, 1978
)
0.26
" The diminished uterine response is not due to a shift in the dose-response curve for E2, but results from a decrease in the magnitude of the maximum uterine response."( Regulation of the uterine response to estrogen by thyroid hormone.
Gardner, RM; Ireland, JS; Kirkland, JL; Stancel, GM, 1978
)
0.26
" The dosage was individually calculated according to the radioiodine uptake, the thyroid weight and the effective half life time of the radioiodine in the thyroid."( [Treatment of thyrotoxicosis with 125-iodine: results in 93 patients 3 to 5 years after treatment, and comparison with 131-iodine therapy (author's transl)].
Glanzmann, Ch; Horst, W, 1979
)
0.26
"A thyroid hormone analogue, sodium dextro-triiodothyronine (NaDT3), at a dosage of 1 mg/day for 1 or 2 yr, decreased serum cholesterol levels about 30% in 26 hyperlipidemic adults."( Thyroid hormone-like effects without thyrotoxicosis during one year's therapy with NA-DT3 for hypercholesterolemia.
Ahmad, U; Bowman, DH; Danowski, TS; Fisher, ER; Nolan, S; Stephan, T; Sunder, JH; Wingert, JP, 1976
)
0.52
" In patients with a high TSH despite being clinically euthyroid, the use of thyroid extract in low dosage (50 mg/day) would appear to be desirable in avoiding the subsequent development of hypothyroidism."( [Biological changes in 88 cases of Basedow's disease treated by radioactive iodine].
Brunelle, P; Courtois, H; Nouel, JP; Poirier, A; Schrub, JC; Segond, G, 1976
)
0.26
" As a control group, six patients with primary hypothyroidism received gradually increasing doses of L-T4 for 4-week periods, and TSH response to TRH was tested at the end of each dosage of L-T4, until complete inhibition of TSH release was obtained."( Low setting of feedback regulation of TSH secretion by thyroxine in pituitary dwarfism with TSH-releasing hormone deficiency.
Ishiguro, K; Isumisawa, A; Sato, T; Suzuki, Y; Taketani, T, 1976
)
0.26
" present the recent progresses reached in the Endocrinology diagnostic with the aid of the radioisotopic techniques; successively they refer about the principles regulating the chemical reactions used in the dosage of the single hormones and about the use of index interesting the clinical practice."( [Use of radioisotope technics for determination of thyroid hormones. Research on blood and urine].
D'Amore, F; Guarino, A; Meo, S, 1975
)
0.25
" In the latter group of patients, an increase of the T3 dosage inhibited the TSH response to TRH."( TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.
Bui, F; Busnardo, B; Girelli, ME; Lazzi, C; Vagelista, R, 1976
)
0.26
"A double-blind investigation of the psychological and hormonal responses to orally administered thyrotropin-releasing hormone (TRH) in a dosage range of 200 to 300 mg daily was conducted in a group of 11 depressed patients hospitalized for an initial 10-day period and followed as outpatients for the balance of a 30-day period of observation."( Therapeutic failure of oral thyrotropin-releasing hormone in depression.
Adrian, AD; Kiely, WF; Lee, JH; Nicoloff, JT,
)
0.13
" When changing from the combined thyroid hormone therapy to treatment with L-thyroxine alone it is enough in most cases to replace the previous amount of L-thyroxine only; previous recommendations for the dosage of thyroid hormone were rather high."( [More recent aspects of treatment for hypothyroidism and goitre in children and adolescents (author's transl)].
Kuhn, N; Stahnke, N; Wiebel, J; Willig, RP, 1976
)
0.26
" The dose-response curve for the thyroid gland factor was not parallel to that obtained using PTH and secretion was not under calcium control."( Secretion of a bone resorbing factor by chick thyroid glands in organ culture.
Feinblatt, JD; Leone, RG; Tai, LR, 1976
)
0.26
" Serial dilutions of hyperthyroid sera gave dose-response curves which were parallel to the rT3 standard curve."( Measurement of serum 3,3',5'-(reverse) T3, with comments on its derivation.
Black, EG; Griffiths, RS; Hoffenberg, R, 1976
)
0.26
"After a brief outline of the physiology of the thyroid hormones and the laboratory tests measuring thyroid function, the dosage of normalised T4 (T4N) in patients suffering from various thyroid diseases and subjected to surgical operation is discussed."( [In vitro thyroid diagnosis in surgery of the thyroid].
Califano, G; Celentano, L; D'Armiento, M; Gravina, E, 1976
)
0.26
" The degradation of T 4 at high dosage is quicker than at lower dosage."( [Absorption and pharmacokinetics of large doses of 1-thyroxine in man (author's transl)].
Fill, H; Obendorf, L; Riccabona, G; Zechmann, W, 1975
)
0.25
" The dosage is made in the presence of 600 mug (micrograms) of Merthiolate in all tubes, in order to inhibit a link between the T3 and the vector proteins, and of HSA in the standards to keep them in the same condition as the samples."( [Direct radioimmunologic determination of T 3 in the serum].
Galbiati, A, 1975
)
0.25
" Evidence of parallelism and even superimposition is provided for both assays between the dose-response curve and the serum dilution curve."( [Radioimmunologic determination of plasmatic triiodothyronine. Verification of operative parameters; 1st clinical results].
Dotti, C, 1975
)
0.51
" The abundance of mitochondrial DNA was unaltered despite the observed changes in mitochondrial transcripts, indicating that mitochondrial gene expression is regulated by transcriptional mechanisms and not by gene dosage as has been postulated by others."( Regulation by thyroid hormone of nuclear and mitochondrial genes encoding subunits of cytochrome-c oxidase in rat liver and skeletal muscle.
Kurowski, TT; Wiesner, RJ; Zak, R, 1992
)
0.28
" Lower dosage of L-thyroxine (50-100 micrograms daily) was required to attain euthyroid state in some patients with postoperative or postradiation hypothyroidism."( [Monitoring of treatment for hypothyroidism with L-thyroxine].
Horst-Sikorska, W; Kosowicz, J; Zamysłowska, H, 1992
)
0.28
" Dose-response to T3, and the relative responses to its active and inactive analogs, confirmed that the process of autoinduction was initiated by thyroid hormone receptor with the same functional characteristics as that found in all amphibian and mammalian tissues."( Autoinduction of thyroid hormone receptor during metamorphosis is reproduced in Xenopus XTC-2 cells.
Machuca, I; Tata, JR, 1992
)
0.28
" Data were analyzed by using information on dose, time after dosing, commercial product, and once-a-day or twice-a-day dosing regimens."( Radioimmunoassay monitoring of thyroid hormone concentrations in dogs on thyroid replacement therapy: 2,674 cases (1985-1987).
Nachreiner, RF; Refsal, KR, 1992
)
0.28
" The brown adipose tissue enzyme T4 5'-deiodinase demonstrated an increased activity in the presence of NMDA, with the lowest dosage eliciting the most significant effect."( N-methyl-D-aspartate does not prevent effects of melatonin on the reproductive and thyroid axes of male Syrian hamsters.
Hoover, PA; Little, JC; Reiter, RJ; Vaughan, MK, 1992
)
0.28
" For patients with subnormal TSH concentration a close follow-up is obligatory and in case od concomitantly raised free-thyroxine level the reduction of the levothyroxine dosage is proposed."( Biologic markers in blood reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Bános, C; Büki, B; Földes, J; Németh, J; Tarján, G; Varga, F, 1992
)
0.28
" The dose-response curves of inhibition of binding of [125I]T3S to anti-T3S antibody by serial dilutions of serum extracts were essentially parallel to the standard curve."( A radioimmunoassay for measurement of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life.
Chopra, IJ; Santini, F; Teco, GN; Wu, SY, 1992
)
0.54
" Dose-response curves for the two calibrators in 'common' matrices were similar to one another and to those for the kit calibrator."( The effects of common matrices for assay standards on performance of 'ultra sensitive' immunometric assays for TSH. Report of a joint WHO/IFCC collaborative study.
Brettschneider, H; Bristow, AF; Gaines-Das, RE, 1991
)
0.28
" For patients with subnormal TSH concentration a close follow-up is obligatory and in case of concomitantly raised free-thyroxine level the reduction of the levothyroxine dosage is proposed."( Biologic blood markers reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Bános, C; Büki, B; Földes, J; Németh, J; Tarján, G; Varga, F, 1991
)
0.28
" However, thyroid hormone potentiates, by one order of magnitude, the dose-response effect of retinoic acid in HL-60 cells."( Stimulatory effect of thyroid hormone on RA-induced granulocytic differentiation in leukemic cells.
Balitrand, N; Ballerini, P; Chomienne, C; Lenoble, M; Najean, Y; Schaison, G, 1991
)
0.28
" The aim of the present study was to examine the apparently very steep dose-response relationship between elevated plasma TSH and thyroid vascular C/mass."( Thyroid vascular conductance: differential effects of elevated plasma thyrotropin (TSH) induced by treatment with thioamides or TSH-releasing hormone.
Chang, BS; Connors, JM; Dey, RD; Hedge, GA; Huffman, LJ; Michalkiewicz, M, 1991
)
0.28
"The aim of this work was to determine the optimum dosage of L-thyroxine (L-T4) given to infants with congenital hypothyroidism (CH)."( [Congenital hypothyroidism. Therapeutic strategy at the early stage of treatment].
Czernichow, P; Léger, J; Touati, G,
)
0.13
"We have examined the effects of triiodothyronine (T3), in dose-response and time-course studies, on T3 receptor (T3R) alpha and beta and glucocorticoid receptor (GR) mRNAs in rate pituitary GH3 cells, in parallel with T3 actions on expression of the growth hormone (GH) target gene."( Thyroid hormone and glucocorticoid regulation of receptor and target gene mRNAs in pituitary GH3 cells.
Franklyn, JA; Sheppard, MC; Williams, GR, 1991
)
0.56
" The dose-response curves for both agonists were shifted to the left in the hypothyroid rats compared to water-treated controls."( The hypothyroid rat as a model of increased sensitivity to dopamine receptor agonists.
Cameron, DL; Crocker, AD, 1990
)
0.28
" Dose-response experiments were carried out in order to obtain insight into the sensitivity of the observed effects."( Effects of hexachlorobenzene and its metabolites pentachlorophenol and tetrachlorohydroquinone on serum thyroid hormone levels in rats.
Bragt, PC; Engel, R; Notten, WR; van den Berg, KJ; van Raaij, JA, 1991
)
0.28
" This study suggests: 1) oral absorption of l-T4 is variable, but clinical response occurs quickly even in myxoedema ileus; 2) the intravenous route involves high peaks of plasma T4 and T3; 3) peripheral conversion of T4 to T3 allows gradually T3 delivery to organ systems, even if only l-T4 is used and 4) initial and daily dosage determinations need further studies."( Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment.
Arlot, S; Debussche, X; Fournier, A; Lalau, JD; Mesmacque, A; Quichaud, J; Tolani, M, 1991
)
0.28
" In 9 normal rabbit hearts a cumulative dose-response curve with logarithmically increasing doses of T3 was obtained."( Triiodothyronine-enhanced left ventricular function after ischemic injury.
Abd-Elfattah, A; Ding, M; Dyke, CM; Lehman, JD; Salter, DR; Wechsler, AS; Yeh, T, 1991
)
1.72
" In older pigs (15 weeks) neither the content of goitrogens nor the I dosage affected the serum T4 level."( Effect of varying glucosinolate and iodine intake via rapeseed meal diets on serum thyroid hormone level and total iodine in the thyroid in growing pigs.
Groppel, B; Hennig, A; Jahreis, G; Lange, R; Lüdke, H; Schöne, F; Seffner, W, 1990
)
0.28
" Thyroid-stimulating hormone exhibited a dose-response decline that was accompanied by a similar decrease in serum thyroid hormone levels."( Chlordimeform-induced alterations in endocrine regulation within the male rat reproductive system.
Cooper, RL; Edwards, TL; Goldman, JM; Hein, JF; Laws, SC; McElroy, WK; Rehnberg, GL, 1990
)
0.28
" Levothyroxine was added to the baseline medication regimen, and the dosage was increased until clinical response occurred or until side effects precluded further increase."( Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.
Bauer, MS; Whybrow, PC, 1990
)
0.28
" The involvement of insulin in the regulation of sulfatide synthesis was further confirmed by dose-response curves relating the activity of CST to hormone concentration in the medium."( Comparison of the mechanisms of action of insulin and triiodothyronine on the synthesis of cerebroside sulfotransferase in cultures of cells dissociated from brains of embryonic mice.
Besnard, F; Ferret-Sena, V; Fressinaud, C; Rebel, G; Sarliève, LL; Sena, A, 1990
)
0.53
" The hGH-CAT expression was specifically inhibited by T3 following a typical dose-response curve while hGH-GH gene expression was not significantly modified."( Triiodothyronine inhibits transcription from the human growth hormone promoter.
Belayew, A; Louette, J; Martial, JA; Morin, A; Tixier-Vidal, A; Voz, ML, 1990
)
1.72
" The test was performed by first collecting blood samples for basal serum T4 and T3 determinations, administering liothyronine at an oral dosage of 25 micrograms three times daily for seven doses, and, on the morning of the third day, again collecting serum samples for T4 and T3 determinations 2 to 4 hours after the seventh dose of liothyronine."( Triiodothyronine (T3) suppression test. An aid in the diagnosis of mild hyperthyroidism in cats.
Gamble, DA; Graves, TK; Peterson, ME,
)
1.57
" The dose producing a 35% decrease in sGaw (PD35) was determined from the cumulative log dose-response curve by linear regression analysis."( Effects of hypothyroidism on bronchial reactivity in non-asthmatic subjects.
Hombach, V; Keck, FS; Schäuffelen, AC; Seibold, H; von Beauvais, H; Wieshammer, S, 1990
)
0.28
" Within the wide dose-response range for nuclear occupancy a spectrum of biological responses are regulated by distinct thyroid hormone dose ranges."( L-triiodothyronine (T3) regulates cellular growth rate, growth hormone production, and levels of nuclear T3 receptors via distinct dose-response ranges in cultured GC cells.
Halperin, Y; Shapiro, LE; Surks, MI, 1990
)
1
" Each patient received 25 microCi [125I]rT3, iv, in the high T4 state and on day 3 of each IA dosing regimen."( Does a hidden pool of reverse triiodothyronine (rT3) production contribute to total thyroxine (T4) disposal in high T4 states in man.
Anderson, KP; LoPresti, JS; Nicoloff, JT, 1990
)
0.57
" Furthermore, the slope of the dose-response curves for systolic (2."( Decreased sensitivity to alpha-adrenergic stimulation in hypothyroid patients.
Kennedy, B; Nicod, P; Polikar, R; Smith, J; Ziegler, M, 1990
)
0.28
" The dose-response curves to increasing doses of "Substance P" showed in hyperthyroid animals increased salivary secretion while in hypothyroid animals the dose-response curve to the drug was decreased."( Influence of thyroid function upon "Substance P" induced secretion of saliva by submaxillary glands.
Houssay, AB; Paz, Cdel V; Sosto, NE; Tumilasci, OR; Varela, V, 1986
)
0.27
" These findings indicate that high free thyroxine levels and the presence of antibodies that inhibit binding of thyrotropin are useful indexes of the fetal need for antithyroid treatment, and that the thionamide dosage that maintains maternal free thyroxine levels in a mildly thyrotoxic range seems appropriate for maintaining euthyroid status in the fetus."( Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status.
Ishikawa, N; Ito, K; Momotani, N; Noh, J; Oyanagi, H, 1986
)
0.27
" That this increase in [3H]uridine transport was nuclear receptor-mediated is supported by the excellent correspondence of the L-T3 dose-response curve for [3H]uridine uptake and that for L-T3 binding to receptor."( Stimulation of facilitated [3H]uridine transport by thyroid hormone in GH1 cells. Evidence for regulation by the thyroid hormone nuclear receptor.
Samuels, HH; Stanley, F; Tsai, JS, 1986
)
0.27
"" The prescribed dosage of levothyroxine as therapy for hypothyroidism is still frequently excessive."( Evidence of hyperthyroidism in apparently euthyroid patients treated with levothyroxine.
Banovac, K; Bilsker, MS; McKenzie, JM; Papic, M; Zakarija, M, 1989
)
0.28
" The dose-response effect for TSH was studied using oral doses of 350, 700, 1400 and 2800 micrograms 3,5,3'-triiodothyroacetic acid."( Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels.
Burger, AG; Juge, C; Menegay, C, 1989
)
0.28
" For several years following treatment, the patient displayed clinical hypothyroidism and persistently low serum thyroxine (T4) and triiodothyronine (T3) levels despite large T4 replacement dosage (0."( Persistence of low serum thyroid hormone levels in a Graves' disease patient receiving supraphysiologic L-thyroxine replacement therapy.
Bregant, R; Burman, KD; Burns, TW; Premachandra, BN; Williams, IK, 1989
)
0.48
" The authors report on the lack of efficacy of adjunctive L-triiodothyronine (T3; 25 micrograms/day) in a sample of 20 outpatient unipolar depressives who had not responded to greater than or equal to 12 weeks of treatment with imipramine (mean dosage = 240 mg/day) and interpersonal psychotherapy."( Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.
Jarrett, DB; Kupfer, DJ; Thase, ME, 1989
)
0.74
" Thus, studies of altered thyroid status in the rat reveal dose-response and time-course variability in the pretranslational control of TSH beta, alpha-subunit, GH, and PRL by thyroid hormone."( The effect of altered thyroid status on pituitary hormone messenger ribonucleic acid concentrations in the rat.
Ridgway, EC; Samuels, MH; Wang, C; Wierman, ME, 1989
)
0.28
" In one experiment, different amounts of the inoculum were applied to see if there exists a dose-response relationship."( Rapid decrease of the peripheral deiodination of thyroxine in malabsorption syndrome in artificially inoculated broilers.
Rudas, P; Sályi, G; Szabó, J,
)
0.13
" Dose-response experiments were performed in intact hypothyroid and euthyroid rats; in addition, studies in vitro examined the effect of T3 on MHC mRNAs in neonatal cardiac myocytes in primary culture."( Differential regulation by thyroid hormones of myosin heavy chain alpha and beta mRNAs in the rat ventricular myocardium.
Ahlquist, JA; Franklyn, JA; Gammage, MD; Green, NK; Sheppard, MC, 1989
)
0.28
" For both fatty acids there was a close parallelism between the dose-response curve for the inhibition of turnover of [3H]acetate from the histones and the increase in receptor levels."( Short chain fatty acids modulate nuclear receptor and extranuclear L-triiodothyronine levels in glial C6 cells by different mechanisms.
Aranda, A; Montiel, F; Ortiz-Caro, J; Pascual, A; Yusta, B, 1988
)
0.51
" The end of the critical period was defined by dosing hypothyroid neonates with T3 daily (0."( Thyroid hormone regulates alpha and alpha + isoforms of Na,K-ATPase during development in neonatal rat brain.
McDonough, AA; Schmitt, CA, 1988
)
0.27
" In 6 of 25 patients, however, a discordant behaviour was clearly documented including dose-response curves."( Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
Hörmann, R; Mann, K; Müller, R; Saller, B, 1985
)
0.27
" At the higher dosage used bovine GH appeared to stimulate the accumulation of creatine kinase."( The postnatal development of sarcoplasmic reticulum Ca2+ transport activity in skeletal muscle of the rat is critically dependent on thyroid hormone.
Simonides, WS; van Hardeveld, C, 1989
)
0.28
" Dose-response curves with NE indicate a reduction of the maximal response after T4 treatment with no change in ED50."( Chronic thyroxine treatment of rats down-regulates the noradrenergic cyclic AMP generating system in cerebral cortex.
Schmidt, BH; Schultz, JE, 1985
)
0.27
" Dose-response studies with T3 indicated that the rapid interaction between T3 and sucrose was limited by the occupancy of the T3 nuclear receptor."( Rapid synergistic interaction between thyroid hormone and carbohydrate on mRNAS14 induction.
Mariash, CN; Oppenheimer, JH; Schwartz, HL; Seelig, S, 1986
)
0.27
" The T4 distribution space (per 100 g BW) was expanded with increasing dosage by as much as 8-fold in the 50 pmm PCB treatment group."( Hypothyroidism and abnormalities in the kinetics of thyroid hormone metabolism in rats treated chronically with polychlorinated biphenyl and polybrominated biphenyl.
Byrne, JJ; Carbone, JP; Hanson, EA, 1987
)
0.27
" Serum free T4 index, free T3 index, and free T4 levels and oral T4 dosage were inferior predictors of TRH responsiveness compared to the basal TSH value."( Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay.
Doss, RC; Eigen, A; Green, BJ; Guttler, RB; Lai-Rosenfeld, AO; LoPresti, J; Marcus, AO; Nicoloff, JT; Nimalasuriya, A; Spencer, CA, 1986
)
0.27
" These findings indicate that the decrease in optimal daily L-thyroxine dosage reported in previous studies is not a universal finding in all elderly hypothyroid patients; the decrease is present only in patients with associated chronic disorders, and hence may be attributed to the presence of an associated chronic disorder or medications consumed for treatment of these disorders rather than old age."( Variability of L-thyroxine replacement dose in elderly patients with primary hypothyroidism.
Kabadi, UM, 1987
)
0.27
" The dose-response and temporal relationships suggest a causal relationship between the TRH-mediated decrease in thyroid hormone receptors and the decrease in thyroid hormone responses in GH4C1 cells."( Regulation of thyroid hormone receptors and responses by thyrotropin-releasing hormone in GH4C1 cells.
Hinkle, PM; Kaji, H, 1987
)
0.27
" Therefore, it was concluded that IRMA-TSH may obviate the need for a TRH test and simplify the evaluation of adequate dosage in patients with congenital hypothyroidism during thyroxine treatment."( Monitoring treatment of congenital hypothyroidism by highly sensitive immunoradiometric assay for thyroid stimulating hormone.
Inomata, H; Nakajima, H; Niimi, H; Sasaki, N; Sato, H, 1987
)
0.27
" A non-linear dose-response relationship with respect to enzyme activity was observed with different doses of T3."( Induction of hepatic mitochondrial alpha-glycerophosphate dehydrogenase by L-triiodothyronine in Singi fish (Heteropneustes fossilis Bloch).
De, S; Ghosh, N; Ghosh, RK; Medda, AK; Ray, AK, 1987
)
0.5
" The mechanism of the effect of T3 is unknown, but the lack of effect on delayed hypersensitivity to SRBC implies that T3 (when administered at the dosage of the present protocol) acts on only some immune cells and does not exert a generalized adjuvant effect."( The effect of triiodothyronine on evanescent delayed hypersensitivity to sheep red blood cells and on the primary antibody response to trinitrophenylated Brucella abortus in severely undernourished weanling mice.
Berdusco, E; Filteau, SM; Perry, KJ; Woodward, B, 1987
)
0.63
" The reduction in serum T4 levels was established from the earliest time point (2 weeks) throughout the whole dosing period (18-23 weeks)."( Effects of 3,4,3',4'-tetrachlorobiphenyl on thyroid function and histology in marmoset monkeys.
Brouwer, A; van den Berg, KJ; Zurcher, C, 1988
)
0.27
"25% SRBC at 37 days of age in Trial 1, and a booster of the same dosage was given to half of these chicks at 61 days of age."( Thiouracil and antibody titers of chickens from lines divergently selected for antibody response to sheep erythrocytes.
Martin, A; McNabb, FM; Siegel, PB, 1988
)
0.27
" While T3 alone had no effect on calcium uptake by gut segments cultured on d 20 of embryonic development, the thyroid hormone amplified the effect of 1,25-(OH)2D3 on calcium transport and effectively shifted the dose-response curve to lower 1,25-(OH)2D3 concentrations."( Calcium and inorganic phosphate transport in embryonic chick intestine: triiodothyronine enhances the genomic action of 1,25-dihydroxycholecalciferol.
Cross, HS; Peterlik, M, 1988
)
0.51
" In addition, a close dose-response relationship was found in the cultures supplemented with T3."( Effect of thyroid hormones on angiotensinogen production in the rat in vivo and in vitro.
Jimenez, E; Montiel, M; Morell, M; Ruiz, M, 1987
)
0.27
" In both age-groups, hypothyroidism increased cellular responsiveness to T3, shifting the dose-response curve to the left."( Effect of hypothyroidism on the in-vivo and in-vitro uptake of sugar by rat thymocytes and on the stimulatory response to 3,5,3'-tri-L-iodothyronine.
Segal, J, 1988
)
0.27
" The serum SHBG concentration was measured on the last day at each dosage level."( Sex hormone-binding globulin in the diagnosis of peripheral tissue resistance to thyroid hormone: the value of changes after short term triiodothyronine administration.
Farriaux, JP; Refetoff, S; Rosenfield, RL; Sarne, DH, 1988
)
0.48
" We conclude that strict adherence to timing of specimen collection in relation to dosage is probably unnecessary."( Intra-individual variation of thyroxin, triiodothyronine, and thyrotropin in treated hypothyroid patients: implications for monitoring replacement therapy.
Bennet, WM; Browning, MC; Jung, RT; Kirkaldy, AJ, 1988
)
0.54
"To investigate the dose-response relationship between thyroid hormone and linear growth, we studied 10 castrated prepubertal cynomolgus monkeys."( Dose-response relationship between thyroid hormone and growth velocity in cynomolgus monkeys.
Caruso-Nicoletti, M; Cassorla, F; Cutler, GB; Garcia, H; Malozowski, S; Ren, SG; Simoni, C, 1988
)
0.27
"025 microgram) and one control dosage (0 microgram) to tadpoles of three Gosner developmental stages--28/29, 30/31, and 32/33; tadpoles were recoved up to 8 d (treatment and control dosages) or 14 d (control dosage) later."( Skull development during anuran metamorphosis: III. Role of thyroid hormone in chondrogenesis.
Hanken, J; Summers, CH, 1988
)
0.27
" These results were most likely due to the low daily dosage administered."( Amiodarone and thyroid status in refractory arrhythmias.
Codecà, L; Colamussi, V; Giganti, M; Giovannini, G; Pelizzola, D; Piffanelli, A; Ricci, L, 1988
)
0.27
" Elevated plasma reverse T3 levels were demonstrated after each treatment, however, suggesting a desirable therapeutic effect at this dosage level for all preparations."( Rectal absorption of propylthiouracil.
Bartle, WR; Silverberg, JD; Walker, SE, 1988
)
0.27
"5 micrograms) plus a control dosage via plastic micropellets implanted within the dermis of tadpoles of three Gosner developmental stages: 28/29, 30/31, 32/33."( Skull development during anuran metamorphosis. II. Role of thyroid hormone in osteogenesis.
Hall, BK; Hanken, J, 1988
)
0.27
" In each patient, the serum TSH level had been normal as determined by conventional TSH radioimmunoassay while the patient had been receiving a constant dosage of T4 for at least three months before the study."( Immunoradiometric assay for basal thyroid-stimulating hormone levels: strategy for the management of thyroxine replacement.
Barsano, CP; Garces, J, 1988
)
0.27
" EGF attenuated the GH response to T3 with similar dose-response characteristics."( Epidermal growth factor decreases thyroid hormone receptors and attenuates thyroid hormone responses in GH4C1 cells.
Hinkle, PM; Kaji, H, 1987
)
0.27
" Return of TT4 and FT4 to normal values by day 32 after TCDD dosage also occurred in a dose-dependent manner, except in rats that died later."( Dose-response and time course of hypothyroxinemia and hypoinsulinemia and characterization of insulin hypersensitivity in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats.
Gorski, JR; Rozman, K, 1987
)
0.27
" The dose-response curve to vasopressin and its maximal effect measured on stimulation of glucose production were unchanged in thyroidectomized rats."( Hormonal control of glucose production and pyruvate kinase activity in isolated rat liver cells: influence of hypothyroidism.
Beylot, M; Comte, B; Khalfallah, Y; Laville, M; Riou, JP; Vidal, H, 1987
)
0.27
" As the dosage decreases to a certain level, a low-limit dose incapable of inducing cancers may be present."( Study on late effects of radioiodine on rats.
Chi, YC; Fu, CS; Gao, FM; Li, ZK; Liu, XT; Liu, ZH; Song, YF; Wei, LX, 1986
)
0.27
" During the follow-up period a transient rise in T4 and T3 concentrations was observed in two patients in Group I when the methimazole dosage was tapered or stopped because of agranulocytosis."( Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole.
Decoster, C; Unger, J; Van Reeth, O, 1987
)
0.27
" There was no significant correlation between serum amiodarone or desethylamiodarone levels and dosage of amiodarone."( Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels.
Garson, A; Kannan, R; McVey, P; Miller, S; Singh, BN; Yabek, SM, 1987
)
0.27
" A transient decrease in total T4, elevation in the T3 resin uptake and consequent increase in the free T4 index (FT4I) were seen 2-5 h after ingestion of frusemide at a chronic morning dosage of 80, 120 or 250 mg."( Effect of oral frusemide on diagnostic indices of thyroid function.
Hamblin, PS; Lim, CF; Long, F; Newnham, HH; Stockigt, JR; Topliss, DJ, 1987
)
0.27
" The enzyme activities in both nuclear fractions were assayed under the condition of dose-response linearity."( Triiodothyronine effects on RNA polymerase activities in isolated neuronal and glial nuclei of the mature rat brain cortex.
Akamizu, T; Imura, H; Mori, T; Nakamura, H; Yokota, T, 1987
)
1.72
"05) for females dosed at 1200 and 2400 ppm for 18 mo and for males dosed at 600, 1200, or 2400 ppm sulfamethazine for 24 mo than for those dosed at levels of 40 ppm or less."( Influence of oral administration of sulfamethazine on thyroid hormone levels in Fischer 344 rats.
Fullerton, FR; Kushmaul, RJ; Littlefield, NA; Suber, RL, 1987
)
0.27
" In other cases, dosing of the free hormones T3 and T4 remains a vital supplementary test."( [Thyroid biological evaluation: critical study].
Heshmati, HM; Izembart, M; Nasser, H; Vallée, G, 1987
)
0.27
" As a single test, serum TSH is therefore not very useful for the assessment of adequate thyroxine dosage in patients with primary hypothyroidism."( Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
Helenius, T; Lamberg, BA; Liewendahl, K; Mähönen, H; Wägar, G, 1987
)
0.59
" Criterion of adequate LT4 dosage was a negative TRH test after dose titration in increments of 25 micrograms/d."( [Optimization of levothyroxine treatment. Dosage dependence on the existing parenchymal mass, age, body weight and fasting intake].
Wenzel, KW, 1986
)
0.27
" There was a striking similarity in the dose-response of butyrate for increasing receptor levels and inhibiting histone deacetylation."( Modulation of thyroid hormone nuclear receptors by short-chain fatty acids in glial C6 cells. Role of histone acetylation.
Aranda, A; Montiel, F; Ortiz-Caro, J; Pascual, A, 1986
)
0.27
" However, to normalize the response of UCP, T3 has to be given in a dosage that produces systemic hyperthyroidism."( Intracellular conversion of thyroxine to triiodothyronine is required for the optimal thermogenic function of brown adipose tissue.
Bianco, AC; Silva, JE, 1987
)
0.54
" In 20 congenitally hypothyroid children, substitutive opotherapy was completely withdrawn for 1 month, resumed in the original dosage for 2 months, and then increased by 20% from day 91 to day 110."( Modification of nonspecific bronchial reactivity in hypothyroid children under different regimens of substitutive opotherapy.
Alonge, C; Bernardi, F; Cacciari, E; Cerimoniale, G; Criscione, S; Macri, F; Ronchetti, R; Villa, MP,
)
0.13
" At 14 days after dosing all TCDD-dosed animals were hypothyroid in terms of T4 but essentially euthyroid in terms of T3."( Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in cold-adapted rats.
Greim, H; Rozman, K, 1986
)
0.27
" Furthermore, they support the hypothesis that the dosage of thionamide compounds and the duration of therapy with the initial doses necessary to induce euthyroidism may vary in various parts of the world."( Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter.
Azizi, F, 1985
)
0.27
" Correlation of these changes with dosage for a variety of growth effectors is a sensitive assay for the effects of these factors, both alone and in combination, and should be useful in comparing effects of agents with similar biological activities and in the search for variant cell types with altered responsiveness."( Colony morphology on agar is a sensitive indicator for growth effectors.
Dairkee, SH; Glaser, DA, 1985
)
0.27
" These abnormal TSH responses normalized on adjusting the L-T4 dosage alone; prolonged therapy with the same dose failed to normalize TSH responses."( Normal thyrotrophin response to intravenous thyrotrophin releasing hormone administration: the best index of optimal L-thyroxine therapy in primary hypothyroidism.
Kabadi, UM, 1985
)
0.27
"2% PTU diets, and a dose-response relationship was established."( Propylthiouracil causes phase delays and circadian period lengthening in male and female hamsters.
Gavin, ML; Morin, LP; Ottenweller, JE, 1986
)
0.27
" This dosage regimen, followed by 42 days of a regular diet, resulted in 33% mortality with a mean time to death of 67 +/- 4 days."( Reduced serum thyroid hormone levels in hexachlorobenzene-induced porphyria.
Gorski, JR; Parkinson, A; Rozman, K; Rozman, P, 1986
)
0.27
" Dose-response effects were seen for the increase of fT4, fT3 and T3."( Effects of small doses of bovine TSH on serum levels of free and total thyroid hormones, their degradation products, and diiodotyrosine.
Benker, G; Meinhold, H; Olbricht, T; Reinwein, D; Splittstösser, C, 1985
)
0.27
"1 mU (ip, daily for 3 days), and there was a linear dose-response thereafter."( Characterization of thyrotropin-induced increase in iodothyronine monodeiodinating activity in mice.
Florsheim, WH; Reggio, R; Wu, SY, 1985
)
0.27
" The present study explored the relationship between serum T3 and T4 and dosage of L-thyroxine."( 'Chemical hyperthyroidism': the significance of elevated serum thyroxine levels in L-thyroxine treated individuals.
Rendell, M; Salmon, D, 1985
)
0.27
" A dose-response study was performed with liver samples, in which both oxygen consumption and heat production rates were measured."( Triiodothyronine (T3)-induced thermogenesis: altered T3-efficiency in tissues from fed, starved, and refed hypothyroid rats.
Arieli, A; Bachmann, K; Burger, AG; Chinet, AE, 1985
)
1.71
"In 23 patients with symptomatic severe supraventricular and ventricular tachyarrhythmias the effectiveness and the side effects of a long-term therapy with the class III antiarrhythmic drug Amiodarone (Cordarone) in a dosage of 100-800 mg/die in monotherapy and combination therapy were investigated."( [Long-term therapy with amiodarone in tachyarrhythmias--report on various experiences with special reference to its side effects].
Assmann, I, 1985
)
0.27
" The importance of adequate dosage and duration in any treatment trial are emphasized, and the evidence in support of combined antidepressants, lithium-antidepressant combinations, the addition of triiodothyronine or tryptophan, the use of anticonvulsants, and the use of vanadium inactivators, is evaluated."( Pharmacological strategies in depression.
Barnes, TR; Katona, CL, 1985
)
0.46
" All these subjects had normal thyroid function before antibiotic dosing and none had thyroid function abnormalities."( Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin.
du Souich, P; Larochelle, P; Morisset, R; Pedneault, L; Phaneuf, D; Pison, C; Poisson, M; Vega, C, 1985
)
0.27
" The mean daily dosage of PTU was 827 (n=11) and of MMI was 88 (n=8)."( Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.
Abuid, J; Larsen, PR, 1974
)
1.7
" The dose-response curves of inhibition of the binding of [(125)I]rT(3) to antibody obtained by serial dilutions of serum extracts were essentially parallel to the standard assay curve."( A radioimmunoassay for measurement of 3,3',5'-triiodothyronine (reverse T3).
Chopra, IJ, 1974
)
0.51
" No detectable change in T(4) deiodination rate was observed with these agents in the dosage ranges employed in this study."( A new method for the measurement of acute alterations in thyroxine deiodination rate in man.
Nicoloff, JT, 1970
)
0.25
" Response to TRH was determined before treatment and after each dosage of a synthetic combination of T(3) + T(4) had been given for 3-4 wk."( Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones.
Snyder, PJ; Utiger, RD, 1972
)
0.25
" Dose-response relationships of a vacriety of thyronine derivatives indicate that this system has a specificity of response which is similar to that observed in vitro."( Thyroid hormone action: a cell-culture system responsive to physiological concentrations of thyroid hormones.
Cintron, R; Samuels, HH; Tsai, JS, 1973
)
0.25
" Dose-response curves to norepinephrine were identical for hearts maintained for 3 hr in triiodothyro-nine-treated or control medium."( Studies of isolated fetal mouse hearts in organ culture. Evidence for a direct effect of triiodothyronine in enhancing cardiac responsiveness to norepinephrine.
Wildenthal, K, 1972
)
0.47
" This index appears to be sensitive and safe and results in a reduction in the required dosage of triiodothyronine."( Thyroid suppression test with serum thyroxine concentration as index of suppression.
Ekins, RP; Ellis, SM; Williams, ES, 1969
)
0.46
" Dose-response curves for alpha-GPD and ME were curvilinear and showed an exponential increase in enzyme activity with progressive receptor saturation."( Response of hepatic mitochondrial alpha-glycerophosphate dehydrogenase and malic enzyme to constant infusions of L-triiodothyronine in rats bearing the Walker 256 carcinoma. Evidence for divergent postreceptor regulation of the thyroid hormone response.
Sahnoun, N; Surks, MI; Tibaldi, JM, 1984
)
0.48
" The positive inotropic and toxic effects of ouabain in cells grown in 10(-8) M T3 were diminished at any given ouabain concentration, and thus, the dose-response curve was shifted to the right."( Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells.
Kim, D; Smith, TW, 1984
)
0.27
" Quinidine inhibited T3 formation, with a dose-response curve which was similar over the concentrations studied to that of DL-propranolol."( Inhibition by propranolol of 3,5,3'-triiodothyronine formation from thyroxine in isolated rat renal tubules: an effect independent of beta-adrenergic blockade.
Campbell, DG; Heyma, P; Larkins, RG, 1980
)
0.54
"Appropriate dosage of levothyroxine for the treatment of hypothyroidism is assessed by determining the serum thyroxine (T4) concentration in secondary and tertiary types."( Laboratory tests for evaluating thyroid therapy.
Kabadi, UM, 1982
)
0.26
" These results support the hypothesis that large antithyroid drug doses may have greater immunosuppressive effects than low dosage regimens."( Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Bromberg, N; Farah, CS; Reis, LC; Rodrigues, HF; Romaldini, JH; Tanaka, LM; Werner, MC; Werner, RS, 1983
)
0.27
" The exceedingly long and variable elimination half-life of amiodarone necessitates individualized loading and maintenance dosage regimens, and the latency of onset of antiarrhythmic action during oral therapy is not shortened by intravenous bolus injections or sustained infusions."( The clinical results of amiodarone in cardiac arrhythmias: optimal dosing.
Ikeda, N; Kannan, R; Nademanee, K; Singh, BN, 1984
)
0.27
" The medium-dose regimen (total dosage per cycle: 192 mg of CPA) is more effective than the low-dose regimen (42 mg of CPA per cycle) in the treatment of patients with moderate hyperandrogenism who do not require the high-dose oral standard antiandrogen therapy (1000 mg of CP A per cycle)."( [Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study].
Kaiser, E; Moltz, L, 1984
)
0.27
" Dose-response studies conducted with T4 showed that maximal stimulatory response was obtained at 10(-10) M)."( Rabbit myocardial membrane Ca2+-adenosine triphosphatase activity: stimulation in vitro by thyroid hormone.
Blas, SD; Davis, FB; Davis, PJ; Mylotte, KM; Rudinger, A, 1984
)
0.27
" The optimal substitution dosage most commonly applied, was on the average of 150 micrograms daily."( [Clinical trial of sodium levothyroxine in the treatment of hypothyroidism in adults (author's transl)].
Charbonnel, B; Guillon, J,
)
0.13
" Significant changes in the thyroid parenchyma proper and in the population of parafollicular or C cells were recorded in response to the increased dosage of the substance injected."( [Morphofunctional changes in the thyroid glands of rats following lithium chloride administration].
Glumova, VA; Kuznetsova, VM; Petrov, NM; Semenov, VV, 1981
)
0.26
" Modern biological tests can establish the diagnosis, even in subclinical cases, and can also ensure close supervision of dosage to avoid long-term adverse effects of too low or too high dosage regimens."( [Treatment of primary hypothyroidism in adults : dosage schedule and biological surveillance (author's transl)].
Brindisi, G; Heim, M; San Marco, JL; Simonin, R,
)
0.13
" The results indicate that T3 selectively increased submandibular and parotid NaK-ATPase units with a single, large dose of T3, different dosage of T3, three successive doses of T3 given on alternate days, and "physiological" doses of T3 with daily injection for 2 weeks."( Effect of triiodothyronine on (Na+ G K+)-adenosine triphosphatase and (Na+ + Mg2+)-dependent phosphorylated intermediate in rat salivary glands.
Cheng, W; Klein, LE; Lo, CS, 1981
)
0.67
" Tapering propranolol dosage is frequently used in the hope of preventing adverse withdrawal events but the success of such a maneuver has not been shown."( Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule.
Lutterodt, A; Nattel, S; Rangno, RE, 1982
)
0.26
" However, La3+ potentiated the response of the cell to T3 in respect to calcium accumulation, cAMP concentration, and 2-DG uptake, shifting the dose-response curve of the latter two effects to the left."( An immediate increase in calcium accumulation by rat thymocytes induced by triiodothyronine: its role in the subsequent metabolic responses.
Ingbar, SH; Segal, J, 1984
)
0.5
"303 patients with non-toxic goitre (aged 14-85 years) were studied to determine the extent to which the level of thyroid-hormone dosage until a negative TRH test is reached can be defined in terms of age, body surface area and goitre size."( [Determination of the optimal L-thyroxine dosage for treating nontoxic goiter].
Albrecht, W; Biersack, HJ; Oehr, P; Rasche, A; Winkler, C, 1983
)
0.27
" Serious adverse effects occurred nearly always in association with four- to fivefold increases of rT3 above baseline values, and disappeared when such levels fell as a result of dosage reduction or after temporary drug discontinuation."( Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy.
Nademanee, K; Singh, BN, 1983
)
0.27
" TSH administration to embryos and chicks resulted in similar time-course and dose-response characteristics, as judged by the thyroid 32P uptake response."( Responses to thyrotropin during development in Japanese quail.
Hughes, TE; McNabb, FM; Stanton, FW; Weirich, RT, 1984
)
0.27
" The patients were striking either because of a disturbed thyroid feed back mechanism or by the need of an increased dosage of L-thyroxine (500 microgram) for treatment."( [Determination of thyroid hormone antibodies and their clinical relevance (author's transl)].
Federlin, K; Grebe, S; Helmke, K; Mäser, E; Teuber, J, 1981
)
0.26
"0-ppm T3 dosage level resulted in depressed body weights within both the K and ADW strains but produced no significant changes within the SLD strain."( Effects of triiodothyronine treatments on body and organ growth and the development of immune function in dwarf chickens.
Lauterio, TJ; Marsh, JA; Scanes, CG, 1984
)
0.66
" We have found a wide dosage range, being not possible to find any significant difference between ranges leading to normal and ranges leading to pathological findings, thus making impossible to suggest a reasonably safe dosage pro kg."( [Hormonal therapy of congenital hypothyroidism in childhood].
Bianchi, C; Bollati, A; Focarile, F; Rondanini, GF,
)
0.13
"Chemical thyroidectomy effectively protected athyroid rats from mortality during 45 days after dosing with 100 micrograms 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)/kg, whereas 70 to 80% of nonthyroidectomized-euthyroid and thyroidectomized-T4 (thyroxine)-maintained-euthyroid rats died within the same period of time."( Effect of thyroidectomy and thyroxine on 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced toxicity.
Greim, H; Rozman, K; Rozman, T, 1984
)
0.27
" There is a dramatic inverse dose-response relationship between triiodothyronine levels and NAD-G3PDH activity."( Triiodothyronine depresses the NAD-linked glycerol-3-phosphate dehydrogenase activity of cultured neonatal rat heart cells.
Freerksen, DL; Hartzell, CR; Schroedl, NA, 1984
)
1.95
" The level of TSH in serum was significantly increased in all TRH injected groups with a peak value at 10 min, while no dose-response relationship was found at 5 min."( Changes in adenylate cyclase activity in rat pituitary after TRH and T3 injection in vivo.
Brozmanová, H; Földes, O; Knopp, J; Langer, P, 1980
)
0.26
" Definite dose-response relations were found for rT3."( Dose related effects of betamethasone on iodothyronines and thyroid hormone-binding proteins in serum.
Gamstedt, A; Järnerot, G; Kågedal, B, 1981
)
0.26
" Administration of exogenous T3 followed by sequential testing with boluses of TRH revealed retention of TSH responsiveness in both daughter and mother during pretreatment with dosage regimens of T3 below 125 micrograms daily."( Familial insensitivity of the pituitary and periphery to thyroid hormone: a case report in two generations and a review of the literature.
Alexander, N; Island, DP; Linde, R; Rabin, D, 1982
)
0.26
" The mean basal metabolic rate, serum cholesterol, and serum creatine phosphokinase were altered by the week of therapy in a dose-response manner, and were in the normal range in G-II."( Rapid pituitary and peripheral tissue responses to intravenous L-triiodothyronine in hypothyroidism.
Goldenheim, PD; Ladenson, PW; Ridgway, EC, 1983
)
0.5
" Administration of 12 IU of oPRL in conjunction with the same dosage of TSH prevented the TSH-induced rise in T4, without affecting serum T3 levels."( Prolactin--thyroid interaction in Fundulus heteroclitus.
Brown, CL; Stetson, MH, 1983
)
0.27
" High pretreatment T3 values were comparatively common among patients in whom a fixed CMI dosage had a insufficient effect."( Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen.
Dahlberg, PA; Karlsson, FA; Lindström, B; Wide, L, 1981
)
0.26
" An exponential dose-response relation was obtained between NADPH and T3 generated."( On the role of NADPH and glutathione in the catalytic mechanism of hepatic thyroxine 5'-deiodination.
Maruyama, S; Nomura, K; Sato, T, 1981
)
0.26
" The dose-response range for T3 stimulation of alkaline phosphatase activity (0."( Triiodothyronine stimulation of in vitro growth and maturation of embryonic chick cartilage.
Burch, WM; Lebovitz, HE, 1982
)
1.71
" A dose-response relationship between triiodothyronine (T3) production and NADPH in vitro showed similar age-related changes, whereas dose-dependency of T3-formation on GSH was decreasing with age, especially under the presence of 1 mM NADPH."( Correlation of hepatic thyroxine 5'-monodeiodination with hexose monophosphate shunt in young rats.
Maruyama, S; Saida, K; Sato, T; Takata, I, 1982
)
0.54
" Her pulse rate, blood pressure, systolic time intervals and exercise tolerance changed minimally and remained within the normal range during the different dosage schedules."( Partial peripheral resistance to thyroid hormone.
Kaplan, MM; Larsen, PR; Swartz, SL, 1981
)
0.26
" 3) A controlled trial of physiologic doses of T3, such as 40 mu g/day, seems indicated, as opposed to pharmacologic dosed of T3 used by previous investigators."( Metabolic insufficiency as a limiting factor in the dietetic treatment of obesity.
Boukis, M; Kitsopanides, J; Koutras, DA; Moulopoulos, SD; Piperingos, GD; Sfontouris, J; Souvatzoglou, A, 1981
)
0.26
"00 ppm had poorer weight gain and feed efficiency than controls, but T4 at that same dosage did not adversely affect performance."( Effect of dietary thyroid hormone on growth and feed efficiency of broilers.
May, JD, 1980
)
0.26
" In addition, the findings support the assumption that therapeutic failure with beta-blockers in hyperthyroidism may be due to suboptimal treatment, and that individualized dosage is necessary."( Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.
Melander, A; Nilsson, OR; Tegler, L, 1980
)
0.26
" Posttherapeutic evaluation was based on peak serum concentrations of T3 and T4, pretreatment (basal) thyroid hormone values, type of replacement therapy, dosage and time of sampling after treatment, concurrent clinical problems, and, most important, clinical response to thyroid replacement therapy."( Canine hypothyroidism: a retrospective study of 108 cases.
Izzo, J; Nesbitt, GH; Peterson, L; Wilkins, RJ, 1980
)
0.26
"The authors have dosed by radioimmunoassay the rT3 concentrations in the amniotic fluid of 12 normal pregnant women and of 25 women with high risk pregnancies at the same period of gestation."( Amniotic fluid reverse triiodothyronine in normal and high risk pregnancies.
Bizzarro, A; De Placido, G; Parlati, O; Tedeschi, A; Tolino, A, 1980
)
0.57
" For the dose-response study, 4 control pigs received increasing doses (4, 20, 200, and 2,000 micrograms) T3 at 15-min intervals, and the hemodynamic response and ECG features were monitored continuously."( Acute increase in cardiac performance after triiodothyronine: blunted response in amiodarone-treated pigs.
Gøtzsche, LB, 1994
)
0.55
" In the case of congenital hypothyroidism (n = 37) application of sodium selenite in the above specified dosage yielded a mean serum selenium increase (0."( Sodium selenite therapy and thyroid-hormone status in cystic fibrosis and congenital hypothyroidism.
Dawczynski, H; Jahreis, G; Janitzky, E; Kauf, E; Winnefeld, K, 1994
)
0.29
" The purpose of the present experiment was to investigate the dose-response relationship for thyroid function alterations in female Sprague-Dawley rats following chronic treatment with TCDD."( Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Clark, GC; Flagler, N; Lucier, GW; Maronpot, RM; Sewall, CH; Tritscher, AM; Vanden Heuvel, JP, 1995
)
0.29
" Female turkeys, 8 weeks of age, were dually cannulated via the right jugular for intermittent (10 min every 2 hr) infusion of tGH at a low dosage (4."( Responses to exogenous pulsatile turkey growth hormone by growing 8-week-old female turkeys.
Bacon, WL; Long, DW; Vasilatos-Younken, R, 1995
)
0.29
" There were dose-response relations between smoking and serum concentrations of total and LDL cholesterol, serum creatine kinase concentrations, and ankle-reflex time in the women with overt hypothyroidism, and between smoking and serum concentrations of total and LDL cholesterol in the women with subclinical hypothyroidism."( Impaired action of thyroid hormone associated with smoking in women with hypothyroidism.
Huber, P; Müller, B; Ratcliffe, JG; Staub, JJ; Zulewski, H, 1995
)
0.29
" All concentrations of PCB depressed circulating T4 levels and ChAT activity in a dose-response manner, but did not modify T3 levels."( Thyroxine normalizes polychlorinated biphenyl (PCB) dose-related depression of choline acetyltransferase (ChAT) activity in hippocampus and basal forebrain of 15-day-old rats.
Juárez de Ku, LM; Meserve, LA; Sharma-Stokkermans, M,
)
0.13
" For further elucidation we evaluated iodothyronine and circadian TSH levels in GH-deficient patients as part of a GH dose-response study."( Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults.
Christiansen, JS; Jørgensen, JO; Laursen, T; Møller, J; Orskov, H; Weeke, J, 1994
)
0.5
" T3 replacement (same dosage schedule)."( Multicompartmental analysis of triiodothyronine kinetics in hypothyroid patients treated orally or intravenously with triiodothyronine.
el Tamer, E; el Tamer, S; Hays, MT; Noli, MI; Zaninovich, AA, 1994
)
0.57
" The latter dose was found in dose-response studies to result in maximal stimulation of AdNT in liver mitochondria."( Thyroid hormone action: effect of triiodothyronine on mitochondrial adenine nucleotide translocase in vivo and in vitro.
Brenner, MA; Sterling, K, 1995
)
0.57
"A bolus dose of methimazole (MMI) was administered IV over 1 minute to 5 healthy adult dogs at a dosage (40 mg/kg of body weight) known to impart protection against cisplatin-induced renal disease."( Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs.
Elfarra, AA; Hutson, PR; Panciera, DL; Vail, DM, 1994
)
0.29
"05) basal as well as glucagon-stimulated lipolysis in a dose-response and time-dependent manner."( Triiodothyronine attenuates somatostatin inhibition of broiler adipocyte lipolysis.
Oscar, TP; Suniga, RG, 1994
)
1.73
" After 6 h exposure, the dose-response curve of 2-DOG uptake to T3-MAAB was shifted to the left by at least one order of magnitude when compared to the dose-response curve obtained with T3."( The production of a monoclonal T3-antiidiotypic antibody (T3-MAAB) that mimics the effects of T3 on 2-deoxy-D-glucose uptake in chick embryo heart cells.
Gafny, M; Gordon, A; Gross, J; Mizrachi, M; Schwartz, H; Swartz, H, 1994
)
0.29
" The study aimed at establishing proper dosage and assaying blood serum T4, T3, and TSH levels."( [Outcome of treating hypothyroidism with thyreoideum].
Horst-Sikorska, W; Kosowicz, J; Lacka, K,
)
0.13
" There were no differences in the etiology of CH, in the mean T4 and T3 serum levels or in the mean LT4 treatment dosage between the two groups."( Early identification of congenital hypothyroid infants with abnormalities in pituitary setpoint for T4-induced TSH release.
Eldar, D; Kaiserman, I; Sack, J, 1993
)
0.29
" Treatment of these rats with human (h) GH significantly increased the LAGS level in a dose-response manner."( The role of growth hormone in regulation of low affinity glucocorticoid-binding sites from male rat liver microsomes.
Boada, LD; Chirino, R; Díaz-Chico, BN; Díaz-Chico, JC; Fernández, L; López-Guerra, A; Valerón, PF, 1994
)
0.29
"0 g/day for 7 days) dosing schedule were employed to achieve varying levels of deiodinase inhibition."( 3,5,3'-Triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man.
LoPresti, JS; Nicoloff, JT, 1994
)
0.74
" To assess the potential impact of impurities the study was performed both with pure and technical grade PCP at the dosage of 3 mg."( Effects of pentachlorophenol (PCP) on the pituitary and thyroidal hormone regulation in the rat.
Eckard, R; Jekat, FW; Meisel, ML; Winterhoff, H, 1994
)
0.29
" Dose-response curves were analysed by a four-parameter sigmoid curve-fitting program to determine competitor potency."( Drug competition for intracellular triiodothyronine-binding sites.
Barlow, JW; Curtis, AJ; Loidl, NM; Raggatt, LE; Stockigt, JR; Topliss, DJ, 1994
)
0.57
" He was started on sodium levothyroxine for thyroid hormone replacement; the dosage was adjusted in accordance with subsequent TSH measurements."( Amiodarone-induced thyroid dysfunction.
Jaffe, CA; Khanderia, U; Theisen, V, 1993
)
0.29
" In the dose-response studies, a biphasic increase in medium IGF-I was observed in both cells and limb bones, with peak stimulatory concentrations of 10(-8) M for T3 and 10(-7) M for T4 in both systems."( Thyroid hormones increase insulin-like growth factor I content in the medium of rat bone tissue.
Caplice, MD; Khanna, V; Lakatos, P; Stern, PH, 1993
)
0.29
" The dosage was doubled for the next 3 weeks (phase 2)."( Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine.
Bracco, D; Burger, AG; Jéquier, E; Liang, H; Morin, O; Schutz, Y, 1993
)
0.29
"Very preterm infants (less than 30 weeks' gestational age) were treated with thyroxine in three different dosage schemes: 10, 8 and 6 micrograms."( Thyroxine administration to infants of less than 30 weeks' gestational age does not increase plasma triiodothyronine concentrations.
de Vijlder, JJ; Endert, E; Kok, JH; van Wassenaer, AG; Vulsma, T, 1993
)
0.5
" Ethanol stimulated iodide uptake in a dose-response manner in TSH-free medium."( Ethanol has thyrotropin-like activity in cultured porcine thyroid follicles.
Nasu, M; Sugawara, M, 1993
)
0.29
"Prednisone was given orally to 12 dogs daily for 35 days at an anti-inflammatory dosage (1."( Effects of oral administration of anti-inflammatory doses of prednisone on thyroid hormone response to thyrotropin-releasing hormone and thyrotropin in clinically normal dogs.
Ferguson, DC; Hoenig, M; Moore, GE, 1993
)
0.29
"Hexachlorobenzene (HCB) residue levels in dosed rats (50."( Body distribution and endocrine toxicity of hexachlorobenzene (HCB) in the female rat.
Foster, WG; Lecavalier, PR; McMahon, A; Pentick, JA,
)
0.13
" Parameter values were estimated by fitting time-course data for a single oral subcutaneous injection of TCDD and dose-response data for biweekly oral dosing."( A mechanistic model of effects of dioxin on thyroid hormones in the rat.
Kohn, MC; Lucier, GW; Portier, CJ; Sewall, CH, 1996
)
0.29
" Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose-response study."( Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
Baxter, RC; Blok, GJ; de Boer, H; Popp-Snijders, C; Stuurman, L; van der Veen, E, 1996
)
0.29
" Any changes in metabolism elicited by either dietary protein levels or hormone treatments may be specific to the particular dosing interval and are not sustained when a common diet is fed during a repletion period."( Carry-over effects of dietary crude protein and triiodothyronine (T3) in broiler chickens.
McMurtry, JP; Mitchell, AD; Rosebrough, RW, 1996
)
0.55
" For the subsequent scan, 6 to 12 months later, the thyroxine dosage was cut in half."( Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing.
DeGroot, LJ; Guimaraes, V, 1996
)
0.29
" When the data obtained with the same doses of GH in the three groups were combined, a dose-response was demonstrated."( Short-term treatment with different doses of human growth hormone in adult patients with growth hormone deficiency.
Hu, HY; Kato, Y; Sohmiya, M, 1996
)
0.29
" As the subjects age, have a fixed thyroid hormone dosage for hypothyroxinemia, or spend an extended number of months in polar conditions, a reflex TSH rise occurs."( Circannual changes in thyroid hormone physiology: the role of cold environmental temperatures.
Reed, HL, 1995
)
0.29
"The optimal dosage regimen for carbimazole (CBZ) in the treatment of hyperthyroidism remains uncertain, despite clinical use of the drug for approximately fifty years."( A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism.
Herbert, M; Hopton, M; Jeffcoate, WJ; Page, SR; Sheard, CE, 1996
)
0.29
" Increasing the dosage of Sandostatin LAR from 20 to 30 mg had no obvious additional effect on GH suppression, but provided a further decrease in IGF-I levels."( Sandostatin LAR in acromegalic patients: long-term treatment.
Bakke, S; Bruns, C; Fløgstad, AK; Halse, J; Jervell, J; Lancranjan, I; Marbach, P, 1997
)
0.3
" T3 augmentation was performed over a four-week period; during the last three weeks the daily dosage was 37."( An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.
Birkenhäger, TK; Nolen, WA; Vegt, M, 1997
)
0.64
" Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes)."( Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states.
Calvert, C; Ferguson, D; Jacobs, G; Sams, R; Whittem, T, 1997
)
0.3
"All patients received each of the 4 levothyroxine products for 6-week periods in the same dosage as their prestudy regimen with no washout period."( Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism.
Bubp, JL; Dong, BJ; Gambertoglio, JG; Gee, L; Greenspan, FS; Hauck, WW; White, JR, 1997
)
0.3
" The most popular treatment choices were increasing dosage of tricyclic medication and change of medication of SSRI."( Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists.
Katona, CL; Shergill, SS, 1997
)
0.3
" The dose-response curve of this acute inhibitory action was unaffected by the presence of T3."( Evidences of antagonism between amiodarone and triiodothyronine on the K+ channel activities of cultured rat cardiomyocytes.
Guo, W; Kamiya, K; Toyama, J, 1997
)
0.55
" Rings were exposed to increasing concentrations of triiodothyronine (4 x 10(-12) to 1 x 10(-4) mol/L) to obtain dose-response curves."( Direct effects of triiodothyronine on human internal mammary artery and saphenous veins.
Carlsson, C; Chen, D; Cooper, SC; Eldridge, CJ; Hellmann, SK; Jeevanandam, V; Krasner, LJ; McClurken, JB; Wendling, WW, 1997
)
0.88
" Dosage of ipodate was increased to 150 mg/d and then to 200 mg/d at 2-week intervals if a good clinical response was not observed."( Ipodate treatment of hyperthyroidism in cats.
Murray, LA; Peterson, ME, 1997
)
0.3
" Hens dosed twice daily with T4 (1 or 3x the daily thyroid secretion rate, TSR, of T4 per dose) had significantly higher plasma and egg yolk T4 concentrations than did control hens dosed with saline."( Maternal thyroid hormones in Japanese quail eggs and their influence on embryonic development.
McNabb, FM; Wilson, CM, 1997
)
0.3
" Analysis of dose-response curves for isoproterenol and CGP-12177 revealed that neither basal nor stimulated AC activities nor 50% stimulatory concentration for these agonists was changed by T3 administration."( Effects of triiodothyronine administration on the adenylyl cyclase system in brown adipose tissue of rat.
Adli, H; Bazin, R; Perret, GY; Vassy, R, 1997
)
0.69
"Optimal daily levothyroxine (LT4) dosage is reported to be significantly smaller in the elderly with primary hypothyroidism when compared with their younger counterparts."( Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology.
Kabadi, UM, 1997
)
0.3
" dosage in 337 patients with primary hypothyroidism grouped according to etiology."( Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology.
Kabadi, UM, 1997
)
0.3
" dosage declined with increasing age in 99 patients with Hashimoto's thyroiditis, in 73 patients with idiopathic variety, and in 47 patients with hypothyroidism due to radical neck surgery and/or neck radiation for non-thyroidal malignancies."( Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology.
Kabadi, UM, 1997
)
0.3
"Optimal daily LT4 dosage does not decline universally in all elderly with primary hypothyroidism: it appears to depend also on the etiology of the disorder."( Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology.
Kabadi, UM, 1997
)
0.3
" These treatment regimens were continued for 24 weeks, and physicians were allowed to adjust MMI dosage during follow-up visits."( Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
Abe, Y; Fukawa, E; Kawakami-Tani, T; Makino, I; Tanaka, H, 1997
)
0.3
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest assigned to an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) in rats. Part II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1997
)
0.3
" Co-incubating 0-10 nmol/l T3 with 100 nmol/l insulin resulted in a downward shift in the dose-response curve without a change in the half-maximal response to T3."( Modulation of T3-induced sex hormone-binding globulin secretion by human hepatoblastoma cells.
Barlow, JW; Lim, CF; Loidl, NM; Payne, KL; Stockigt, JR; Topliss, DJ, 1997
)
0.3
" In a dose-response study half-maximal stimulation by T4 was achieved at a concentration of 100 nM, whereas 50% of maximal induction was produced by 1 nM T3 and 6 nM triiodothyroacetic acid (TRIAC)."( L-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRbeta.
Bartalena, L; Bogazzi, F; Brogioni, S; Burelli, A; Dell'Unto, E; Grasso, L; Manetti, L; Martino, E, 1997
)
0.3
"In patients showing hyperthyreosis or a TRAK value > 11 U/l at the beginning of RIT, a significantly lower therapeutic dosage and effective iodine half-life were found than in non-hyperthyreotic patients or patients with TRAK < or = 11 U/l."( [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Bares, R; Büll, U; Dohmen, BM; Kaiser, HJ; Sabri, O; Schreckenberger, M; Schulz, G; Wagenknecht, G; Zimny, D; Zimny, M, 1998
)
0.3
"Since most treatment failures occurred in patients under thyreostatic medication we recommend raising the target dosage to 250 Gy for these cases."( [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Bares, R; Büll, U; Dohmen, BM; Kaiser, HJ; Sabri, O; Schreckenberger, M; Schulz, G; Wagenknecht, G; Zimny, D; Zimny, M, 1998
)
0.3
" Daily oral dosing with T3 (10-170 nmol/kg) or L94901 (100-1000 nmol/kg) for 7 days decreased plasma LDL cholesterol in thyroidectomized rats by 60-80%, respectively."( Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression.
Chambers, CM; Cornelius, P; Harwood, HJ; Long, CA; Lopez, D; Ness, GC; Newsome, WP, 1998
)
0.67
" Each of the observed biological events is operative within distinct dose-response ranges in cultured GH4C1 cells."( Thyroid hormone receptor occupancy and biological effects of 3,5,3,-L-triiodothyronine (T3) in GH4C1 rat pituitary tumour cells.
Brtko, J; Filipcík, P; Strbák, V, 1998
)
0.53
" Lindane treatment in euthyroid rats at a dosage of 20mg/kg did not modify the content of liver microsomal cytochromes P450 and b5, the activity of NADPH-cytochrome P450 reductase and NADH-cytochrome b5 reductase, and the production of superoxide radical (O2."( Liver microsomal parameters related to oxidative stress and antioxidant systems in hyperthyroid rats subjected to acute lindane treatment.
Junqueira, VB; Rodrigues, L; Rodrigues, T; Simon Giavarotti, KA; Videla, LA, 1998
)
0.3
" In patients who have experienced only partial treatment results, the clinician should first consider optimizing antidepressant dosage or lengthening therapy."( Practical management of treatment-resistant depression.
Cadieux, RJ, 1998
)
0.3
"To explore the therapeutic effect and its mechanism mainly using traditional Chinese medicine (TCM) of replenishing Qi and nourishing Yin (RQNY) with a small dosage of Tapazol for treatment of Graves disease (GD)."( [Therapeutic effect and its mechanism exploration on mainly using traditional Chinese medicine of replenishing qi and nourishing yin in treating Graves disease].
Zha, LL, 1997
)
0.3
" As adjunctive COL treatment in hyperthyroidism allows reducing MMI dosage it may decrease the rate of dose dependent MMI side effects."( Role of colestipol in the treatment of hyperthyroidism.
Hagag, P; Nissenbaum, H; Weiss, M, 1998
)
0.3
" The dosage of 10 mg iodine/kg diet decreased serum T3 concentration."( [Iodine deficiency, iodine requirement and iodine excess of farm animals--experiments on growing pigs].
Schöne, F, 1999
)
0.3
" Recently, comprehensive dose-response studies of GH have been conducted in broilers during late post-hatch development (8 to 9 weeks of age)."( New insights into the mechanism and actions of growth hormone (GH) in poultry.
Beard, JL; Buys, N; Darras, V; Day, JR; Decuypere, E; McMurtry, JP; Rosebrough, RW; Tomas, F; Vasilatos-Younken, R; Wang, XH; Zhou, Y, 1999
)
0.3
" This study compared the response of Fischer (F344) and Sprague-Dawley (SD) rats to a thyrotropin-releasing hormone (TRH) ECT and a thyroid-stimulating hormone (TSH) ECT and characterized the dose-response curve."( Response of the pituitary and thyroid to tropic hormones in Sprague-Dawley versus Fischer 344 male rats.
Anderson, SA; Fail, PA; Friedman, MA, 1999
)
0.3
" The gene dosage of TBG was evaluated by coamplification with autosomal betaGlobin or X-chromosomal Duchenne Muscular Dystrophy (DMD) and subsequent quantitation by HPLC."( Gene amplification as a common cause of inherited thyroxine-binding globulin excess: analysis of one familial and two sporadic cases.
Fujieda, K; Hasegawa, T; Hirooka, Y; Jing, P; Kayama, M; Mitsuma, T; Mori, Y; Nogimori, T, 1999
)
0.3
" According to these guidelines a substantial number of patients is not sufficiently treated and, thus, should be reassessed for dosage and length of antidepressant medications."( [Therapy refractory depression].
Hatzinger, M; Holsboer-Trachsler, E, 1999
)
0.3
"The effects of GH therapy on thyroid function among previous reports have shown remarkable discrepancies, probably due to differences in hormone assay methods, degree of purification of former pituitary-derived GH preparations, dosage schedules, diagnostic criteria, patient selection, duration of treatment and study design."( Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children.
Abucham, J; MacCagnan, P; Oliveira, JH; Portes, ES, 2000
)
0.31
" Dose-response curves show that the difference between Triac and T(3) is maximal in the 1-10 nM range."( Triac regulation of transcription is T(3) receptor isoform- and response element-specific.
Langlois, MF; Messier, N, 2000
)
0.31
" Additional dose-response studies in hypercholesteremic rats confirmed the preferential effect of GC-1 on TRbeta-mediated parameters by showing a much higher potency to influence cholesterol and TSH than heart rate."( The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.
Baxter, JD; Chiellini, G; Dillmann, WH; Gloss, B; Grover, GJ; Scanlan, TS; Swanson, E; Trost, SU; Volodarsky, T; Wang-Iverson, DB; Zhang, H, 2000
)
0.31
" The beginning of therapy, dosage of drugs, length of application and results of treatment are critically evaluated, with special emphasis on the rate and time of remission, on the frequency of recurrences and on the success of additional treatments such as surgery and/or radioiodine application."( [Graves' disease. Clinical features and treatment results].
Amor, H; Crivellaro, C; Leimgruber, K; Oberhofer, R, 2001
)
0.31
" Thirty-four male goats were divided into five groups dosed with KCN at 0 (control)."( Physiopathological effects of the administration of chronic cyanide to growing goats--a model for ingestion of cyanogenic plants.
Górniak, SL; Kimura, ET; Soto-Blanco, B, 2001
)
0.31
" This work demonstrates gene dosage effect in nuclear coactivators manifesting as haploinsufficiency and functional redundancy of SRC-1 and TIF-2."( Thyroid function in mice with compound heterozygous and homozygous disruptions of SRC-1 and TIF-2 coactivators: evidence for haploinsufficiency.
Chambon, P; Gehin, M; O'Malley, BW; Refetoff, S; Sadow, PM; Weiss, RE; Xu, J, 2002
)
0.31
" Blood was sampled every 15 min for 2 h before and 4 h after dosing for determination of circulating hormonal changes."( Endocrine and respiratory responses to ergotamine in Brahman and Hereford steers.
Browning, R; Thompson, FN, 2002
)
0.31
" Dose-dependent inhibition of resorption was seen with SB-273005 after 7 days of dosing using Dpd as a measure of bone resorption."( Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist.
Gowen, M; Hoffman, SJ; Lark, MW; Miller, WH; Stroup, G; Vasko-Moser, J, 2002
)
0.31
" Ovary weight, uterus weight, peak plasma GH concentration, and hepatic CYP2A1 content were decreased 37 days after treatment with tamoxifen at a dosage of 20 mg/kg, but expression of other P450 enzymes was not affected."( Persistent suppression of hepatic CYP2A1 expression and serum triiodothyronine levels by tamoxifen in intact female rats: dose-response analysis and comparison with 4-hydroxytamoxifen, fulvestrant (ICI 182,780), and 17beta-estradiol-3-benzoate.
Bandiera, SM; Ickenstein, LM, 2002
)
0.56
" The description of the biochemical dynamics of TSH and free T4 (FT4) during the first period of thyroxine treatment is important to depict the practical outlines of the initial dosage of T4 and dosage adjustments for newborns with variable forms of CH."( Dynamics of the plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism.
Bakker, B; De Vijlder, JJ; Kempers, MJ; Van Bruggen, M; Van Tijn, DA; Vulsma, T; Wiedijk, BM, 2002
)
0.31
" Thus, insufficient replacement may be reflected by inappropriately elevated TSH levels, and may lead to dosage increment."( Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
Cohen, O; Lubetsky, A; Olchovsky, D; Shimon, I, 2002
)
0.31
" Breeding pairs were dosed continuously with 0, 1 nM, 1 micro M, or 1 mM concentrations of AP in drinking water from the time of cohabitation until pups from the third litter were weaned."( Effects of in utero and lactational ammonium perchlorate exposure on thyroid gland histology and thyroid and sex hormones in developing deer mice (peromyscus maniculatus) through postnatal day 21.
Anderson, T; Gentles, BA; Kendall, RJ; Mitchell, LP; Roots, EH; Smith, EE; Thuett, KA, 2002
)
0.31
" In contrast, supplemental T(3) decreased IVL in euthyroid birds, regardless of the dosing interval, but had no effect on ME activity."( Methimazole and thyroid hormone replacement in broilers.
McMurtry, JP; Rosebrough, RW, 2003
)
0.32
" Dose-response studies demonstrated enhanced [3H]-thymidine incorporation for T3 at 10(-9), 10(-8), 10(-7) and 20(-7) M, with a maximal response of 162."( The effects of triiodothyronine on human osteoblast-like cells metabolism and interactions with growth hormone.
Gozariu, L; Kasperk, CH; Pepene, CE; Pfeilschifter, J; Seck, T; Ziegler, R, 2003
)
0.67
" A host of birth defects, including cleft palate, anasarca, ventricular septal defect, and enlargement of the right atrium, were seen in both rats and mice, primarily in the 10 and 20 mg/kg dosage groups, respectively."( Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations.
Barbee, BD; Butenhoff, JL; Grey, BE; Hanson, RG; Lau, C; Richards, JH; Rogers, JM; Stevenson, LA; Thibodeaux, JR, 2003
)
0.32
" These findings have implications for future expanded studies and alternative dosing regimens in treating patients with both multinodular goiter and subclinical hyperthyroidism."( Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters.
Baskin, HJ; Duick, DS,
)
0.13
"05), whereas radiotherapy dosage was found in significant relationship with the development of hypothyroidism (p<0."( [The effect of laryngectomy and postoperative radiotheraphy on thyroid gland functions].
Akgül, G; Alkan, S; Cinar, U; Dadaş, B; Topuz, E; Unsal, O; Uslu, B; Yiğit, O, 2003
)
0.32
" The newest addition to available male hormone preparations is fluoxymesterone which is anabolic in smaller dosage than the older forms."( Newer hormonal preparations.
ESCAMILLA, RF, 1960
)
0.24
" After dose-response investigations, doses of 100 microM T3 and 550 microM of NA, producing clear DNA damaging effects and good cell viability, were chosen for further experiments with the antioxidant, catalase."( The effect of the antioxidant catalase on oestrogens, triiodothyronine, and noradrenaline in the Comet assay.
Anderson, D; Djelic, N, 2003
)
0.57
" Proper dosage is established based on thyrotropin (TSH) testing and clinical evaluation."( Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease.
Danzi, S; Klein, I, 2003
)
0.32
" Female sparrows were dosed daily with either 5 mg p,p'-DDT per kg body mass or corn oil vehicle over 3 days."( The effect of flight, fasting and p,p'-DDT on thyroid hormones and corticosterone in Gambel's white-crowned sparrow, Zonotrichia leucophrys gambelli.
Carr, JA; Cobb, GP; Scollon, EJ, 2004
)
0.32
" The most potent natural thyroid hormone, 3,5,3'-triidothyronine or T3, shows similar binding affinity and transactivation dose-response curves for both thyroid hormone receptor isotypes, designated TRalpha and TRbeta."( Induction of larval tissue resorption in Xenopus laevis tadpoles by the thyroid hormone receptor agonist GC-1.
Chiellini, G; Ermio, DJ; Furlow, JD; Hsu, M; Lim, W; Scanlan, TS; Yang, HY, 2004
)
0.32
" Dams were dosed daily with 0, 1, or 4 mg/kg A1254 from gestational day 6 (GD6) until they were sacrificed on GD16."( Polychlorinated biphenyls (PCBs) exert thyroid hormone-like effects in the fetal rat brain but do not bind to thyroid hormone receptors.
Bansal, R; Gauger, KJ; Haraguchi, K; Kato, Y; Lehmler, HJ; Robertson, LW; Zoeller, RT, 2004
)
0.32
" While the data indicate humans and rats exhibit similar dose-response relationships in terms of acute inhibition of thyroidal iodide uptake, the two species appear to exhibit notable differences in terms of thyroid hormone response, the toxicologically significant consequence of iodide uptake inhibition."( Interspecies differences in susceptibility to perturbation of thyroid homeostasis: a case study with perchlorate.
Beck, BD; Lewandowski, TA; Seeley, MR, 2004
)
0.32
" After dose-response studies, doses of 80 microM T3, 80 microM T4, 300 microM NA and 175 microM DES, which produced DNA damage but retained good cell viability, were chosen for further experiments with the antioxidant catalase and the flavonoids kaempferol and quercetin."( Antioxidants modulate thyroid hormone- and noradrenaline-induced DNA damage in human sperm.
Anderson, D; Baumgartner, A; Dobrzyńska, MM, 2004
)
0.32
"TriAc in the dosage and formulation studied was safe but no more effective than placebo in treating plaque psoriasis."( Inefficacy of topical thyroid hormone analogue TriAc in plaque psoriasis: results of a double-blind placebo-controlled trial.
Carlsson, B; Törmä, H; Vahlquist, A, 2004
)
0.32
" However, exposure to the higher dosage (100 nM) of T3 caused mild disintegration of sarcomeric a-actin in some myocytes, suggesting an over-dosage."( Enhanced connexin-43 and alpha-sarcomeric actin expression in cultured heart myocytes exposed to triiodo-L-thyronine.
Kostin, S; Mamedova, LK; Manoach, M; Moshel, S; Shainberg, A; Shneyvays, V; Tribulova, N; Weismann, P; Zinman, T, 2004
)
0.32
" Because of the long half-life of levothyroxine sodium small dosage adjustments may be performed by adding or withdrawing a tablet once or twice weekly."( Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.
Andersen, S; Bülow Pedersen, I; Carlé, A; Laurberg, P, 2005
)
0.33
" In contrast, supplemental T3 decreased IVL in euthyroid birds, regardless of the dosing interval, but had no effect on ME activity."( Methimazole, thyroid hormone replacement, and lipogenic enzyme gene expression in broilers.
Poch, SM; Richards, MP; Rosebrough, RW; Russell, BA, 2004
)
0.32
" After 4 weeks of treatment with sertraline at a standard dosage of 50 mg/day, both the single TRH test and the combined T3/TRH test were repeated in the depressed patients."( The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients.
Alajbegovic, L; Baghai, TC; Eser, D; Möller, HJ; Rupprecht, R; Schaaf, L; Schüle, C; Schwarz, M; Zwanzger, P, 2005
)
0.33
" To address this question, we studied the dose-response relationship of T(3) administered by constant infusion in hypothyroid animals with the simultaneous in vivo transcription rate of the cardiac-specific alpha-myosin heavy chain (MHC) gene, measured by quantitating alpha-MHC heteronuclear (hn)RNA content."( Effect of serum triiodothyronine on regulation of cardiac gene expression: role of histone acetylation.
Danzi, S; Dubon, P; Klein, I, 2005
)
0.67
"To evaluate the results of treatment of infants with congenital hypothyroidism (CH) with a low initial dosage of levothyroxine."( [Low initial dose of levothyroxine for treatment of congenital hypothyroidism].
Chen, HY; Chen, XX; Liang, L; Yang, RL; Yang, RW; Zhao, ZY, 2005
)
0.33
" The dosage for cases with low circulating thyroxine before treatment was higher than that of the other groups (P<0."( [Low initial dose of levothyroxine for treatment of congenital hypothyroidism].
Chen, HY; Chen, XX; Liang, L; Yang, RL; Yang, RW; Zhao, ZY, 2005
)
0.33
"he levothyroxine dosage of (4."( [Low initial dose of levothyroxine for treatment of congenital hypothyroidism].
Chen, HY; Chen, XX; Liang, L; Yang, RL; Yang, RW; Zhao, ZY, 2005
)
0.33
"Appropriate methimazole dosing for initial treatment of childhood Graves' disease is uncertain."( Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
Boudreau, C; Slyper, AH; Wyatt, D, 2005
)
0.56
" Groups of five male and five female Fischer rats and B6C3F1 mice were administered 2MI by dosed feed at 0, 1,200, 3,300, or 10,000 ppm or 4MI at 0, 300, 800, or 2,500 ppm for 15 days, and groups of 10 male and 10 female Fischer rats and B6C3F1 mice were administered 2MI or 4MI at 0, 625, 1,250, 2,500, 5,000 or 10,000 ppm for 14 weeks."( Induction of thyroid lesions in 14-week toxicity studies of 2 and 4-methylimidazole in Fischer 344/N rats and B6C3F1 mice.
Chan, P; Mahler, J; Nyska, A; Travlos, G; Wenk, M, 2006
)
0.33
" Under laboratory conditions, juvenile fish were fed by hand twice daily to satiation diets dosed with one of several concentrations of 4-NP (doses varied between 0 (control) and 2000 mg/kg) for 4 weeks, then immediately transferred to sea water."( Effects of dietary exposure of 4-nonylphenol on growth and smoltification of juvenile coho salmon (Oncorhynchus kisutch).
Hall, KJ; Higgs, DA; Ikonomou, M; Keen, PL, 2005
)
0.33
" Adult male rats were dosed for 30 days with daily intraperitoneal (ip) injection of 2 mg/kg Aroclor or vehicle (corn oil)."( Studies on the protective role of vitamin C and E against polychlorinated biphenyl (Aroclor 1254)--induced oxidative damage in Leydig cells.
Arunakaran, J; Balasubramanian, K; Murugesan, P; Muthusamy, T, 2005
)
0.33
" A blood sample was taken from each patient, for dosing TT3, TT4, FT3, FT4, TSH, TgAb, TPOAb."( [Evaluation of thyroid function in a group of over-eighty year-old people].
Dattilo, B; De Nardo, F; Galasso, D; Galasso, S; Gareri, P; La Cava, R; Ruotolo, G; Talarico, F; Tancrè, D, 2005
)
0.33
"Our objective was to test whether adjustment of T(4) dosage aiming for a serum TSH concentration less than 2 mU/liter improves well-being compared with a serum TSH concentration in the upper reference range."( Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial.
Bhagat, CI; Burke, V; Gilbert, R; Gillett, MJ; Henley, D; Shiels, L; Stuckey, BG; Tanner, M; Walsh, JP; Ward, LC, 2006
)
0.33
"Small changes in T(4) dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life, despite the expected changes in serum TSH and markers of thyroid hormone action."( Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial.
Bhagat, CI; Burke, V; Gilbert, R; Gillett, MJ; Henley, D; Shiels, L; Stuckey, BG; Tanner, M; Walsh, JP; Ward, LC, 2006
)
0.33
" After 15 days, the 40 mg dosage was decreased to 20mg/kg body weight for an additional 20 days (35 days of PTU)."( Serum thyroid hormones and performance of offspring in ewes receiving propylthiouracil with or without melatonin.
Duffey, JL; Gifford, CA; Hallford, DM; Knight, RL, 2007
)
0.34
" Single daily replacement doses may suppress levels of converting enzymes in the brain, suggesting that physiologic 'mimicry' provided by a constant infusion may be the preferred dosing option."( Neonatal thyroxine supplementation for transient hypothyroxinemia of prematurity : beneficial or detrimental?
Ares, S; Fisher, D; Golombek, SG; Kok, JH; La Gamma, EF; Morreale de Escobar, G; Paneth, N; Quero, J; van Wassenaer, AG, 2006
)
0.33
" To address bioequivalence, we explored how to best account for varying and unmeasured endogenous T(4) following dosing with exogenous oral L-T(4) in euthyroid volunteers in required pharmacokinetic (PK) studies, by simulating various dosing scenarios and developing a new and simple correction method."( L-T4 bioequivalence and hormone replacement studies via feedback control simulations.
DiStefano, JJ; Eisenberg, M; Samuels, M, 2006
)
0.33
" We also determined the effect of two doses of T(3) on the NH3 dose-response curve."( Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats.
Barbounis, P; Boulet, J; Domogauer, J; Dong, G; Dunn, C; Grover, GJ; Nguyen, NH; Scanlan, TS, 2007
)
0.34
" This suggests that T(4) dosage based on bw and aiming at fT4 in the upper reference range is superior to titration of T(4) aiming at middle normal fT4 concentrations in those patients."( Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine.
Beuschlein, F; Borm, K; Hug, MJ; Klawitter, B; Lubrich, B; Meiser, E; Nauck, M; Olschewski, M; Peper, M; Reincke, M; Schories, M; Slawik, M; Zwermann, O, 2007
)
0.54
" For the patients with a small maintenance dosage of levothyroxine (15."( [Observation time for drug administration and withdrawal in the treatment of children with congenital hypothyroidism].
Chen, XX; Mao, HQ; Shi, YH; Xu, YH; Yang, RL; Zhao, ZY; Zhou, XL, 2007
)
0.34
" (3) During the 8 days of dosing with PFOS, TSH was not elevated in male rats, while TT4 and TT3 were decreased."( Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS).
Bjork, JA; Butenhoff, JL; Chang, SC; Eastvold, ML; Ehresman, DJ; Froehlich, JW; Lau, C; Singh, RJ; Thibodeaux, JR; Wallace, KB, 2008
)
0.35
"These findings suggest that oral dosing in rats with PFOS results in transiently increased tissue availability of the thyroid hormones and turnover of T4 with a resulting reduction in serum TT4."( Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS).
Bjork, JA; Butenhoff, JL; Chang, SC; Eastvold, ML; Ehresman, DJ; Froehlich, JW; Lau, C; Singh, RJ; Thibodeaux, JR; Wallace, KB, 2008
)
0.35
"A biologically based dose-response (BBDR) model was developed for dietary iodide and the hypothalamic-pituitary-thyroid (HPT) axis in adult rats."( A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency.
Andersen, ME; Fisher, JW; McLanahan, ED, 2008
)
0.35
" Mice were dosed with PBDE-47 on postnatal day 10, and serum collected either 1, 5, or 10 days after the dose."( Lack of alterations in thyroid hormones following exposure to polybrominated diphenyl ether 47 during a period of rapid brain development in mice.
Gee, JR; Hedge, JM; Moser, VC, 2008
)
0.35
" The combined T(4) + T(3) dosing needed to normalize both plasma and tissue T(3) levels was 105 microg L-T(4) + 9 microg T(3) per day."( Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis.
DiStefano, JJ; Eisenberg, M; Samuels, M, 2008
)
0.35
" Parenteral T(4) administration-TSH, T(3), and T(4) levels were maintained within normal ranges for all four of these dosing schemes (1x vs."( Extensions, validation, and clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis.
DiStefano, JJ; Eisenberg, M; Samuels, M, 2008
)
0.35
" This case series shows that T(3) may be successfully employed as a long term treatment augmentation of major depression if over time dosage levels are increased beyond the traditional 50 mcg."( Long term augmentation with T3 in refractory major depression.
Kelly, TF; Lieberman, DZ, 2009
)
0.35
" Concerns remain about efficacy and safety of the current protocol, based on PK analysis following supraphysiological L-T(4) dosing in euthyroid volunteers, and recent recalls due to intrabrand manufacturing problems also suggest need for further refinement."( TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalence.
Distefano, JJ; Eisenberg, M, 2009
)
0.35
" Bioequivalence: We explored a TSH-based protocol, using normal replacement dosing in simulated thyroidectomized patients, switching brands after 8 weeks of full replacement dosing."( TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalence.
Distefano, JJ; Eisenberg, M, 2009
)
0.35
"A pharmacodynamic TSH-measurement bioequivalence protocol, using normal L-T(4) replacement dosing in athyreotic volunteers, is likely to be more sensitive and safer than current FDA Guidance based on T(4) PK."( TSH-based protocol, tablet instability, and absorption effects on L-T4 bioequivalence.
Distefano, JJ; Eisenberg, M, 2009
)
0.35
" Male Wistar and TR(-) rats were dosed orally (4 days) with phenobarbital (PB; 100 mg/kg) or DMP 904 (200 mg/kg), after which T4 homeostasis and hepatic cytochromes P450, UDP-glucuronosyltransferase, xenobiotic transporters, and T4 glucuronidation were determined."( Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR- rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidism.
Dieter, MZ; Gemzik, B; Klaassen, CD; Lecureux, L; Lehman-McKeeman, LD; Nelson, DM; Watson, L; Wong, H, 2009
)
0.35
" Using in vitro cultures of testicular fragments we demonstrated that cx43 mRNA levels were regulated in a dose-response manner by 3,5,3'-triiodo-l-thyronine (0-370 nM) and cAMP (0-100 ng/ml) but levels were not regulated by 11-KT."( Seasonal variations in testicular connexin levels and their regulation in the brook trout, Salvelinus fontinalis.
Audet, C; Cyr, DG; de Montgolfier, B; Faye, A, 2009
)
0.35
" Significantly higher hormone levels were observed in the Chinese bullfrog compared to the other two species, for both the time-course and dose-response experiments."( Ovine thyroid stimulating hormone (TSH) heterologously stimulates production of thyroid hormones from Chinese soft-shell turtle (Pelodiscus sinensis) and bullfrog (Rana catesbeiana and Rana rugulosa) thyroids in vitro.
Chien, JT; Huang, WT; Jeng, YY; Lu, LC; Weng, CF; Yu, JY, 2009
)
0.35
" Linear regression analysis evaluated relationships of dosage (mg/kg), dosing interval (q24h versus q12h), and time after methimazole to all thyroid hormone concentrations."( Optimal testing for thyroid hormone concentration after treatment with methimazole in healthy and hyperthyroid cats.
Kruger, JM; Nachreiner, RF; Rutland, BE,
)
0.13
" In hyperthyroid cats, there were no significant relationships between thyroid hormone concentrations and time postpill or dosing interval."( Optimal testing for thyroid hormone concentration after treatment with methimazole in healthy and hyperthyroid cats.
Kruger, JM; Nachreiner, RF; Rutland, BE,
)
0.13
" Blood samples were taken before dosing the animals and 48 hours post exposure to determine the serum thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) concentrations."( Prospective role of ascorbic acid (vitamin C) in attenuating hexavalent chromium-induced functional and cellular damage in rat thyroid.
Mahmood, T; Qureshi, IZ, 2010
)
0.56
" T3 levels in postmenopausal women were positively associated with the risk of breast cancer in a dose-response manner."( Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women.
Bondeson, AG; Bondeson, L; Ericsson, UB; Malm, J; Manjer, J; Tosovic, A, 2010
)
0.67
"We noted all patients' reduced LT4 dosage needs, including 7 (47%) who did not require any LT4 through the 9-month follow-up."( Low-level laser therapy in chronic autoimmune thyroiditis: a pilot study.
Cerri, GG; Chammas, MC; Chavantes, MC; Höfling, DB; Juliano, AG; Romão, R; Yoshimura, EM, 2010
)
0.36
" The putative antagonist Amiodarone, Bisphenol A (BPA) and its halogenated derivatives (TCBPA and TBBPA) for which effects reported in the literature are not consistent, showed comparable dose-response curves with a slight agonistic effect (5% of T(3)-max) followed by a slight antagonistic effect."( Detection of thyroid hormone receptor disruptors by a novel stable in vitro reporter gene assay.
Cano, P; Craig-Veit, C; Freitas, J; Furlow, JD; Goodson, ML; Murk, AJ, 2011
)
0.37
" Using logistic regression, we tested a variety of continuous risk models and conducted categorical analyses for all subjects combined and for females (53 cases, n  =  5,767) and males (23 cases, n  =  6,086) separately but found no convincing evidence of a dose-response relationship between (131)I and hyperthyroidism."( Prevalence of hyperthyroidism after exposure during childhood or adolescence to radioiodines from the chornobyl nuclear accident: dose-response results from the Ukrainian-American Cohort Study.
Bouville, A; Brenner, A; Furukawa, K; Hatch, M; Markov, V; McConnell, R; Olinjyk, V; Ostroumova, E; Ron, E; Shpak, V; Terekhova, G; Tronko, M; Zablotska, L, 2010
)
0.36
" The diet was added CS at dosage of 100 mg/kg bw on the first day of the treated phase."( [Effects of cysteamine on the plasma levels of SS and some metabolic hormones in adult geese].
Ai, XJ; Chen, WH; Han, ZK; Zheng, YL, 2004
)
0.32
" Even at a very high dosage TRH did not affect the obesity of genetically obese mice."( Effects of long-term intraperitoneal injection of thyrotropin-releasing hormone (TRH) on aging- and obesity-related changes in body weight, lipid metabolism, and thyroid functions.
Lesnikov, VA; Pierpaoli, W, 2011
)
0.37
" The goals of this study were to provide parametric and dose-response information for development of a quantitative model of the thyroid axis."( Marginal iodide deficiency and thyroid function: dose-response analysis for quantitative pharmacokinetic modeling.
Blount, BC; Crofton, KM; Fisher, JW; Gilbert, ME; Hedge, J; McLanahan, ED; Valentín-Blasini, L, 2011
)
0.37
" Insufficient thyroid hormone levels are one mechanism that hampers development of the alcohol-exposed brain, and we hypothesized that altered dosage of the imprinted thyroid hormone-inactivating gene deiodinase-III (Dio3) is responsible."( Strain-specific vulnerability to alcohol exposure in utero via hippocampal parent-of-origin expression of deiodinase-III.
Herzing, LB; Redei, EE; Shukla, PK; Sittig, LJ, 2011
)
0.37
" We conclude from this series of experiments that to maintain an accurate and stable dosing of patients receiving intravenous thyroid hormones, 1 mg/mL of albumin must be added to the infusate to prevent lost on the plastic intravenous tubing."( Stability of thyroid hormones during continuous infusion.
Alpan, G; Corbi, D; Frey, M; Golombek, SG; Lagamma, EF, 2011
)
0.37
"Triiodothyronine in the studied dosage and formulation was safe but not more effective than placebo."( Hair regrowth with topical triiodothyronine ointment in patients with alopecia areata: a double-blind, randomized pilot clinical trial of efficacy.
Haghpanah, V; Heshmat, R; Larijani, B; Nasiri, S; Saeedi, M; Taheri, E, 2012
)
2.12
" Although the effects of PB in blocking the surge release of luteinizing hormone (LH), inducing anovulation and prolonging the diestrous period has been well established, there is still no research describing the appearance of persistent estrous states in normal cycling rats dosed with PB."( Hypothyroidism caused by phenobarbital affects patterns of estrous cyclicity in rats.
Ishiguro, T; Kawakami, Y; Kumazawa, T; Li, Y; Matsumoto, Y; Nishitani, H; Tagawa, Y, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" The study results indicate that the current regulatory criteria for the value of similarity factor in comparative dissolution testing, as well as request for very rapid dissolution (more than 85% of drug dissolved in 15 min), are very restricted for immediate-release dosage forms containing highly soluble drug substance and need further investigation."( An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.
Dacevic, M; Homsek, I; Kocic, I; Miljkovic, B; Parojcic, J, 2011
)
0.37
" After complete thyroidectomy and substitution with levothyroxine (l-T(4)), the preoperative, inadequately low T(4) and free T(4) remained, while increasing the l-T(4) dosage led to T(3) serum concentrations above the normal range."( Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy.
Chiu-Ugalde, J; de Angelis, MH; Grüters, A; Klein, MO; Köhrle, J; Krude, H; Mossbrugger, I; Quintanilla-Martinez, L; Riebel, T; Rothe, K; Sapin, R; Schmid, KW; Schweizer, U; Sheu, SY; Wirth, EK, 2011
)
0.59
" Rats were perinatally dosed with a commercial PBDE mixture, DE-71."( Altered cardiovascular reactivity and osmoregulation during hyperosmotic stress in adult rats developmentally exposed to polybrominated diphenyl ethers (PBDEs).
Coburn, CG; Currás-Collazo, MC; Gaertner, M; Gillard, ER; Kodavanti, PR; Leon-Olea, M; Nichol, R; Shah, A; Shahidzadeh, A; Watson-Siriboe, A; Whitley, R, 2011
)
0.37
" LT(4) may be the preferred option for most children, given the convenience of single daily dosing and familiarity of pediatric endocrinologists with its administration."( Simulation of post-thyroidectomy treatment alternatives for triiodothyronine or thyroxine replacement in pediatric thyroid cancer patients.
Ben-Shachar, R; DiStefano, JJ; Eisenberg, M; Huang, SA, 2012
)
0.62
"To determine the dose-response relationship of the thyroid for radiation-induced hypothyroidism in head-and-neck radiation therapy, according to 6 normal tissue complication probability models, and to find the best-fit parameters of the models."( Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy.
Bakhshandeh, M; Hashemi, B; Kazemnejad, A; Mahdavi, SR; Nikoofar, A; Vasheghani, M, 2013
)
0.39
" The mean dose model can be used as the best model to describe the dose-response relationship for hypothyroidism complication."( Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy.
Bakhshandeh, M; Hashemi, B; Kazemnejad, A; Mahdavi, SR; Nikoofar, A; Vasheghani, M, 2013
)
0.39
" Our method, online SPE LC-MS/MS monitoring using a stable isotope tracer, has the potential to be used as a diagnostic tool to investigate the pathogenesis of thyroid disease and is valuable for optimizing the dosage in thyroid hormone replacement therapy."( Influence of iodine-deficiency on thyroid hormones homeostasis in rats.
Imazu, T; Minato, K; Nagao, H; Takahashi, K, 2012
)
0.38
" In order to verify the hypotheses that MAPK pathways would play roles in disturbance of TH levels caused by PCBs, and that TH-associated receptors could function in certain MAPK pathway, Sprague-Dawley rats were dosed with PCB153 intraperitoneally (i."( JNK pathway decreases thyroid hormones via TRH receptor: a novel mechanism for disturbance of thyroid hormone homeostasis by PCB153.
Cui, Y; Fu, W; Ha, M; Liu, C; Quan, C; Wang, C; Yan, M; Yang, K; Zhou, J, 2012
)
0.38
" The short half-life of T3 can be remedied by taking the patient's daily T3 dose and dividing it into two slow-release capsules to be dosed every 12 hours."( Bioidentical thyroid replacement therapy in practice: Delivering a physiologic T4:T3 ratio for improved patient outcomes with the Listecki-Snyder protocol.
Listecki, RE; Snyder, S,
)
0.13
" The EEG-defined parameters were significantly influenced by the microinjections in a biphasic dose-response relationship; the lowest (0."( Effects of acute microinjections of thyroid hormone to the preoptic region of euthyroid adult male rats on sleep and motor activity.
Giannopoulos, PF; James, TD; Martin, JV; Moffett, SX, 2013
)
0.39
"A population model was developed based on a simultaneous analysis of concentration-time data of T₄, T₃ and TSH in dogs following once daily oral dosing for up to 6-months of a myeloperoxidase inhibitor (MPO-IN1) with TPO inhibiting properties."( Systems pharmacology modeling of drug-induced modulation of thyroid hormones in dogs and translation to human.
Andersson, H; Ekerot, P; Ferguson, D; Glämsta, EL; Nilsson, LB; Rosqvist, S; Visser, SA, 2013
)
0.39
" After establishing hypothyroidism, rats were assigned to 1 of 5 graded T(3) dosages plus PTU for a 2-week dose-response experiment."( Restoration of cardiac tissue thyroid hormone status in experimental hypothyroidism: a dose-response study in female rats.
Chen, YF; Colligiani, D; Gerdes, AM; Ojamaa, K; Pol, CJ; Saba, A; Savinova, OV; Schlenker, EH; Weltman, NY; Zucchi, R, 2013
)
0.39
" The biphasic dose-response observed after either T1AM or T3 administration seems to indicate shared mechanisms and/or functions of sleep regulation in the preoptic region."( Effects of acute microinjections of the thyroid hormone derivative 3-iodothyronamine to the preoptic region of adult male rats on sleep, thermoregulation and motor activity.
James, TD; Martin, JV; Moffett, SX; Scanlan, TS, 2013
)
0.39
"Although our professional organizations continue to recommend L-T4 alone for the treatment of hypothyroidism, the possibility of a D2 gene polymorphism should be considered in patients on L-T4 monotherapy who continue to complain of fatigue in spite of dosage achieving low normal serum thyroid stimulating hormone levels."( Combination L-T3 and L-T4 therapy for hypothyroidism.
Wartofsky, L, 2013
)
0.39
" We identified 54 patients who were submitted to TSH, fT₄, and fT₃ evaluation, with the indication that the same dosage of L-T₄ be consumed 30 min before breakfast."( Oral liquid levothyroxine treatment at breakfast: a mistake?
Cappelli, C; Castellano, M; Formenti, A; Gandossi, E; Pirola, I, 2014
)
0.4
" Time-course and dose-response experiments for free- and total thyroxine (T4) and triiodothyronine (T3) plasma levels for thyroid-stimulating hormone (TSH) and thyroid gland histomorphology were determined in male Wistar rats."( Irreversible thyroid disruption induced after subchronic exposure to hexachlorobenzene in male rats.
Chalouati, H; Gamet-Payrastre, L; Saad, MB, 2016
)
0.66
" Women with normal pregnancy were included in a first study and only women with no abnormal thyroid dosage at baseline and tested positive with anti-TPO were prospectively enrolled."( Anti-TPO antibodies diffusion through the placental barrier during pregnancy.
Amand, G; Ceccaldi, PF; Guibourdenche, J; Luton, D; Seror, J, 2014
)
0.4
" As a result of changes in thyroid hormone metabolism and thyroid axis setpoint, long-term TSH-suppressive therapy contributes to a reduction in the dosage of levothyroxine per kilogram body weight required for full TSH suppression over time."( The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy.
Grelle, I; Mäder, U; Peeters, RP; Reiners, C; Smit, JW; Verburg, FA; Visser, TJ, 2014
)
0.4
" In order to elucidate effects of PCBs and DDT on thyroid hormone homeostasis, Sprague-Dawley rats were dosed with PCB153 and p,p'-DDE intraperitoneally (ip) for five consecutive days and sacrificed within 24 h after the last dose."( PCB153 and p,p'-DDE disorder thyroid hormones via thyroglobulin, deiodinase 2, transthyretin, hepatic enzymes and receptors.
Ha, M; Li, L; Liu, C; Yang, K, 2014
)
0.4
" In the present study, we report the dose-response characteristics of this developmental malformation and the connectivity of heterotopic neurones with other brain regions, as well as their functionality."( Subcortical band heterotopia in rat offspring following maternal hypothyroxinaemia: structural and functional characteristics.
Gilbert, ME; Goodman, JH; McCloskey, DP; Ramos, RL, 2014
)
0.4
"01) and stimulated DIO1 at 10 nM dosage (p < 0."( Thyroid hormone deiodinases D1, D2, and D3 are expressed in human endothelial dermal microvascular line: effects of thyroid hormones.
Balzan, S; Del Turco, S; Iervasi, G; Kusmic, C; Lubrano, V; Sabatino, L, 2015
)
0.42
"Severe hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up."( Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Alberti, C; Boizeau, P; Carel, JC; Chevenne, D; Guilmin Crepon, S; Harvengt, J; Léger, J; Paulsen, A; Simon, D; Zenaty, D, 2015
)
1.86
" We suggest that serum NO level may be an indicator for the introduction and dosage of levothyroxine (LT4) replacement therapy in SH patients."( Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients.
Bajic, V; Gluvic, Z; Isenovic, ER; Obradovic, M; Panic, A; Sudar-Milovanovic, E; Trebaljevac, J; Zarkovic, M, 2016
)
0.43
" The clinical consequences of these inaccuracies may affect whether dosing with T4 or combination of T4 with T3 is selected for treatment."( Is measurement of TT3 by immunoassay reliable at low concentrations? A comparison of the Roche Cobas 6000 vs. LC-MSMS.
Masika, LS; Soldin, SJ; Zhao, Z, 2016
)
0.43
" The peak T3 concentration after dosing of liothyronine during week 6 was 292."( Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters.
Burman, KD; Jonklaas, J, 2016
)
0.66
"Once-daily dosing of liothyronine at doses of 30-45 μg did not return serum TSH to the values seen during levothyroxine therapy."( Daily Administration of Short-Acting Liothyronine Is Associated with Significant Triiodothyronine Excursions and Fails to Alter Thyroid-Responsive Parameters.
Burman, KD; Jonklaas, J, 2016
)
0.66
" 5'-deiodinase-poor tissues should produce superimposable dose-response curves if T4 does not require conversion to T3."( Rethinking the biological relationships of the thyroid hormones, l-thyroxine and 3,5,3'-triiodothyronine.
Helbing, CC; Ichu, TA; Lesperance, M; Lu, L; Maher, SK; Propper, CR; Veldhoen, N; Wojnarowicz, P, 2016
)
0.66
" SBH increased with increasing dosage of PTU, but counter to our hypothesis, no SBH was detected in the offspring of FeD dams."( Thyroid hormone-dependent formation of a subcortical band heterotopia (SBH) in the neonatal brain is not exacerbated under conditions of low dietary iron (FeD).
Anderson, GW; Bastian, TW; Gilbert, ME; Kosian, P; Spring, SR; Wang, Y,
)
0.13
" Moreover, in a small group (n=119) of athyreotic patients treated with an unchanged dosage of L-T4 monotherapy, hormones were measured both in the coldest and in the hottest seasons of the same year (longitudinal study)."( Seasonal variations in TSH serum levels in athyreotic patients under L-thyroxine replacement monotherapy.
Belfiore, A; Frasca, F; Gullo, D; Latina, A; Squatrito, S; Vigneri, R, 2017
)
0.46
" After exposure to BPS, the mRNA expression of corticotrophin releasing hormone (crh) and thyroglobulin (tg) genes were up-regulated at ≥10 μg/L of BPS, in a dose-response manner."( Waterborne exposure to BPS causes thyroid endocrine disruption in zebrafish larvae.
Yang, ZL; Zhang, DH; Zhou, EX, 2017
)
0.46
" Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism."( Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S, 2017
)
0.46
"High initial LT4 dosing was effective and safely achieved optimal cognitive development in patients with CH, including those severely affected."( Mean High-Dose l-Thyroxine Treatment Is Efficient and Safe to Achieve a Normal IQ in Young Adult Patients With Congenital Hypothyroidism.
Aleksander, PE; Blankenstein, O; Brückner-Spieler, M; Craig, ME; Ernert, A; Grüters, A; Krude, H; Kühnen, P; Lankes, E; Schnabel, D; Stäblein, W; Stoehr, AM, 2018
)
0.48
" Fish with a low dosage of exogenous triiodothyronine and those treated with thiourea exhibited retarded development of bony plates compared to both control fish and those treated with higher a triiodothyronine dosage."( Heterochronic development of lateral plates in the three-spined stickleback induced by thyroid hormone level alterations.
Bolotovskiy, AA; DeFaveri, J; Levin, BA; Levina, MA; Merilä, J, 2018
)
0.75
" Dosing male C57BL/6 mice with sobetirome and Sob-AM2 at concentrations ≥10 μg/kg/d for 29 days induces a state similar to central hypothyroidism characterized by depleted circulating T4 and T3 and normal TSH levels."( Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics.
Bourdette, D; Ferrara, SJ; Scanlan, TS, 2018
)
0.48
" A dose-response relationship was identifiable."( Triiodothyronine replacement in critically ill adults with non-thyroidal illness syndrome.
Haddara, WMR; Kanji, S; Kim, J; Meggison, H; Neilipovitz, B; Neilipovitz, J; Patel, R; Pittman, M, 2018
)
1.92
"Decisions surrounding the timing and dosing of nutrition support are made for thousands of ICU patients daily and yet remain a topic of controversy."( Feeding During Phases of Altered Mitochondrial Activity: A Theory.
Bonini, M; Braunschweig, C; McKeever, L, 2018
)
0.48
"87) as was vasopressor dosage (6 vs 12 μg/min of norepinephrine, NE, P = 0."( A randomized trial comparing triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable brain-dead organ donors.
Dhar, R; Marklin, G; Stahlschmidt, E; Yan, Y, 2019
)
0.81
" This delivery system enabled the slow and sustained delivery of triiodothyronine into the micro-environment, reducing seepage of excess into systemic circulation and eliminating the necessity of repeated dosage forms."( Nanofiber-Mediated Sustained Delivery of Triiodothyronine: Role in Angiogenesis.
Korrapati, PS; Satish, A, 2019
)
1.02
"Using a retrospective cohort study design, we collected health examination reports from employees who worked on jobs with occupational exposure to radiation at a hospital to evaluate possible changes in the serum thyroid hormones and determine whether there is a dose-response effect."( The Relationship Between Occupational Exposure to Low-dose Ionizing Radiation and Changes in Thyroid Hormones in Hospital Workers.
Cheng, TJ; Cheng, YY; Guo, HR; Huang, CC; Wong, YS; Yeh, JJ, 2019
)
0.51
" In addition, we found negative dose-response relationships between exposure duration and declines in the serum levels of T3 (a change of -0."( The Relationship Between Occupational Exposure to Low-dose Ionizing Radiation and Changes in Thyroid Hormones in Hospital Workers.
Cheng, TJ; Cheng, YY; Guo, HR; Huang, CC; Wong, YS; Yeh, JJ, 2019
)
0.51
" However, the appropriate dosage and the route of supplementation of BP in broiler rabbits need further research."( Effect of bee pollen on growth performance, carcass traits, blood parameters, and the levels of metabolic hormones in New Zealand White and Rex rabbits.
Abdel-Hamid, TM; El-Tarabany, MS, 2019
)
0.51
" After stratifying the subjects according to category of selenium exposure, we observed a dose-response relation between serum selenium and risk of high total cholesterol, and between hair selenium and risk of high total and low-density lipoprotein cholesterol, high pancreatic lipase, altered thyroid-stimulating hormone and free triiodothyronine levels."( Exposure to a high selenium environment in Punjab, India: Effects on blood chemistry.
Chaudhary, R; Chawla, R; Cilloni, S; Datt, C; Dhillon, KS; Filippini, T; Loomba, R; Singh, S; Vinceti, M, 2020
)
0.73
" The objectives of this single-center, phase I, placebo-controlled, clinical trial were to determine the safety, tolerability, and optimal dosing of L-T3 in people with MS in preparation for a phase 2 remyelination clinical trial."( Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes.
Altowaijri, G; Bourdette, D; Cameron, M; Hildebrand, A; Oken, B; Samuels, M; Wooliscroft, L, 2020
)
0.56
" In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power."( Design of the Optimal Trial of Combination Therapy.
Cappola, AR, 2020
)
0.56
"A 31-year-old woman had unstable thyroid function during the third trimester of pregnancy, making it impossible to reduce her dosage of antithyroid medication."( Fetal goiter identified in a pregnant woman with triiodothyronine-predominant graves' disease: a case report.
Adachi, H; Ariake, C; Fujishima, A; Fukuoka, Y; Kameyama, S; Miura, H; Sato, A; Shimoda, Y; Terada, Y, 2020
)
0.81
" Comparator: Placebo with composition and dosage identical apart from the active substance."( Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Armaganidis, A; Kostopanagiotou, G; Mourouzis, I; Pantos, C; Trikas, A; Tseti, I, 2020
)
2
"The integrated probabilistic risk assessment (IPRA) combines dose-response and exposure data to estimate the likelihood of adverse effects."( A Probabilistic Approach to Evaluate the Risk of Decreased Total Triiodothyronine Hormone Levels following Chronic Exposure to PFOS and PFHxS via Contaminated Drinking Water.
Jakobsson, K; Lindh, C; Öberg, M; Ringblom, J; Scott, K; Silva, AV, 2020
)
0.8
" After 7 days of exposure, BP reduced D1 activity in kidney in a dose-dependent manner, while decrease in D1 activity was significant only after dosing with BP1 for 21 days (p < 0."( Effects of butylparaben exposure on thyroid peroxidase (TPO) and type 1 iodothyronine deiodinase (D1) in female Wistar rats.
Gogoi, P; Kalita, JC, 2020
)
0.56
" There was no statistical correlation between drug dosage and increased serum CK level."( Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs.
Cheng, Y; Ren, L; Sun, Z; Yang, H; Zhong, D, 2020
)
0.56
" Moreover, it is necessary to set parameters for evaluating the safety and effectiveness and understand which hormone (thyroxine or triiodothyronine), what dosage and at what stage of the disease should be applied."( [Use of thyroid hormones in the treatment of cardiovascular diseases: literature review].
Borisov, DV; Gubaeva, DN; Praskurnichiy, EA, 2020
)
0.76
" Urinary bis(1,3-dichloro-2-propyl)-phosphate concentrations were generally associated with decreased triiodothyronine and thyroxine levels and increased thyroid-stimulating hormone levels in maternal and newborn thyroid hormones in quartile dose-response analyses and multiple informant models."( Maternal Urinary Organophosphate Esters and Alterations in Maternal and Neonatal Thyroid Hormones.
Braun, JM; Calafat, AM; Cecil, KM; Chen, A; Dietrich, KN; Hoofnagle, A; Lanphear, BP; Ospina, M; Percy, Z; Vuong, AM; Xie, C; Xu, Y; Yolton, K, 2021
)
0.84
" TRH stimulation testing was performed following CH diagnosis, with LT4 replacement dosage adjusted to maintain F-T4 at the pre-treatment level."( Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022
)
0.72
" Understanding the impact of patient weight and residual thyroid function on initial levothyroxine dosage and consideration of age, comorbidities, thyrotropin goal, life stage, and quality of life as levothyroxine is adjusted can be challenging and continually evolving."( Optimal Thyroid Hormone Replacement.
Jonklaas, J, 2022
)
0.72
" The Bayesian kernel machine regression (BKMR) and restricted cubic spline (RCS) models showed a U-shaped dose-response relationship between bisphenol A (BPA) and free triiodothyronine (FT3) (p < 0."( Associations of bisphenol exposure with thyroid hormones in pregnant women: a prospective birth cohort study in China.
Fan, H; Huang, D; Huang, H; Liang, J; Liao, Q; Liu, S; Long, J; Pan, D; Qiu, X; Tang, P; Yu, C; Zeng, X, 2022
)
0.92
"A personalized simulation tool, p-THYROSIM, was developed (1) to better optimize replacement LT4 and LT4+LT3 dosing for hypothyroid patients, based on individual hormone levels, BMIs, and gender; and (2) to better understand how gender and BMI impact thyroid dynamical regulation over time in these patients."( Optimized Replacement T4 and T4+T3 Dosing in Male and Female Hypothyroid Patients With Different BMIs Using a Personalized Mechanistic Model of Thyroid Hormone Regulation Dynamics.
Chu, BB; Cruz-Loya, M; DiStefano, J; Jonklaas, J; Schneider, DF, 2022
)
0.72
" We also optimized combination T3+T4 dosing and computed unmeasured residual thyroid function (RTF) across a wide range of BMIs from male and female patient data."( Optimized Replacement T4 and T4+T3 Dosing in Male and Female Hypothyroid Patients With Different BMIs Using a Personalized Mechanistic Model of Thyroid Hormone Regulation Dynamics.
Chu, BB; Cruz-Loya, M; DiStefano, J; Jonklaas, J; Schneider, DF, 2022
)
0.72
"Compared with 3 other dosing methods, the accuracy of p-THYROSIM optimized dosages for LT4 monotherapy was better overall (53% vs."( Optimized Replacement T4 and T4+T3 Dosing in Male and Female Hypothyroid Patients With Different BMIs Using a Personalized Mechanistic Model of Thyroid Hormone Regulation Dynamics.
Chu, BB; Cruz-Loya, M; DiStefano, J; Jonklaas, J; Schneider, DF, 2022
)
0.72
" However, there are inconsistencies in the dose-response effects on the thyroid and kidneys."( Effects of lead exposure on biomarkers of thyroid and renal function tests among panel beaters in Enugu Metropolis, Nigeria.
Aguwa, EN; Kassy, CW; Meka, IA; Okwor, CJ; Onodugo, NP; Onodugo, OD, 2022
)
0.72
" There are no established recommendations for the dosage of sirolimus for this particular indication."( Severe consumptive hypothyroidism in hepatic hemangioendothelioma.
Dubinski, I; Häberle, B; Küppers, J; Lurz, E; Schmid, I; Schmidt, H; Walther, A, 2022
)
0.72
" The dose-response relationship between PAH metabolites and thyroid hormones was analyzed using the generalized linear model and restricted cubic spline model."( Associations between prenatal exposure to polycyclic aromatic hydrocarbons and thyroid hormones in umbilical cord blood.
Fu, M; Ma, Y; Nie, J; Tang, D; Wang, H; Wang, Y; Yao, X, 2023
)
0.91
" We observed a positive trend in the cumulative effects of BPs and iodine on serum triiodothyronine (FT3) and free thyroxine (FT4), as well as a U-shaped dose-response relationship between BPs and the probability of occurrence of thyroperoxidase autoantibody positivity in women with low urinary iodine concentration."( The Joint Effects of Bisphenols and Iodine Exposure on Thyroid during Pregnancy.
Hong, X; Lu, W; Mai, S; Qu, M; Shen, L; Shi, Z; Song, Q; Sun, Z; Wang, Y; Wang, Z; Zang, J, 2023
)
1.14
" The existence of a dose-response relationship was established between Ni and all the measured parameters of thyroid functions in entire population and in both sexes."( Nickel as a potential disruptor of thyroid function: benchmark modelling of human data.
Antonijevic, B; Baralic, K; Bulat, Z; Djordjevic, AB; Djukic-Cosic, D; Javorac, D; Mandic-Rajcevic, S; Maric, D; Zarkovic, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
thyroid hormoneAny hormone produced by the thyroid gland
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
thiolactoneA cyclic thioester of a mercapto carboxylic acid, containing a 1-thiacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
tetrahydrothiophenes
iodothyronineAn iodoamino acid in which the amino acid specified is thyronine.
iodophenol
2-halophenolA halophenol in which the halogen atom is bonded to the carbon atom adjacent to the C-OH group.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Thyroid Hormone Synthesis106
Thyroid hormone synthesis06
Thyroid hormones production and peripheral downstream signaling effects2216
Role of hypoxia, angiogenesis, and FGF pathway in OA chondrocyte hypertrophy123
Growth factors and hormones in Beta-cell proliferation03
Selenium micronutrient network095
Biochemical pathways: part I0466
Oligodendrocyte specification and differentiation, leading to myelin components for CNS302

Protein Targets (82)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency25.49570.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency15.67930.000221.22318,912.5098AID743063
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency1.25890.707912.194339.8107AID720542
progesterone receptorHomo sapiens (human)Potency41.67310.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.16230.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency17.50470.000214.376460.0339AID720692
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.43450.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency14.12540.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency25.11890.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.23390.000229.305416,493.5996AID588513; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
glucocerebrosidaseHomo sapiens (human)Potency56.23410.01268.156944.6684AID2101
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency16.73570.001019.414170.9645AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency19.75870.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00520.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.666319.739145.978464.9432AID1159509
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency7.94330.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.39880.000323.4451159.6830AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency48.55770.000627.21521,122.0200AID651741
gemininHomo sapiens (human)Potency16.80070.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.42390.005612.367736.1254AID624032
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency79.43280.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency2.81840.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.79430.015812.3113615.5000AID1489; AID2567
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Bile salt export pumpHomo sapiens (human)IC50 (µMol)11.27000.11007.190310.0000AID1443987
Androgen receptorHomo sapiens (human)IC50 (µMol)50.00000.00000.875310.0000AID633579
Thyroid hormone receptor alphaHomo sapiens (human)IC50 (µMol)0.00060.00000.35494.5000AID1073540; AID1797782; AID1797786; AID1797795; AID1797797; AID254851; AID299560
Thyroid hormone receptor alphaHomo sapiens (human)Ki0.00130.00020.00390.0096AID345695; AID385607; AID664441; AID722581
Thyroid hormone receptor betaHomo sapiens (human)IC50 (µMol)0.00060.00000.50185.1286AID1073539; AID1797784; AID1797787; AID1797796; AID1797797; AID254845; AID299561; AID299948
Thyroid hormone receptor betaHomo sapiens (human)Ki0.00120.00010.00070.0023AID213186; AID345696; AID385608; AID664440; AID722580
Proliferating cell nuclear antigenHomo sapiens (human)IC50 (µMol)3.60003.60004.95006.3000AID739861
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)23.00000.00011.14948.0000AID226684
Thyroid hormone receptor betaRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00020.00830.0350AID146670
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)23.00000.00011.03936.0000AID226684
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)23.00000.00011.29158.0000AID226684
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)23.00000.00011.30188.0000AID226684
Adenosine receptor A1Homo sapiens (human)IC50 (µMol)0.41090.00020.68187.7010AID625194
Adenosine receptor A1Homo sapiens (human)Ki0.23970.00020.931610.0000AID625194
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)23.00000.00010.98006.0000AID226684
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)23.00000.00011.19936.0000AID226684
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)23.00000.00010.93746.0000AID226684
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)23.00000.00011.01936.0000AID226684
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
Solute carrier organic anion transporter family member 1C1Mus musculus (house mouse)Ki24.20000.27001.11002.1500AID681369
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)IC50 (µMol)23.00000.00011.02016.0000AID226684
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain X, Thyroid hormone receptor beta-1Homo sapiens (human)Kd0.00010.00010.00100.0020AID977611
Chain X, Thyroid hormone receptor beta-1Homo sapiens (human)Kd0.00010.00010.00100.0020AID977611
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
ProthrombinHomo sapiens (human)EC50 (µMol)0.00290.00121.85227.4000AID1668603; AID1668605; AID1668607
Thyroid hormone receptor alphaHomo sapiens (human)EC50 (µMol)0.00690.00040.25843.7400AID1073537; AID1139981; AID1168701; AID1668604; AID1668606; AID1799414; AID1799415; AID1893234; AID1910211; AID213168; AID213169; AID323176; AID323178
Thyroid hormone receptor alphaHomo sapiens (human)Kd0.00010.00010.00210.0098AID1799413; AID1799448; AID213166; AID213172; AID213173; AID323174
Thyroid hormone receptor betaHomo sapiens (human)EC50 (µMol)0.00810.00020.03480.2400AID1073536; AID1139979; AID1799414; AID1799415; AID1893235; AID1910212; AID213179; AID213180; AID323177; AID323179
Thyroid hormone receptor betaHomo sapiens (human)Kd0.00010.00010.00170.0098AID1799413; AID1799448; AID213176; AID213183; AID213185; AID323175
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.73677.0000AID71696
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.00011.46937.0000AID71696
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)5.80000.00000.992210.0000AID1668534
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd0.71000.00120.95314.9800AID1668536
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01902.149910.0000AID71696
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.73677.0000AID71696
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)EC50 (µMol)0.00240.00240.00240.0024AID323176
GABA theta subunitRattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)EC50 (µMol)7.00000.01901.70547.0000AID71696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Km5.87000.24003.28416.5300AID679490
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km7.33004.30006.39608.8000AID679480
TransthyretinHomo sapiens (human)Concentration0.60000.01000.13800.6000AID161428
Solute carrier organic anion transporter family member 1A2Homo sapiens (human)Km6.50006.40007.42009.6000AID682051
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Km34.30001.00004.43338.5000AID681577; AID681578
Solute carrier organic anion transporter family member 4C1Homo sapiens (human)Km5.90000.38004.69337.8000AID679306
Solute carrier organic anion transporter family member 4C1Rattus norvegicus (Norway rat)Km1.90001.90004.95008.0000AID679783
Solute carrier organic anion transporter family member 4A1Homo sapiens (human)Km0.90000.90000.90000.9000AID678978
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Km6.40000.03912.93886.4000AID678809
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Km2.70000.00763.201810.0000AID681342
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (401)

Processvia Protein(s)Taxonomy
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cartilage condensationThyroid hormone receptor alphaHomo sapiens (human)
ossificationThyroid hormone receptor alphaHomo sapiens (human)
regulation of thyroid hormone mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
learning or memoryThyroid hormone receptor alphaHomo sapiens (human)
regulation of heart contractionThyroid hormone receptor alphaHomo sapiens (human)
female courtship behaviorThyroid hormone receptor alphaHomo sapiens (human)
response to coldThyroid hormone receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of RNA polymerase II transcription preinitiation complex assemblyThyroid hormone receptor alphaHomo sapiens (human)
erythrocyte differentiationThyroid hormone receptor alphaHomo sapiens (human)
thyroid gland developmentThyroid hormone receptor alphaHomo sapiens (human)
regulation of myeloid cell apoptotic processThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of female receptivityThyroid hormone receptor alphaHomo sapiens (human)
regulation of lipid catabolic processThyroid hormone receptor alphaHomo sapiens (human)
type I pneumocyte differentiationThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of cold-induced thermogenesisThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcription initiationThyroid hormone receptor alphaHomo sapiens (human)
thyroid hormone mediated signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
cell differentiationThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayThyroid hormone receptor alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
DNA-templated transcriptionThyroid hormone receptor betaHomo sapiens (human)
sensory perception of soundThyroid hormone receptor betaHomo sapiens (human)
negative regulation of female receptivityThyroid hormone receptor betaHomo sapiens (human)
regulation of heart contractionThyroid hormone receptor betaHomo sapiens (human)
female courtship behaviorThyroid hormone receptor betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
retinal cone cell developmentThyroid hormone receptor betaHomo sapiens (human)
type I pneumocyte differentiationThyroid hormone receptor betaHomo sapiens (human)
cellular response to thyroid hormone stimulusThyroid hormone receptor betaHomo sapiens (human)
retinal cone cell apoptotic processThyroid hormone receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
cell differentiationThyroid hormone receptor betaHomo sapiens (human)
thyroid hormone mediated signaling pathwayThyroid hormone receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIThyroid hormone receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIProliferating cell nuclear antigenHomo sapiens (human)
base-excision repair, gap-fillingProliferating cell nuclear antigenHomo sapiens (human)
mismatch repairProliferating cell nuclear antigenHomo sapiens (human)
heart developmentProliferating cell nuclear antigenHomo sapiens (human)
translesion synthesisProliferating cell nuclear antigenHomo sapiens (human)
epithelial cell differentiationProliferating cell nuclear antigenHomo sapiens (human)
replication fork processingProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of deoxyribonuclease activityProliferating cell nuclear antigenHomo sapiens (human)
response to estradiolProliferating cell nuclear antigenHomo sapiens (human)
cellular response to UVProliferating cell nuclear antigenHomo sapiens (human)
estrous cycleProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA repairProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA replicationProliferating cell nuclear antigenHomo sapiens (human)
response to cadmium ionProliferating cell nuclear antigenHomo sapiens (human)
cellular response to hydrogen peroxideProliferating cell nuclear antigenHomo sapiens (human)
cellular response to xenobiotic stimulusProliferating cell nuclear antigenHomo sapiens (human)
response to dexamethasoneProliferating cell nuclear antigenHomo sapiens (human)
liver regenerationProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA-directed DNA polymerase activityProliferating cell nuclear antigenHomo sapiens (human)
response to L-glutamateProliferating cell nuclear antigenHomo sapiens (human)
mitotic telomere maintenance via semi-conservative replicationProliferating cell nuclear antigenHomo sapiens (human)
leading strand elongationProliferating cell nuclear antigenHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
spermatogenesisSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
cell differentiationSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (117)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityThyroid hormone receptor alphaHomo sapiens (human)
nuclear receptor activityThyroid hormone receptor alphaHomo sapiens (human)
protein bindingThyroid hormone receptor alphaHomo sapiens (human)
zinc ion bindingThyroid hormone receptor alphaHomo sapiens (human)
TBP-class protein bindingThyroid hormone receptor alphaHomo sapiens (human)
protein domain specific bindingThyroid hormone receptor alphaHomo sapiens (human)
chromatin DNA bindingThyroid hormone receptor alphaHomo sapiens (human)
thyroid hormone bindingThyroid hormone receptor alphaHomo sapiens (human)
general transcription initiation factor bindingThyroid hormone receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificThyroid hormone receptor betaHomo sapiens (human)
transcription coactivator bindingThyroid hormone receptor betaHomo sapiens (human)
DNA bindingThyroid hormone receptor betaHomo sapiens (human)
DNA-binding transcription factor activityThyroid hormone receptor betaHomo sapiens (human)
nuclear receptor activityThyroid hormone receptor betaHomo sapiens (human)
protein bindingThyroid hormone receptor betaHomo sapiens (human)
zinc ion bindingThyroid hormone receptor betaHomo sapiens (human)
enzyme bindingThyroid hormone receptor betaHomo sapiens (human)
chromatin DNA bindingThyroid hormone receptor betaHomo sapiens (human)
thyroid hormone bindingThyroid hormone receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingThyroid hormone receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor betaHomo sapiens (human)
purine-specific mismatch base pair DNA N-glycosylase activityProliferating cell nuclear antigenHomo sapiens (human)
chromatin bindingProliferating cell nuclear antigenHomo sapiens (human)
damaged DNA bindingProliferating cell nuclear antigenHomo sapiens (human)
protein bindingProliferating cell nuclear antigenHomo sapiens (human)
enzyme bindingProliferating cell nuclear antigenHomo sapiens (human)
nuclear estrogen receptor bindingProliferating cell nuclear antigenHomo sapiens (human)
receptor tyrosine kinase bindingProliferating cell nuclear antigenHomo sapiens (human)
dinucleotide insertion or deletion bindingProliferating cell nuclear antigenHomo sapiens (human)
MutLalpha complex bindingProliferating cell nuclear antigenHomo sapiens (human)
histone acetyltransferase bindingProliferating cell nuclear antigenHomo sapiens (human)
identical protein bindingProliferating cell nuclear antigenHomo sapiens (human)
protein-containing complex bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase processivity factor activityProliferating cell nuclear antigenHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4C1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4C1Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
protein bindingSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 4A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 4A1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 4A1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (84)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleusThyroid hormone receptor alphaHomo sapiens (human)
nucleoplasmThyroid hormone receptor alphaHomo sapiens (human)
cytosolThyroid hormone receptor alphaHomo sapiens (human)
chromatinThyroid hormone receptor alphaHomo sapiens (human)
nucleusThyroid hormone receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexThyroid hormone receptor alphaHomo sapiens (human)
nucleoplasmThyroid hormone receptor betaHomo sapiens (human)
nuclear bodyThyroid hormone receptor betaHomo sapiens (human)
RNA polymerase II transcription regulator complexThyroid hormone receptor betaHomo sapiens (human)
chromatinThyroid hormone receptor betaHomo sapiens (human)
nucleusThyroid hormone receptor betaHomo sapiens (human)
chromosome, telomeric regionProliferating cell nuclear antigenHomo sapiens (human)
male germ cell nucleusProliferating cell nuclear antigenHomo sapiens (human)
nucleusProliferating cell nuclear antigenHomo sapiens (human)
nuclear laminaProliferating cell nuclear antigenHomo sapiens (human)
nucleoplasmProliferating cell nuclear antigenHomo sapiens (human)
replication forkProliferating cell nuclear antigenHomo sapiens (human)
centrosomeProliferating cell nuclear antigenHomo sapiens (human)
nuclear bodyProliferating cell nuclear antigenHomo sapiens (human)
nuclear replication forkProliferating cell nuclear antigenHomo sapiens (human)
PCNA complexProliferating cell nuclear antigenHomo sapiens (human)
extracellular exosomeProliferating cell nuclear antigenHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexProliferating cell nuclear antigenHomo sapiens (human)
chromatinProliferating cell nuclear antigenHomo sapiens (human)
replisomeProliferating cell nuclear antigenHomo sapiens (human)
PCNA-p21 complexProliferating cell nuclear antigenHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
azurophil granule membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
specific granule membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
extracellular exosomeSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 4C1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 4A1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (333)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146021Displacement of radiolabelled L-T3 from thyroid hormone receptor in intact rat hepatic nuclei relative to T31977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities.
AID386161Toxic cardiac effect on Sprague-Dawley rat assessed as increase in heart rate at >= 0.065 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID385930Reduction in plasma cholesterol level in cholesterol fed Sprague-Dawley rat2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1073538Selectivity ratio of IC50 for human recombinant TRalpha1 ligand binding domain to IC50 for human recombinant TRbeta1 ligand binding domain2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID1146020In vivo antigoiter activity in rat1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities.
AID1910225Inhibition of lipid metabolism in mouse primary hepatocytes assessed as reduction in intracellular tryglyceride level at 10 uM incubated for 24 hrs2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID681333TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Jan-19, Volume: 254, Issue:2
Identification of thyroid hormone transporters.
AID386198Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-tetraiodo-L-thyronine level at 300 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID722576Selectivity ratio of Ki for human TRalpha to Ki for human TRbeta2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1443987Inhibition of recombinant human BSEP expressed in baculovirus infected sf21 cell membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles after 5 mins by TopCount method2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID323174Displacement of [125I]T3 from human TRalpha receptor2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID678808TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000FEBS letters, Jun-02, Volume: 474, Issue:2-3
Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver.
AID386206Effect on food intake in Sprague-Dawley rat at 650 ug/kg/day, sc after 8 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1688787Toxicity in F344 rat assessed as effect on serum cholesterol level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 67.2 +/- 2.5 mg/dl)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID386165Toxic cardiac effect on Sprague-Dawley rat assessed as increase in systolic aortic pressure at >= 0.065 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1073515Toxicity in cholesterol-fed Sprague-Dawley rat assessed as TSH level at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 3.0 +/- 1.0 uIU/ml)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID299565Increase in heart rate in po dosed cholesterol-fed rat2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1668600Drug level in human serum2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID385937Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat heart2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID597764Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.01 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID386199Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in serum TSH level at 300 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID664444Selectivity ratio of Ki for human thyroid hormone receptor alpha to Ki for human thyroid hormone receptor beta2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID1910212Agonist activity at human TR beta LBD (202 to 461 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1688788Toxicity in F344 rat assessed as effect on serum triglycerides level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 86.8 +/- 10.4 mg/dl)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID1910222Inhibition of lipid metabolism in human HepG2 assessed as reduction in intracellular tryglyceride level at 1 to 10 uM incubated for 24 hrs2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID213179Effective concentration binding towards TR-beta-1 in E25B2 cells (agonistic activity)2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
AID170336Effect on the plasma cholesterol levels after subcutaneous administration of 8 nmol/kg in Dawley rats.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID161427Relative binding affinity to prealbumin was determined from the competition binding assays and is expressed relative to L-T41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Structurally specific binding of halogenated biphenyls to thyroxine transport protein.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID751642Displacement of [125I]Triiodothyronine from thyroid hormone receptor in Wistar rat liver after 18 hrs2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1073516Toxicity in cholesterol-fed Sprague-Dawley rat assessed as heart weight at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 1.14 +/- 0.12 g)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID1668530Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid at 10 uM incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID386200Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in TSH-beta mRNA level at 300 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386197Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-triiodo-L-thyronine level at 300 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1515621Agonist activity at human TRalpha after 24 hrs by cell based luciferase reporter gene assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Structure-Activity Relationships of Central Nervous System Penetration by Fatty Acid Amide Hydrolase (FAAH)-Targeted Thyromimetic Prodrugs.
AID345697Agonist activity at thyroid hormone receptor in Sprague-Dawley rat assessed as liver mGPDH activity at 1 mg/kg administered through osmotic pump infusion per ug protein2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
AID71696Non-competitive inhibitory activity against recombinant Gamma-aminobutyric acid A (GABA-A) receptor2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology.
AID386194Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-tetraiodo-L-thyronine level at 30 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID255360Ratio of IC50 of thyroid hormone receptor alpha 1 to that of thyroid hormone receptor beta 12005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
AID213169Half-maximum activation of human Thyroid hormone receptor alpha-1 (hTRalpha1)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID385934Effect on LDLR mRNA expression in po dosed Sprague-Dawley rat liver2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1675039Selectivity index, ratio of EC50 for THRalpha (unknown origin) to EC50 for THRbeta (unknown origin)2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres.
AID681135TP_TRANSPORTER: uptake in OATP-F-expressing CHO cells2002Molecular endocrinology (Baltimore, Md.), Oct, Volume: 16, Issue:10
Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.
AID299561Binding affinity at human thyroid hormone receptor beta-1 expressed in CHOK1 cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1910216Selectivity ratio of EC50 for agonist activity at wild type human TR alpha LBD expressed in Escherichia coli BL21 (DE3) to EC50 for agonist activity at human TR beta LBD (202 to 461 residues) expressed in Escherichia coli BL21 (DE3) cells2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID213180Half-maximum activation of human Thyroid hormone receptor beta 1 (hTRbeta1)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID664445Antidyslipidemic activity in high-cholesterol diet-fed Wistar rat assessed as decrease in cholesterol level at 5 ml/kg, sc administered QD for 2 days2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID1140021Antidyslipidemic activity in diet-induced obese C57Bl/6J mouse model assessed as reduction in cholesterol level at 10 to 100 ug/kg, po administered daily for 24 days2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID597763Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.1 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID1910220Binding affinity to human TR alpha LBD assessed as change in melting temperature at 10 uM by thermal shift assay2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1313989Pro-angiogenic activity in Balb/c mouse subcutaneously implanted 4 times with 10 ug/implant compound treated mouse EHS-derived matrigel assessed as FGF2-induced matrigel plug vascularization by measuring increase in hemoglobin level measured after 7 to 102016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Synthesis of MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-angiogenesis modulator.
AID385609Ratio of Ki for recombinant thyroid hormone receptor alpha to Ki for recombinant thyroid hormone receptor beta2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1364744Upregulation of Hr expression levels in ip dosed mouse brain for 7 days measured after 2 hrs post last dose by STBR green dye-based qPCR analysis2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.
AID386163Toxic cardiac effect on Sprague-Dawley rat assessed as increase in first derivative of left ventricular pressure at >= 0.065 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1073522Reduction in plasma total cholesterol in cholesterol-fed Sprague-Dawley rat at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 190 +/- 49 mg/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID75733Effect on rat hepatic glycerophosphate dehydrogenase alpha (GPD) activity 3 days after injection of 10e-6 mol/kg.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID195669Thyromimetic activity (induction of GPDH) in rat heart expressed as percentage of ratio of the ED50 for T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID224962Atrial tension was determined after administration to rats at 100 ug/Kg for 7 days at 40 pulse/min2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine.
AID664446Antidyslipidemic activity in high-cholesterol diet-fed Wistar rat assessed as decrease in thyroxine T4 level at 5 ml/kg, sc administered QD for 2 days2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1668576Agonist activity at recombinant human pFA-CMV-fused HNF4alpha LBD expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid at 0.01 to 10 uM incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID210552Relative binding affinity for nuclear receptor from rat liver compared to thyroxine (T4) as KA(comp)/KA(T41987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID146670In vitro inhibition of the bound [125I]L-T3 rat liver nuclear L-triiodothyronine receptor1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146022Binding affinity to rat hepatic solubilized nuclear thyroid hormone receptor relative to L-T31977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities.
AID1149270Thyroxine-like activity in rat by antigoiter assay relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson Analysis.
AID323176Effect on human TRalpha transactivation activity in U2OS cells by luciferase reporter assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID213183Binding affinity against human Thyroid hormone receptor beta 1 (hTRbeta1) using radiolabeled T32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID329525Activity at androgen receptor ligand binding domain assessed as inhibition of SRC2-3 interaction at 50 uM after 2 hrs by fluorescence polarization assay2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
A surface on the androgen receptor that allosterically regulates coactivator binding.
AID385853Effect on hepatic LDLR mRNA level in LDLR deficient C57BL/6 mouse at 0.5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID678720Metabolic stability in human liver microsomes assessed as low signal/noise ratio (S/N of 1 to 10) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID386192Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in TSH-beta mRNA level at 3 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID213186Inhibitory activity against [125I]T3 binding to human TRbeta1 receptor2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
AID1668603Agonist activity at GST-labelled THRbeta ( 202 to 461 residues) (unknown origin) incubated for 2 hrs in presence SRC1-2 co-activator peptide by Alphascreen assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID385859Effect on hepatic LDLR mRNA level in wild-type C57BL/6 mouse at 0.5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID385931Effect on CYP7A mRNA expression in po dosed Sprague-Dawley rat liver2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1910211Agonist activity at wild type human TR alpha LBD expressed in Escherichia coli BL21 (DE3) assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID345698Agonist activity at thyroid hormone receptor in Sprague-Dawley rat assessed as heart mGPDH activity at 1 mg/kg administered through osmotic pump infusion per ug protein2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
AID597765Induction of oligodendrocyte precursor cell differentiation isolated from Wistar rat fetal brain cortex at 0.03 uM after 3 days by anti O1-antibody immunostaining method2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
AID170333Effect on the plasma cholesterol levels after subcutaneous administration of 16 nmol/kg in Dawley rats.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID385634Decrease in cholesterol level in LDLR deficient C57BL/6 mouse at 5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386202Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-tetraiodo-L-thyronine level at 1000 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID224961Atrial tension was determined after administration to rats at 100 ug/Kg for 7 days at 20 pulse/min2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID385626Decrease in cholesterol level in wild-type C57BL/6 mouse at 5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1688758Toxicity in F344 rat assessed as reduction in liver and body weight ratio at 50 to 100 ug per 100 g body weight, ig administered daily for 3 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID1688785Toxicity in F344 rat assessed as effect on serum bilirubin level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 1.4 +/- 0.2 mg/dl)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID385933Effect on SREBP-1c mRNA expression in po dosed Sprague-Dawley rat liver2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386411Effect on hepatic LDLR mRNA level in diet-induced obese C57BL/6 mouse at 0.15 mg/kg, po after 8 hrs by RT-PCR2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID213188In vitro concentration required to displace [125I]L-T3 from rat hepatic nuclei.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID1139981Agonist activity at recombinant His6-tagged THR-alpha (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID1668607Agonist activity at human THRbeta expressed in green monkey CV1 cells after 24 hrs by luciferase assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID681578TP_TRANSPORTER: uptake in OAT-K1-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID1073540Displacement of [125I]-Triiodothyronine from human recombinant TRalpha1 ligand binding domain after 2 to 3 hrs by beta counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID104519Effect on rat hepatic Malic enzyme activity 3 days after injection of 10e-5 mol/kg.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID664447Ratio of ED30 for decrease in thyroxine T4 level in Wistar rat to ED50 for decrease in cholesterol level in Wistar rat2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID26068pKa for compound was evaluated1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID385608Displacement of [125I]T3 from recombinant thyroid hormone receptor beta expressed in sf9 cells by scintillation proximity assay2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID38733In vivo percentage antigoiter activity of compound was determined1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Role of iodine in thyroid hormones: molecular conformation of a halogen-free hormone analogue.
AID385932Effect on malic enzyme mRNA expression in po dosed Sprague-Dawley rat liver2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1668538Agonist activity at recombinant human pFA-CMV fused RXRalpha LBD expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID1675040Agonist activity at recombinant hexa-His-tagged THRalpha LBD (202 to 461 residues) (unknown origin)/recombinant human EE-tagged RXRalpha LBD (225 to 462 residues) assessed as increase in biotinylated GRIP1 peptide recruitment preincubated for 30 mins foll2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres.
AID386190Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-tetraiodo-L-thyronine level at 3 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID225470Heart weight was determined after administration to rats at 100 ug/Kg perorally for 7 days (in vivo on cardiovascular activity)2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine.
AID386203Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in serum TSH level at 1000 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID385637Decrease in cholesterol level in wild-type C57BL/6 mouse at 0.5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386209Effect on plasma fatty acid level in Sprague-Dawley rat at 650 ug/kg/day, sc after 8 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID681249TP_TRANSPORTER: inhibition of 3,3',5-triiodothyronine uptake (3,3',5-triiodothyronine:10nM, L-3,3',5-triiodothyronine: 10 uM) in Xenopus laevis oocytes2003The Journal of biological chemistry, Oct-10, Volume: 278, Issue:41
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.
AID680349TP_TRANSPORTER: inhibition of Digoxin uptake in Xenopus laevis oocytes2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1146023Binding affinity to thyroxine binding globulin (unknown origin) relative to T41977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities.
AID213151In vitro percentage thymocyte activity of compound was determined in rat1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Role of iodine in thyroid hormones: molecular conformation of a halogen-free hormone analogue.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID681151TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Feb, Volume: 120, Issue:2
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
AID386189Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-triiodo-L-thyronine level at 3 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID104517Effect on rat hepatic Malic enzyme activity relative to L-T3.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1073513Toxicity in cholesterol-fed Sprague-Dawley rat assessed as TSH level at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 62 +/- 7 ng/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID678809TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Gastroenterology, Jun, Volume: 120, Issue:7
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.
AID386196Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in TSH-beta mRNA level at 30 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID751708Displacement of [125I]Triiodothyronine from thyroid hormone receptor in Wistar rat liver at 10 uM after 18 hrs relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1910227Induction of mitochondrial basal respiration in human HepG2 cells assessed as increase in oxygen consumption rate at 10 uM measured after 24 hrs by Seahorse XFe96 flux analyzer2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID681380TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Jan-19, Volume: 254, Issue:2
Identification of thyroid hormone transporters.
AID1910223Inhibition of lipid metabolism in human HepG2 assessed as reduction in intracellular total cholesterol level at 1 to 10 uM incubated for 24 hrs2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID176209Effective dose was determined in hypercholesterolemic rats for lowering total serum cholesterol compared to control upon peroral administration1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID173068Percent change in serum LDL level was determined in hypercholesterolemic rats at 100 ug/Kg upon peroral administration1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID1675041Agonist activity at recombinant hexa-His-tagged THRbeta LBD (148 to 410 residues) (unknown origin)/recombinant human EE-tagged RXRalpha LBD (225 to 462 residues) assessed as increase in biotinylated GRIP1 peptide recruitment preincubated for 30 mins follo2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres.
AID664442Agonist activity at human thyroid hormone receptor beta expressed in african green monkey COS1 cells at 10' -5 M after 1 day by luciferase reporter gene analysis relative to T32012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID323175Displacement of [125I]T3 from human TRbeta receptor2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID299567Ratio of ED15 for heart rate in cholesterol-fed rat to ED50 for cholesterol level in cholesterol-fed rat2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID225468Heart rate was determined after administration to rats at 100 ug/Kg perorally for 7 days (in vivo on cardiovascular activity)2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine.
AID386157Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat pituitary gland2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID173065Percent change in serum HDL level was determined in hypercholesterolemic rats at 100 ug/Kg upon peroral administration1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID160006In vitro inhibition of bound [125I]L-T3 rat plasma membrane 3,5,3'' L-triiodothyronine receptor1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID299562Selectivity ratio of IC50 for thyroid hormone receptor alpha-1 to IC50 for thyroid hormone receptor beta-12007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1073518Reduction in plasma triglyceride level in cholesterol-fed Sprague-Dawley rat at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 62 +/- 25 mg/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID1688786Toxicity in F344 rat assessed as effect on serum glucose level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 151 +/- 13.5 mg/dl)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID1073514Toxicity in cholesterol-fed Sprague-Dawley rat assessed as total T4 level at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 3.8 +/- 0.9 ug/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1073519Reduction in plasma HDL-cholesterol in cholesterol-fed Sprague-Dawley rat at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 22 +/- 6 mg/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID679783TP_TRANSPORTER: cell accumulation in OATP4C1-expressing MDCK cells2004Proceedings of the National Academy of Sciences of the United States of America, Mar-09, Volume: 101, Issue:10
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.
AID722580Displacement of [125I]-T3 from human TRbeta expressed in insect cells after 16 to 48 hrs by gamma-counting2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID75734Effect on rat hepatic glycerophosphate dehydrogenase alpha (GPD) activity relative to L-T3.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID682051TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Endocrinology, May, Volume: 142, Issue:5
Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID195675Thyromimetic activity (induction of GPDH) in rat liver expressed as percentage of ratio of the ED50 for T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID213167Activation of human Thyroid hormone receptor alpha1 (hTRalpha1)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID386204Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in TSH-beta mRNA level at 1000 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386195Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in serum TSH level at 30 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID345696Displacement of [125I]3,5,3'-triiodo-L-thyronine His-tagged human recombinant TRbeta1 by scintillation proximity assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
AID3248Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine.
AID1910228Induction of mitochondrial uncoupled respiration in human HepG2 cells assessed as increase in oxygen consumption rate at 10 uM measured after 24 hrs by Seahorse XFe96 flux analyzer2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1688756Toxicity in F344 rat assessed as increase in heart weight at 50 to 100 ug per 100 g body weight, ig administered daily for 3 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID722583Agonist activity at human TRalpha expressed in COS1 cells after 1 day by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID680905TP_TRANSPORTER: competitive PCR in Caco-2 cells2002American journal of physiology. Gastrointestinal and liver physiology, Apr, Volume: 282, Issue:4
Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells.
AID213176Binding affinity towards thyroid hormone receptor (hTR beta 1)2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
A designed antagonist of the thyroid hormone receptor.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID254851Inhibitory concentration against cloned human thyroid hormone receptor alpha 12005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
AID345695Displacement of [125I]3,5,3'-triiodo-L-thyronine from His-tagged human recombinant TRalpha1 by scintillation proximity assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID386160Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat kidney2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID104520Effect on rat hepatic Malic enzyme activity 3 days after injection of 10e-6 mol/kg.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID681832TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 1 uM, T3: 200 uM, data not shown) in Xenopus laevis oocytes1998The Journal of biological chemistry, Aug-28, Volume: 273, Issue:35
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.
AID1668534Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1910218Agonist activity at human TR beta LBD (202 to 461 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay relative to control2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID161428Concentration at which 50% total binding against prealbumin protein occurs1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Structurally specific binding of halogenated biphenyls to thyroxine transport protein.
AID679480TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Aug-28, Volume: 273, Issue:35
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.
AID722582Agonist activity at human TRbeta expressed in COS1 cells after 1 day by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID323177Effect on human TRbeta transactivation activity in U2OS cells by luciferase reporter assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID170335Effect on the plasma cholesterol levels after subcutaneous administration of 4 nmol/kg in Dawley rats.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID1910226Inhibition of lipid metabolism in human HepG2 cells assessed as reduction in total lipid accumulation at 10 uM incubated for 24 hrs by oil red O staining based inverted microscopic analysis2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID1073517Toxicity in cholesterol-fed Sprague-Dawley rat assessed as heart rate at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 383.0 +/- 26.7 bpm)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679306TP_TRANSPORTER: cell accumulation in OATP4C1-expressing MDCK cells2004Proceedings of the National Academy of Sciences of the United States of America, Mar-09, Volume: 101, Issue:10
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.
AID254845Inhibitory concentration against cloned human thyroid hormone receptor beta 12005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID664441Displacement of [125I]T3 from human recombinant thyroid harmone receptor alpha after 16 to 48 hrs by gamma-ray detection2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID1139982Agonist activity at recombinant His6-tagged THR-alpha (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay relative to T32014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID1168701Agonist activity at human thyroid hormone receptor alpha expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1688783Toxicity in F344 rat assessed as effect on serum AST/GOT level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 153 +/- 11 U/L)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID1668606Agonist activity at human THRalpha expressed in baculovirus infected SF9 cells after 15 mins by gel electrophoresis2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID213166Binding affinity towards thyroid hormone receptor (hTR alpha 1)2001Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21
A designed antagonist of the thyroid hormone receptor.
AID299948Inhibition of human thyroid hormone receptor beta 12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
QSAR study of selective ligands for the thyroid hormone receptor beta.
AID1140023Toxicity in diet-induced obese C57Bl/6J mouse model assessed as reduction in bone mineral density at 10 to 100 mg/kg, po administered daily for 24 days relative to vehicle-treated control2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID1140025Toxicity in diet-induced obese C57Bl/6J mouse model assessed as increase in heart size at 10 to 100 mg/kg, po administered daily for 24 days2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID385632Decrease in cholesterol level in LDLR deficient C57BL/6 mouse at 0.5 mg/kg/day once daily for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1140024Toxicity in diet-induced obese C57Bl/6J mouse model assessed as increase in kidney size at 10 to 100 mg/kg, po administered daily for 24 days2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID386191Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in serum TSH level at 3 mg/kg/day, po for 7 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1515622Agonist activity at human TRbeta after 24 hrs by cell based luciferase reporter gene assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Structure-Activity Relationships of Central Nervous System Penetration by Fatty Acid Amide Hydrolase (FAAH)-Targeted Thyromimetic Prodrugs.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID189943Affinity to rat hepatic nuclei relative to L-T3.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID681240TP_TRANSPORTER: inhibition of thyroxine uptake (thyroxine:10nM, L-3,3',5-triiodothyronine: 10 uM) in Xenopus laevis oocytes2003The Journal of biological chemistry, Oct-10, Volume: 278, Issue:41
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.
AID146674In vitro binding affinity of compound to the rat Hepatic nuclear protein receptors was determined1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Role of iodine in thyroid hormones: molecular conformation of a halogen-free hormone analogue.
AID385938Effect on UCP3 mRNA expression in po dosed Sprague-Dawley rat muscle2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID681342TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of biological chemistry, Jun-11, Volume: 274, Issue:24
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.
AID1688784Toxicity in F344 rat assessed as effect on serum ALT/GPT level at 20 ug per 100 g of body weight, ig administered daily for 3 days (Rvb = 46 +/- 4 U/L)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID386156Effect on TSH-beta mRNA expression in po dosed Sprague-Dawley rat pituitary gland2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID681577TP_TRANSPORTER: uptake in OAT-K2-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID385865Increase in hepatic LDLR mRNA level in thyroidectomized Sprague-Dawley rat at 0.5 mg/kg after 24 hrs by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386207Effect on fasting blood glucose level in Sprague-Dawley rat at 650 ug/kg/day, sc after 8 days by oral glucose tolerance test2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1910224Inhibition of lipid metabolism in mouse primary hepatocytes assessed as reduction in intracellular total cholesterol level at 10 uM incubated for 24 hrs2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID385936Effect on MHCbeta mRNA expression in po dosed Sprague-Dawley rat heart2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID722579Agonist activity at human TRalpha expressed in COS1 cells at 10' -5 M after 1 day by luciferase reporter gene assay relative to T32013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID161435Relative binding affinity for thyroxin binding prealbumin (TBPA) from rat liver compared to thyroxine (T4) as KA(comp)/KA(T4)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID1668605Agonist activity at human THRbeta expressed in CHO cells after 24 hrs by luciferase assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID722578Agonist activity at human TRbeta expressed in COS1 cells at 10' -5 M after 1 day by luciferase reporter gene assay relative to T32013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID1073536Agonist activity at human recombinant TRbeta1 transfected in CV-1 cells after 8 to 10 hrs by alkaline phosphatase reporter gene assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID386208Effect on plasma insulin level in Sprague-Dawley rat at 650 ug/kg/day, sc after 8 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1073539Displacement of [125I]-Triiodothyronine from human recombinant TRbeta1 ligand binding domain after 2 to 3 hrs by beta counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID678978TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Endocrinology, May, Volume: 142, Issue:5
Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.
AID299569Ratio of ED30 for TSH in cholesterol-fed rat to ED50 for cholesterol level in cholesterol-fed rat2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID213173Binding affinity of compound was determined against Thyroid hormone receptor alpha12003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Structural determinants of selective thyromimetics.
AID234536Selectivity of compound was determined against thyroid hormone receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Structural determinants of selective thyromimetics.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID323179Effect on human TRbeta transactivation activity in HeLa cells by luciferase reporter assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID299566Decrease in cholesterol in po dosed cholesterol-fed rat2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1140022Antidyslipidemic activity in diet-induced obese C57Bl/6J mouse model assessed as reduction in liver size at 10 to 100 ug/kg, po administered daily for 24 days2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID185045Minimum effective dose was determined in hypercholesterolemic rats for lowering total cholesterol level compared to control upon peroral administration1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID680921TP_TRANSPORTER: Western blot, Caco-2 cells2002American journal of physiology. Gastrointestinal and liver physiology, Apr, Volume: 282, Issue:4
Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells.
AID386159Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat spleen2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID213177Activation of human Thyroid hormone receptor beta 1 (hTRbeta1)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID679702TP_TRANSPORTER: inhibition of MTX uptake (MTX: 0.1 uM, T3: 50 uM) in OAT-K2-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386205Effect on body weight in Sprague-Dawley rat at 650 ug/kg/day, sc after 8 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID385935Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat liver2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID1910217Agonist activity at wild type human TR alpha LBD expressed in Escherichia coli BL21 (DE3) assessed as induction of N-terminal biotinylated coactivator SRC2-3 peptide recruitment by alphascreen assay relative to control2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
AID566277Inhibition of rat thyroid hormone receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID1073521Reduction in plasma LDL-cholesterol in cholesterol-fed Sprague-Dawley rat at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 51 +/- 15 mg/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1668604Agonist activity at human THRalpha expressed in CHO cells after 24 hrs by luciferase assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID1668536Binding affinity to recombinant PPARgamma LBD (unknown origin) by isothermal titration calorimetry2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID299568Decrease in TSH in po dosed cholesterol-fed rat2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID213172Binding affinity against human Thyroid hormone receptor alpha-1 (hTRalpha1) using radiolabeled T32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID1073537Agonist activity at human recombinant TRalpha1 transfected in CV-1 cells after 8 to 10 hrs by alkaline phosphatase reporter gene assay2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID386401Effect on hepatic LDLR mRNA level in diet-induced obese C57BL/6 mouse at 0.15 mg/kg, po after 3 hrs by RT-PCR2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386158Effect on type 1 iodothyronine deiodinase mRNA expression in po dosed Sprague-Dawley rat thyroid gland2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID226684Direct channel-gating action blocked by picrotoxin2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
GABA-Activated ligand gated ion channels: medicinal chemistry and molecular biology.
AID1140054Selectivity ratio of EC50 for recombinant His6-tagged THR-alpha (unknown origin) expressed in Escherichia coli BL21(DE3) to EC50 for recombinant His6-tagged THR-beta (unknown origin) expressed in Escherichia coli BL21(DE3) relative to T32014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID1139980Agonist activity at recombinant His6-tagged THR-beta (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay relative to T32014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID681369TP_TRANSPORTER: inhibition of L-T4 uptake in Oatp14-expressing HEK293 cells2004Endocrinology, Sep, Volume: 145, Issue:9
Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1668602Agonist activity at Xenopus laevis THRalpha transfected in green monkey CV1 cells after 48 hrs by reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID208543Relative binding affinity towards T3 nuclear receptor in rat heart, expressed as percent ratio of IC50 for T3 to that of compound1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID208544Relative binding affinity for T3 thyroid hormone nuclear receptor in rat liver, expressed as percent ratio of IC50 compared to T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID213185Binding affinity of compound was determined against thyroid hormone receptor beta 12003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Structural determinants of selective thyromimetics.
AID1139984Cardiotoxicity in thyroidectomized rat assessed as induction of alpha-MHC hnRNA expression in cardiac myocyte at 3 ug, ip measured after 6 hrs2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID1668535Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid assessed as maximum fold activation incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID722581Displacement of [125I]-T3 from human TRalpha expressed in insect cells after 16 to 48 hrs by gamma-counting2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptor β (TRβ) selective agonists.
AID664440Displacement of [125I]T3 from human recombinant thyroid harmone receptor beta after 16 to 48 hrs by gamma-ray detection2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID1893235Agonist activity at human THR-beta expressed in CHO-K1 cells by PathHunter assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID386193Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-triiodo-L-thyronine level at 30 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID173587Dose which was not showing any cardiac effect in normal cholesterol rats upon peroral administration1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine.
AID739861Inhibition of human recombinant PCNA interaction with PIP box protein N-5-carboxyfluorescein-SAVLQKKITDYFHPKK after 30 mins by fluorescence polarization assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
AID1073534Selectivity ratio of EC50 for human recombinant transfected in CV-1 cells to EC50 for human recombinant TRbeta1 transfected in CV-1 cells2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID664443Agonist activity at human thyroid hormone receptor alpha expressed in african green monkey COS1 cells at 10' -5 M after 1 day by luciferase reporter gene analysis relative to T32012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia.
AID208848Percentage thyroxine-binding globulin (TBG) binding activity of compound was determined in human serum1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Role of iodine in thyroid hormones: molecular conformation of a halogen-free hormone analogue.
AID299560Binding affinity at human thyroid hormone receptor alpha 1 expressed in CHOK1 cells2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID213168Effective concentration binding towards TRalpha in E25B2 cells (agonistic activity)2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
AID1893234Agonist activity at human THR-alpha expressed in CHO-K1 cells by PathHunter assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID1139979Agonist activity at recombinant His6-tagged THR-beta (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dys
AID679650TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Endocrinology, May, Volume: 142, Issue:5
Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.
AID323178Effect on human TRalpha transactivation activity in HeLa cells by luciferase reporter assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
AID679451TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Triiodothyronine at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID680615TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 5 uM, T3: 50 uM) in Xenopus laevis oocytes2001Endocrinology, May, Volume: 142, Issue:5
Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.
AID385607Displacement of [125I]T3 from recombinant thyroid hormone receptor alpha expressed in sf9 cells by scintillation proximity assay2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID386201Toxicity in Sprague-Dawley rat assessed as suppression of thyroid hormone axis measured by decrease in total 3,5,3',5'-triiodo-L-thyronine level at 1000 mg/kg/day, po for 7 days2007Proceedings of the National Academy of Sciences of the United States of America, Sep-25, Volume: 104, Issue:39
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1073520Reduction in plasma free cholesterol in cholesterol-fed Sprague-Dawley rat at 50 ug/kg/day, po qd for 1 week measured 3 to 6 hrs post last dose (Rvb = 36 +/- 9 mg/dl)2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679490TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Aug-28, Volume: 273, Issue:35
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.
AID633579Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID227016Selectivity measured as ratio of TRalpha Ki/TRbeta Ki2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
AID1688757Toxicity in F344 rat assessed as increase in heart and body weight ratio at 50 to 100 ug per 100 g body weight, ig administered daily for 3 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
AID1668539Binding affinity to RXRalpha LBD (unknown origin) by isothermal titration calorimetry2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1799448TR Receptor Ligand Binding Assay from Article 10.1016/s1074-5521(98)90168-5: \\A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor.\\1998Chemistry & biology, Jun, Volume: 5, Issue:6
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor.
AID1797784TRbeta-Binding Assay from Article 10.1021/jm021080f: \\Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.\\2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
AID1799414Transactivation Assay in U2OS cells from Article 10.1021/cb600311v: \\Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.\\2006ACS chemical biology, Oct-24, Volume: 1, Issue:9
Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.
AID1799413Competition Binding Assay from Article 10.1021/cb600311v: \\Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.\\2006ACS chemical biology, Oct-24, Volume: 1, Issue:9
Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.
AID1799415Transactivation Assay in HeLa cells from Article 10.1021/cb600311v: \\Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.\\2006ACS chemical biology, Oct-24, Volume: 1, Issue:9
Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist.
AID1797796TRbeta-Binding Assay from Article 10.1016/j.bmcl.2005.11.002: \\Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.\\2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
AID1797797TRalpha-Binding Assay. from Article 10.1016/j.bmcl.2004.04.032: \\Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.\\2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
AID1797786TRalpha-Binding Assay and Thyroid Response Element (TRAFalpha1) Reporter Assay. from Article 10.1016/j.bmcl.2007.05.049: \\Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacolog2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1797795TRalpha-Binding Assay. from Article 10.1016/j.bmcl.2005.11.002: \\Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.\\2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
AID1797782TRalpha-Binding Assay. from Article 10.1021/jm021080f: \\Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.\\2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1797787TRbeta-Binding Assay and Thyroid Response Element (TRAFbeta1) Reporter Assay. from Article 10.1016/j.bmcl.2007.05.049: \\Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacologic2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2004The Journal of biological chemistry, Dec-31, Volume: 279, Issue:53
Thyroxine-thyroid hormone receptor interactions.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004The Journal of biological chemistry, Dec-31, Volume: 279, Issue:53
Thyroxine-thyroid hormone receptor interactions.
AID1346773Human Thyroid hormone receptor-alpha (1A. Thyroid hormone receptors)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
AID1346752Human Thyroid hormone receptor-beta (1A. Thyroid hormone receptors)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25,169)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012751 (50.66)18.7374
1990's4844 (19.25)18.2507
2000's3628 (14.41)29.6817
2010's3047 (12.11)24.3611
2020's899 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.63 (24.57)
Research Supply Index10.21 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index161.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.63%)5.53%
Trials861 (3.28%)5.53%
Reviews26 (8.20%)6.00%
Reviews1,127 (4.29%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1,151 (4.39%)4.05%
Observational0 (0.00%)0.25%
Observational69 (0.26%)0.25%
Other289 (91.17%)84.16%
Other23,039 (87.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]